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T cells play a central role in the pathogenesis of allergic asthma. 
However, many studies into the roles of T cells in asthma had been performed 
using ovalbumin as a surrogate allergen. This is mainly due to the greater 
availability of research tools for use in the ovalbumin model. However, true 
asthma allergens had been shown to behave very differently than ovalbumin. 
In this study, we aim to expand the tools available for the study of mite 
allergen-induced asthma. 
Using a plasmid DNA immunization method, we induced T cell 
responses against allergens from Blomia tropicalis and Dermatophagoides 
pteronyssinus. We identified a number of epitopes recognized by allergen-
specific CD4 T cells, including several novel epitopes for Blo t 5. We next 
demonstrated that the Blo t 5-specific CD4 T cells identified in this study were 
recruited into the lungs following Blo t 5 inhalation. When administered 
intradermally, the peptides induced a tolerogenic response and attenuated the 
allergic airway inflammation induced by Blo t 5 sensitization and challenge. 
The identification of CD4 T cell epitopes for Blo t 5 would allow for the study 
of T cell responses to Blomia tropicalis, a major source of mite allergen in the 
tropics that remained poorly studied to date. 
Work done on the OVA model suggested a role for CD8 T cells in the 
attenuation of the allergic airway responses to allergen. In this study, we 
adoptively transferred Der p 1 specific T cells into mice sensitized and 
challenged with house dust mite (HDM) extract. CD8 T cell responses were 
tracked by class I MHC tetramers produced in-house. Our results showed that, 
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unlike in the ovalbumin model, the CD8 T cells were unable to attenuate the 
allergic airway inflammatory responses to HDM. However, we showed that 
the Th2 airway inflammation was reduced following the adoptive transfer of 
Der p 1 specific CD8 T cells when mice were sensitized and challenged by 
purified Der p 1 protein. We proceeded to demonstrate in vivo and in vitro that 
exogenous HDM was a poor inducer of CD8 T cell responses. Finally, using 
peptide-pulsed BMDCs to induce a Der p 1-specific immune response, we 
observed that CD8 T cell responses exacerbated the allergic lung 
inflammation response to HDM by increasing the number of infiltrating 
immune cells and the production of IL-5 and IL-13. Therefore, our results 
suggested that the induction of a CD8 T cell response by HDM was markedly 
inefficient and it is unlikely that CD8 T cells could play a role in the acute 
phase of asthma development. However, our results showed also that a CD8 T 
cell response might actually be detrimental and exacerbate the inflammatory 
responses in the lung. 
Finally, we cloned and characterized the T cell receptor (TCR) gene 
from a Der p 1 specific CD8 T cell. The TCR genes were cloned into 
expression cassettes for the generation of TCR transgenic mice with CD8 T 
cells specific for the HDM allergen, Der p 1. We believe that these mice could 
be useful in the study of chronic asthma, where CD8 T cells had been shown 











List of publications 
 
1. Wong KL, Tang LF, Lew FC, Wong HS, Chua YL, MacAry PA, 
Kemeny DM. CD44high memory CD8 T cells synergize with CpG 
DNA to activate dendritic cell IL-12p70 production. J Immunol. 2009 
Jul 1; 183(1):41-50 
 
2. Tang Y, Guan SP, Chua BY, Zhou Q, Ho AW, Wong KH, Wong KL, 
Wong WS, Kemeny DM. Antigen-specific effector CD8 T cells 
regulate allergic responses via IFN-γ and dendritic cell function. J 
Allergy Clin Immunol. 2012 Jun; 129(6):1611-20.e4 
 
3. Ge MQ, Ho AW, Tang Y, Wong KH, Chua BY, Gasser S, Kemeny 
DM. NK cells regulate CD8+ T cell priming and dendritic cell 
migration during influenza A infection by IFN-γ and perforin-
dependent mechanisms. J Immunol. 2012 Sep 1; 189(5):2099-109.  
 
4. Prabhu N, Ho AW, Wong KH, Hutchinson PE, Chua YL, Kandasamy 
M, Lee DC, Sivasankar B, Kemeny DM. Gamma interferon regulates 
contraction of the influenza virus-specific CD8 T cell response and 




	   TABLE	  OF	  CONTENTS	   	  	   	  
vi 
 
Table of Contents 
Chapter 1.	   Introduction ....................................................................... 1	  
1.1	   Asthma ................................................................................................. 1	  
1.1.1	   Prevalence and cost of asthma ....................................................... 1	  
1.1.2	   Causes of asthma ............................................................................ 2	  
1.2	   The immunology of allergic asthma .................................................. 4	  
1.2.1	   The innate immune response in allergic asthma ............................ 7	  
1.2.1.1	   Dendritic	  cells	  and	  their	  role	  in	  allergic	  asthma	  .............................................	  8	  
1.2.1.2	   Eosinophils	  ...................................................................................................................	  11	  
1.2.1.3	   Mast	  cells	  .......................................................................................................................	  12	  
1.2.1.4	   Basophils	  .......................................................................................................................	  13	  
1.2.1.5	   Neutrophils	  ...................................................................................................................	  15	  
1.2.1.6	   Macrophages	  ................................................................................................................	  16	  
1.2.1.7	   Innate	  lymphoid	  cells	  ...............................................................................................	  17	  
1.2.1.8	   Natural	  killer	  T	  (NKT)	  cells	  and	  γδ	  T	  cells	  .......................................................	  17	  
1.2.1.9	   The	  airway	  epithelium	  ............................................................................................	  18	  
1.2.2	   The adaptive immune system and allergic asthma ...................... 19	  
1.2.2.1	   CD4	  T	  cells	  in	  allergic	  asthma	  ..............................................................................	  20	  
1.2.2.2	   CD8	  T	  cells	  in	  allergic	  asthma	  ..............................................................................	  26	  
1.2.2.3	   The	  humoral	  response	  in	  allergic	  asthma	  .......................................................	  28	  
1.3	   Asthma allergens ............................................................................... 29	  
1.3.1	   The mite allergens ........................................................................ 30	  
1.3.2	   Mite allergens and the immune system ........................................ 32	  
1.4	   Aims of the study ............................................................................... 34	  
Chapter 2.	   Materials and Methods ................................................... 38	  
2.1	   Media and buffers ............................................................................. 38	  
2.1.1	   PBS buffer .................................................................................... 38	  
2.1.2	   MACS buffer ............................................................................... 38	  
2.1.3	   FACS buffer ................................................................................. 38	  
2.1.4	   Red Blood cell  (RBC) lysis solution ........................................... 39	  
2.1.5	   Complete RPMI for cell culture ................................................... 39	  
2.1.6	   Buffers for ELISA ........................................................................ 40	  
2.1.7	   LB broth ....................................................................................... 40	  
2.1.8	   LB agar ......................................................................................... 40	  
2.1.9	   CaCl2 solution for preparation of competent cells ....................... 40	  
2.1.10	   SDS-PAGE gel electrophoresis buffers ..................................... 40	  
2.1.11	   Buffers for protein purification from E.coli ............................... 41	  
2.1.12	   Buffers for protein refolding and purification ........................... 41	  
2.2	   List of antibodies used ...................................................................... 42	  
2.3	   Mice .................................................................................................... 43	  
2.4	   Molecular biology protocols ............................................................. 43	  
2.4.1	   Preparation of chemically competent E.coli ................................ 43	  
2.4.2	   Transformation of E.coli .............................................................. 44	  
2.4.3	   General PCR protocol .................................................................. 45	  
2.4.4	   Agarose gel extraction ................................................................. 47	  
2.4.5	   Subcloning into TOPO vector by TA cloning ............................. 47	  
2.4.6	   Plasmid miniprep ......................................................................... 49	  
2.4.7	   Restriction enzyme digest ............................................................ 49	  
2.4.8	   PCR purification .......................................................................... 50	  
  
	   TABLE	  OF	  CONTENTS	   	  	   	  
vii 
2.4.9	   Ligation into plasmid vector ........................................................ 51	  
2.4.10	   RNA extraction and purification ................................................ 51	  
2.4.11	   Reverse transcription of mRNA ................................................. 52	  
2.4.12	   5’ RACE reaction ....................................................................... 52	  
2.5	   Protein expression and purification protocols ............................... 55	  
2.5.1	   SDS-PAGE gel electrophoresis ................................................... 55	  
2.5.2	   Production of class I MHC tetramers ........................................... 56	  
2.5.3	   Production of recombinant Blo t 5 ............................................... 60	  
2.6	   Cell isolation protocols ..................................................................... 62	  
2.6.1	   Processing of splenic and lymph node cells ................................ 62	  
2.6.2	   Isolation of CD8 cells by magnetic separation ............................ 63	  
2.7	   Cell culture ........................................................................................ 64	  
2.7.1	   T cell line production and maintenance ....................................... 64	  
2.7.2	   Bone-marrow derived Dendritic Cells ......................................... 65	  
2.8	   Protocols for evaluation of cell functionality .................................. 66	  
2.8.1	   IFN-γ ELISPOT ........................................................................... 66	  
2.8.2	   ELISA .......................................................................................... 68	  
2.8.3	   3H-thymidine proliferation assay ................................................ 68	  
2.8.4	   Chromium-51 release assay ......................................................... 69	  
2.9	   Flow cytometry .................................................................................. 70	  
2.9.1	   Cell surface marker staining for flow cytometry ......................... 70	  
2.9.2	   Intracellular cytokine staining for flow cytometry ...................... 70	  
2.9.3	   Peptide exchange and class I MHC tetramer staining ................. 71	  
2.10	   Intradermal immunization of mice with plasmid DNA by skin 
tattoo 72	  
2.11	   Murine model of asthma ................................................................ 72	  
2.11.1	   Intranasal sensitization or challenge of mice ............................. 72	  
2.11.2	   Bronchoalveolar lavage analysis ................................................ 72	  
2.11.3	   Analysis of lung cells ................................................................. 73	  
2.11.4	   Culture of lung-draining mediastinal lymph node (MLN) cells 74	  
2.11.5	   Lung histology ........................................................................... 75	  
Chapter 3.	   Expression and purification of recombinant Blo t 5 .... 78	  
3.1	   Introduction ....................................................................................... 78	  
3.2	   The Blo t 5 gene ................................................................................. 79	  
3.3	   Cloning of the Blo t 5 gene into pET 28 expression vector ............ 81	  
3.4	   Expression of recombinant Blo t 5 in E. coli BL 21 ....................... 83	  
3.5	   Purification of recombinant tBlo t 5 ................................................ 85	  
Chapter 4.	   Production of class I MHC tetramers ........................... 90	  
4.1 Introduction .......................................................................................... 90	  
4.1	   Expression and purification of class I MHC proteins ................... 91	  
4.2	   Testing the functionality of UV cleavable class I MHC tetramers
 96	  
Chapter 5.	   Mapping of mite allergen T cell epitopes ...................... 99	  
5.1	   Introduction ...................................................................................... 99	  
5.2	   DNA immunization constructs ...................................................... 102	  
5.3	   DNA vaccination of mice ............................................................... 109	  
5.4	   Epitope mapping studies ................................................................ 112	  
5.1.1	   Mapping of Blo t 5 epitopes ....................................................... 116	  
  
	   TABLE	  OF	  CONTENTS	   	  	   	  
viii 
5.1.2	   Mapping of Der p 2 epitopes ..................................................... 124	  
5.5	   Further characterization of Blo t 5 epitopes ................................ 128	  
5.6	   Discussion ........................................................................................ 138	  
Chapter 6.	   Der p 1 specific CD8 T cells and HDM-induced asthma.
 145	  
6.1	   Introduction .................................................................................... 145	  
6.2	   Immunization of mice .................................................................... 147	  
6.3	   Generation of a Der p 1 specific CD8 T-cell line. ........................ 153	  
6.4	   Characterization of T cell receptor gene ...................................... 156	  
6.5	   Cloning of T cell receptor gene into cassette vectors .................. 162	  
6.6	   Role of CD8 T cells in immune response to mite allergens ......... 173	  
6.7	   Discussion ........................................................................................ 198	  
Chapter 7.	   Final discussion ............................................................. 203	  
7.1	   Summary of findings ...................................................................... 203	  
7.2	   Limitation of current study ............................................................ 210	  
7.3	   Future work ..................................................................................... 212	  































	   LIST	  OF	  FIGURES	   	  	   	  
ix 
 
List of Figures 
 
Figure 1.1 Overview of the immune responses involved in allergic asthma ..... 6	  
Figure 1.2 Mite allergens and their biological activities .................................. 31	  
Figure 3.1 DNA sequence of Blo t 5 and the amino acid translation of codon80	  
Figure 3.2 SignalP 4.1 prediction of signal peptide cleavage in Blo t 5. . ....... 80	  
Figure 3.3 Blo t 5 and tBlo t 5 gene constructs in pET28 plasmid. ................. 82	  
Figure 3.4 Overview of the process for the expression of Blo t 5  .................. 84	  
Figure 3.5 Ammonium sulfate purification of bacterial lysate containing 
recombinant Blo t 5 protein.. ................................................................... 87	  
Figure 3.6 Anion exchange chromatography and SDS-PAGE gel analysis.. .. 88	  
Figure 3.7 Size exclusion chromatography and SDS-PAGE analysis of 
fractions.. .................................................................................................. 89	  
Figure 4.1 Steps involved in the production of class I MHC tetramers ........... 93	  
Figure 4.2 Large-scale expression of class I MHC subunits ........................... 94	  
Figure 4.3 S75 gel filtration chromatography for purification of class I MHC 
monomers.. ............................................................................................... 95	  
Figure 4.4 UV-mediated peptide exchange for class I MHC tetramers ........... 97	  
Figure 4.5 Functinoality of refolded UV-cleavable class I MHC tetramers .... 98	  
Figure 5.1 Murine optimized Blo t 5 gene with restriction sites and Kozak 
initiation sequence ................................................................................. 105	  
Figure 5.2 Murine optimized Der p 2 gene with restriction sites and Kozak 
initiation sequence ................................................................................. 106	  
Figure 5.3 Gene constructs produced for immunization studies and list of 
primers used in the cloning process ....................................................... 107	  
Figure 5.4 PCR cloning of Der p 2-SIINFEKL into pVAX1. ....................... 108	  
Figure 5.5 Plasmid DNA immunization of mice by skin tattoo.. .................. 111	  
Figure 5.6 List of peptides used in mapping epitopes of the Bo t 5 protein. . 113	  
Figure 5.7 List of peptides used in mapping epitopes of the house dust mite 
protein, Der p 2. Peptides are 15 amino acids in length (except Dp2#27, a 
16-mer peptide) and overlap by 10 amino acids. ................................... 114	  
Figure 5.8 Overview of the epitope mapping process. .................................. 115	  
Figure 5.9 Mapping of Blo t 5 epitopes in C57BL/6 mice.. .......................... 119	  
Figure 5.10 Mapping of Blo t 5 epitopes in BALB/c mice.. .......................... 120	  
Figure 5.11 Top 20 peptides predicted to bind H-2Db and H-2Kb. .............. 122	  
Figure 5.12 Tetramer guided epitope mapping.  ............................................ 123	  
Figure 5.13 Mapping of Der p 2 epitopes in C57BL/6 mice. ........................ 126	  
Figure 5.14 Mapping of Der p 2 epitopes in BALB/c mice. .......................... 127	  
Figure 5.15 IFNγ producing T cells recognizing Blo t 5 epitopes in C57BL/6 
mice following plasmid DNA immunization. ........................................ 129	  
Figure 5.16 T cells induced by intradermal plasmid DNA immunization were 
able to induce lung inflammation following antigen exposure. ............. 131	  
Figure 5.17 Intracellular cytokine staining of draining lymph node cells. .... 135	  
Figure 5.18 Peptide immunotherapy of Blo t 5 sensitized and challenged mice.
................................................................................................................ 137	  
Figure 5.19 Summary of T cell epitopes identified in this study.. ................. 140	  
Figure 5.20 Murine Der p 2 T cell epitopes identified in other studies. ........ 140	  
Figure 6.1 Gene construct for immunization of mice.. .................................. 150	  
  
	   LIST	  OF	  FIGURES	   	  	   	  
x 
Figure 6.2 Immunization of mice with pVAX-TTFH-FGISNYCQI. Mice were 
immunized intradermally by skin tattoo. Splenocytes of immunized mice 
were screened for antigen specific cells by (a) ELISPOT or (b) class I 
MHC tetramer staining. ......................................................................... 152	  
Figure 6.3 Establishment of a Der p 1 specific T cell line. ............................ 155	  
Figure 6.4 Molecular characterization of TCR chains. .................................. 159	  
Figure 6.5 Primers used in 5' RACE characterization of TCR chains. .......... 160	  
Figure 6.6 T cell receptor chains of the Der p 1 specific T cell line. ............. 161	  
Figure 6.7 List of primers used. ..................................................................... 167	  
Figure 6.8 Genomic DNA sequences of the TCR chains of the Der p 1 specific 
CD8 T cell line.. ..................................................................................... 168	  
Figure 6.9 Cloning of TCRα chain into pTαcass.  .......................................... 170	  
Figure 6.10 Cloning of TCRβ chains into pTβcass.  ....................................... 172	  
Figure 6.11 Murine model for house dust mite-induced asthma.. ................. 174	  
Figure 6.12 Adoptive transfer of Der p 1 specific CD8 T cells into the murine 
model of HDM-induced asthma.. ........................................................... 179	  
Figure 6.13 DNA immunization with plasmid encoding epitope recognized by 
Der p 1 specific CD8 T cells and the effect on lung responses to HDM.
................................................................................................................ 182	  
Figure 6.14 Role of Der p 1 specific CD8 T cells in lung responses to Der p 1.
................................................................................................................ 188	  
Figure 6.15 Sensitization by HDM-pulsed BMDCs followed  by CD8 adoptive 
transfer and HDM challenge.. ................................................................ 191	  
Figure 6.16 Der p 1 CD8 T cell responses to house dust mite extract. .......... 195	  
Figure 6.17 Induction of pulmonary CD8 T cell response by transfer of 
peptide-pulsed BMDCs and the effect on asthma development.. .......... 197	  
























	   LIST	  OF	  ABBREVIATIONS	   	  	   	  
xi 
List of abbreviations 
 
AHR – Airway Hyperresponsiveness 
AF488 – Alexa Fluor 488 
AF647 – Alexa Fluor 647 
APC - Allophycocyanin 
APC – Antigen Presenting Cell 
BMDC – Bone Marrow-derived Dendritic Cell 
BV421 – Brilliant Violet 421 
CD – Cluster of Differentiation 
DC – Dendritic cell 
ELISA – Enzyme-Linked ImmunoSorbent Assay 
FACS – Fluorescense activated cell sorting 
FBS – Fetal bovine serum 
HDM – House Dust Mite 
IFN – Interferon 
IL – Interleukin 
LB – Luria Bertani 
MACS – Magnetic Activated Cell Sorting (Miltenyi, Singapore) 
MHC – Major Histocompatibility Complex 
PB – Pacific Blue 
PBS – Phosphate Buffered Saline 
PCR – Polymerase Chain Reaction 
PE – Phycoerythrin 
PE-Cy7 – Phycoerythrin-Cyanine 7 
PerCP – Peridinin-Chlorophyll Protein 
  
	   LIST	  OF	  ABBREVIATIONS	   	  	   	  
xii 
PerCP-Cy5.5 – Peridinin-Chlorophyll Protein – Cyanine 5.5 
PFA – Paraformaldehyde 
PRR – Pattern Recognition Receptor 
RPMI – Roswell Park Memorial Institute 
TCR – T cell receptor 
TLR – Toll-like Receptor 
TSLP – Thymic Stromal Lymphopoietin 
































	   CHAPTER	  1:	  INTRODUCTION	   	  	   	  
1 




Asthma is a chronic airway disease characterized by chronic airway 
inflammation, airway remodeling and hyperresponsiveness and presents with 
symptoms of recurrent attacks of breathlessness, wheezing and coughing. 
Clinically, the measurement of forced expiratory volume in 1 second (FEV1) 
by spirometry is often used in the diagnosis and management of asthma. 
Airway obstruction that is at least partially reversible following the 
administration of a bronchodilator such as salbutamol strongly supports the 
diagnosis of asthma. It is a highly heterogeneous disease, varying in severity 
and frequency from patient to patient and with a number of different triggering 
factors that affect different individuals in different ways.  
1.1.1 Prevalence and cost of asthma 
Asthma is not a recent disease. The term “asthma” was derived from the 
Greek verb “aazein”, meaning to pant or to exhale with the mouth open. In the 
Corpus Hippocraticum by the ancient Greek physician Hippocrates (460-360 
BC), the word asthma was used for the first time as a medical term.  
Worldwide, an estimated 300 million people suffer from asthma, leading 
to approximately 250,000 annual deaths (1). The World Health Organization 
projects that the number of people afflicted with asthma would increase by 
over 100 million by 2025 (1). Developed, highly urbanized countries have a 
particularly high prevalence of asthma, with the highest prevalence found in 
the United Kingdom (greater than 15%), New Zealand (15.1%), Australia 
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(14.7%) and the United States (10.9%) (2, 3). In Singapore, asthma is 
estimated to affect 5% of all adults and 20% of children (statistics from Health 
Promotion Board, Singapore).  
The Centre for Disease Control and Prevention (CDC), USA, estimated 
that the Unites States spent approximately USD30 billion per year on 
treatment and prevention of asthma. In Singapore, the total cost of asthma was 
estimated to be USD33.93 million per annum in 1999 and is likely to be much 
higher now (4). This includes the direct cost incurred by hospitalization and 
other medical costs as well as indirect costs incurred due to the loss of 
productivity. Generally, asthma is expected to account for approximately 1-
2% of the healthcare budgets of developed countries each year (2, 3). 
Therefore, asthma is a disease with a profound health and economic 
impact on the global population. The disease burden is expected to increase 
significantly, with increasing industrialization and development in many 
countries, particularly in the populous nations such as the People’s Republic 
of China and India. As the treatment of asthma is generally restricted to 
symptomatic treatments, there exists a need for greater understanding of the 
mechanism of the disease to assist in the development of a cure or at least, 
more effective therapies. 
1.1.2 Causes of asthma 
 
Asthma is a complex disease that can be induced by a number of 
environmental factors, alone or in combination, and also potentially involves a 
large number of susceptibility genes (5-8). This complexity is a part of the 
problem of asthma treatment as the disease often varies from patient to patient 
in severity and causative agent. Patients allergic to the same triggering factor 
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differ in the severity of their responses and many patients were responsive to 
more than one triggering factor. 
The most common form of asthma and the focus of most of the research 
in the field is allergic asthma. Patients demonstrated aberrant pulmonary 
responses to any number of allergens, commonly house dust mites (HDM), 
pollen, ragweed, cockroach or mold. The lung is generally a tolerogenic 
environment, as is the nature of most organs with direct exposure to the 
external environment. However, in allergic asthma patients, inhalation of these 
allergens triggered an immune response in the lung, leading to the 
development of Th2 inflammation and the infiltration of immune cells such as 
eosinophils, mast cells and the production of IgE antibodies. Studies have 
shown that the nature of these allergens plays a big role in the induction of a 
pulmonary immune response. This, particularly in the context of the house 
dust mite, would be further discussed later in this chapter.  
 Asthma could also be induced by air pollutants such as ozone, cigarette 
smoke and diesel exhaust particles (reviewed in (9)). Recent studies have 
suggested that exposure to these factors may trigger epigenetic changes in the 
patients. Cigarette smoke, for example, has been shown to inhibit the 
expression of histone deacetylase (HDAC) in alveolar macrophages, leading 
to the increase in transcription of genes encoding inflammatory cytokines (10). 
Changes to DNA methylation and microRNA expression were also reported 
(11, 12). 
However, there also exists a genetic factor that could impact susceptibility 
to developing asthma. While studies did not indicate a classical Mendellian 
inheritance of asthma susceptibility, it was shown that certain asthma 
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phenotypes such as AHR or total serum IgE could have a heritable component 
(7). The ADAM33 gene, first identified in A/J mice, had been implicated in 
the susceptibility to develop AHR (13). Since then, many other susceptibility 
genes have been identified (5-8). 
1.2 The immunology of allergic asthma 
The human immune system is a highly sophisticated mechanism that 
protects us from external threats. The protection mechanism is layered and in 
order of increasing specificity. Initial protection is offered by physical barriers 
that prevent the entry of pathogenic organisms into the host. This includes the 
barriers such as the skin or cilia in the respiratory tract that actively propel 
mucus away from the lung, removing any particulate matter including 
pathogens. Chemical means, such as β-defensins secreted by the skin and 
respiratory tract and lysozyme in tears and saliva, also help prevent the entry 
of infectious agents. 
Should the physical barriers not suffice, other elements of the innate 
immune system would then be recruited as the next line of defense. Innate 
immune cells such as neutrophils and macrophages actively phagocytose and 
kill the infectious agents. Another phagocytic cell type, the dendritic cells, 
also phagocytose the infectious agents. Additionally, these cells then present 
antigens from the phagocytosed invaders to T cells, triggering an adaptive 
immune response. Hence, dendritic cells provide an important link between 
the innate and the adaptive immune response. Basophils, eosinophils and mast 
cells release immune mediators that can modulate the immune response. 
Eosinophils can also degranulate to release an array of cytotoxic granule 
proteins that can kill bacteria and parasites. Finally, natural killer (NK) cells 
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can recognize and kill cells infected with the foreign organism. Unlike the 
adaptive immune response, the innate immune response is not specific and 
does not develop a memory response. This means that the innate immune 
response would not respond more effectively upon re-encounter with the same 
pathogen. 
Finally, the adaptive immune system comes into play. The adaptive 
immune response is triggered more slowly than the innate response and 
requires a period of time to become fully effective. T cells, specifically 
recognizing the invader, come into play. T helper cells produce a number of 
inflammatory cytokines that orchestrate the immune response to the invader, 
while cytotoxic T cells actively kill infected host cells. B cells produce 
antibodies specific to the invader, which help to neutralize the invading 
organism. The adaptive immune response is generally long lasting and highly 
specific. Memory T cells and plasma cells persist long after the infection had 
abated and respond more rapidly and effectively upon re-encounter with the 
same invader. 
However, there exist occasions where an immune response occurs when 
undesired. This could lead to the manifestation of diseases such as asthma and 
autoimmunity. In allergic asthma, the exposure to innocuous antigens present 
in the inhaled air induced an immune response similar to that against an 
invading pathogen. Both the adaptive and innate immune systems were 
directed against these allergenic antigens, leading to infiltration of immune 
cells and pulmonary inflammation. The inflammatory responses in the lung 
could also result in structural changes such as airway smooth muscles 
hypertrophy, increased mucus production and increased airway resistance. 
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Figure 1.1 Overview of the immune responses involved in allergic asthma 
The protease activity of the allergen allows the allergen to penetrate through 
the epithelium. Activation of PRRs on the dendritic cells lead to the 
maturation of the dendritic cells and antigen presentation to T cells. TSLP and 
IL-33 produced by the epithelial cells induce the polarization of the immune 
response to a Th2-type response. Th2 CD4 T cells secrete a variety of 
cytokines that act on other immune cells. This leads to immunoglobulin class-
switching and IgE secretion from B cells. The cross-linking of FcεR1 
receptors on mast cells by allergen binding to IgE result in mast cell 
degranulation and release of various immune mediators. IL-5 produced from 
Th2 T cells recruit eosinophils into the lungs. Also, IL-13 had been shown to 
induce airway hyperresponsiveness and mucus production by goblet cells. 
Regulatory T cells (Treg) have been shown to suppress the immune response 
to allergens and are a key target in asthma therapy. Additionally, some studies 
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1.2.1 The innate immune response in allergic asthma 
The innate immune system is made up of a number of different cell types 
that express pattern recognition receptors (PRRs) that can recognize pathogen-
associated molecular patterns (PAMPs) or danger-associated molecular 
patterns (DAMPs). PAMPs are molecules found on pathogens that can be 
recognized by receptors present on immune cells. This includes bacterial cell 
wall components such as lipopolysaccharides (LPS), peptidoglycan, flagellin, 
bacterial DNA or double stranded virus RNA. Unlike PAMPs, DAMPs do not 
originate from pathogens but are found within the host cells. The presence of 
DAMPs such as adenosine, ATP, heat shock proteins, uric acid and DNA are 
indicative of cell damage or death and are capable of eliciting an immune 
response. These are recognized by PRRs found on innate cells encompassing 
the Toll-like receptors (TLRs), the nucleotide binding oligomerization domain 
(NLRs), C-type lectin receptors (CLRs) and scavenger receptors (14). A 
number of secreted PRRs such as complement proteins, mucins, ficolins, 
pentraxins also play a role in protection from infections.  
The role of the innate immune system of the lung is not only to protect the 
host from respiratory pathogens but also to maintain homeostasis. The innate 
immune system is the first component of the immune system to make contact 
with the allergen and hence a key determinant in the nature of the response 
mounted against the allergen. In many cases, encounter with the allergen 
results in elimination of the allergen and maintenance of immune tolerance. 
However, in allergic asthma, this may lead to the triggering of an immune 
response to the allergen. 
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1.2.1.1 Dendritic cells and their role in allergic asthma 
The first dendritic cells (DCs) were observed by Paul Langerhans and 
were named “Langerhans cells”. This subset of innate immune cells were 
coined as dendritic cells in 1973, in reference to their distinct morphology, 
specifically the presence of numerous long branched projections (dendrites) 
(15). DCs are specialized antigen-presenting cells (APCs) and are extremely 
effective in initiating T cell responses compared to other APCs (16, 17). 
Importantly, dendritic cells are highly effective in priming naïve T cells (18-
20).  Immature DCs efficiently phagocytose and process antigens but are not 
efficient antigen presenters. DC maturation can be induced by engagement of 
pattern recognition receptors found on these cells such as the TLR 4 receptor 
that recognizes bacterial lipopolysaccharide. Upon maturation, DCs down-
regulate their antigen uptake capability but upregulate the surface expression 
of class I and class II MHC molecules as well as co-stimulatory molecules 
such as CD40, CD80 and CD86 (21). Mature dendritic cells also upregulate 
the expression of CCR7, a chemokine receptor that allows the dendritic cells 
to home to lymphoid tissues, where the naïve T cells are located (22). 
DCs are a heterogeneous population of cells that can be broadly 
categorized into several subsets. Firstly, DCs can be divided into classical DCs 
or plasmacytoid DCs (pDCs). Classical DCs possess the typical DC 
morphology, with long dendrites, and express high levels of CD11c and 
intermediate to high levels of class II MHC on the cell surface. pDCs, 
however, lack dendrites but have a plasmacytoid shape and do not express 
CD11c. pDCs express TLR 7 and 9 and respond to viral infections by 
producing large quantities of IFNα/β. These cells express lower levels of class 
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II MHC and are very much less effective at presenting antigen to T cells 
compared to classical DCs.  
Classical DCs can arise from either lymphoid or myeloid progenitors. 
These cells can be divided into steady state DCs which can be further divided 
according to their tissue localization, for example, Langerhans cells in the 
epidermis, dermal DCs in the skin dermis and lung DCs. There also exist a 
subset of inflammatory DCs such as monocyte-derived DCs, which are not 
found in steady state but induced to develop following infection or an 
inflammatory response.  
In the lung, two major subsets of DCs had been identified: the 
CD11b+CD103- and the CD11b-CD103+ DCs (23, 24). CD11b+CD103- DCs 
effectively present antigen to CD4 T cells via the class II MHC molecule 
while CD11b-CD103+ DCs were shown to be more effective at cross-
presentation of exogenous antigens to CD8 T cells (25). Cross-presentation 
refers to the phenomenon where exogenous antigens bound for class II MHC 
presentation, were diverted to the class I MHC presentation pathway, normally 
reserved for endogenous antigens. DCs can be found in the upper layers of the 
epithelium and lamina propria of the airways. These DCs are at an immature 
state. Therefore, at steady state, uptake and presentation of antigen by these 
DCs would result in tolerance rather than induce an inflammatory response. 
For example, the administration of ovalbumin (OVA) into the lung of mice 
had been shown to result in immunologic tolerance rather than an allergic lung 
response to the antigen (26, 27). Immature or partially mature DCs can induce 
regulatory T cells that produce the immunosuppressive cytokines IL-10 and 
TGF-β (28, 29). When the DCs encounter a danger signal in the form of a 
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PAMP or DAMP, they undergo maturation and migrate to the draining lymph 
nodes. These DCs then prime naïve T cells specific for the antigen, eliciting an 
immune response against the antigen. A study by Piggott el al, 2005, 
demonstrated that the co-administration of OVA with a low level of TLR 4 
agonists was sufficient to induce a Th2 response by inducing DC maturation 
(30). Therefore, in order for the lung DCs to induce an immune response to 
the allergen, both the antigen and a danger signal must be present to induce 
DC maturation and antigen presentation. Strikingly, it has been demonstrated 
that uric acid, a DAMP, was released following primary exposure to HDM in 
the lungs of mice as well as upon allergen challenge in both human and mice. 
The uric acid released was shown to be sufficient to induce a Th2 response 
and the symptoms of allergic asthma (31). Similarly, extracellular ATP 
released as a result of allergen challenge had also been shown to activate lung 
dendritic cells and induce a Th2 inflammation in the lung (32). 
Adoptive transfer of antigen-pulsed DCs into the lungs of mice showed 
that DCs were able to induce Th2 allergic lung responses to the inhaled 
allergen (33). Depletion of lung CD11c+ dendritic cells prior to allergen 
challenge abolished the key features of asthma such as eosinophilic infiltration, 
AHR and mucus secretion (34, 35).  This shows that DCs are key to initiating 
a Th2 lung response to the allergen. Finally, it was demonstrated that the 
induction of a Th2 response is mediated by the FCεR1+ inflammatory DCs 
(generated in the presence of GM-CSF or IL-3) but not the conventional 
steady state DCs (generated in the presence of Flt3L) (35). Furthermore, uric 
acid released following allergen challenge efficiently recruited inflammatory 
DCs into the lung, leading to the priming of a Th2 response (31). 
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1.2.1.2 Eosinophils 
Eosinophils were first described in 1879 by Paul Ehrlich. These cells 
were termed eosinophils as they were stained by eosin, an acidic dye. 
Eosinophils develop from the pluripotent progenitor cells in the bone marrow 
and can be found in small numbers in the peripheral blood. The large specific 
granules of the eosinophils are stores for an array of effector molecules, 
predominantly the peroxidase enzyme, major basic protein (MBP), the 
eosinophil cationic protein (ECP) and the eosinophil-derived neurotoxin 
(EDN) but also smaller quantities of cytokines, enzymes and growth factors 
(36).  
Eosinophils express the IL-5 receptor subunit α (IL-5Rα) and the CCR3 
receptor (36). IL-5 plays a central role in the development and activation of 
eosinophils (37). The presence of IL-5 has also been shown to prolong the 
survival of eosinophils, which otherwise would only have a life-span of 18 
hours (38). CCL11 (eotaxin) is the ligand for CCR3 and together with IL-5, 
plays a key role in the recruitment of eosinophils (39). The sialic acid-binding 
immunoglobulin-like lectin, Siglec-F (in mice) or Siglec-8 (in human) is also 
expressed on eosinophils. 
Eosinophilia is a common feature of allergic asthma. IL-5 produced by 
Th2 helper T cells induced the development and recruitment of eosinophils 
into the lung. This was augmented by the production of IL-4 and IL-13, which 
upregulate CCL11 and promote eosinophil trafficking to the site of 
inflammation (40). Although not strictly a “professional APC”, eosinophils do 
express class II MHC molecules and the co-stimulatory molecules CD80 and 
CD86 and are able to stimulate T cells in an antigen-specific manner (41). 
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Eosinophils also release CCL17 and CCL22, which recruit Th2 T cells into the 
site of inflammation (42). They also release cytokines such as IL-4 and IL-13 
and may be an important early source of IL-4 for Th2 polarization(43) (44). 
The MBP found in the granules of eosinophils were also found to contribute to 
AHR (40).  
Due to the seemingly important role of eosinophils in allergic asthma, two 
humanized monoclonal antibodies designed to block IL-5 binding to IL-
5Rα (mepolizumab and reslizumab) were tested in clinical trials. Although 
these antibodies successfully reduced eosinophil numbers by up to 50%, no 
measureable clinical improvements were reported (45, 46). However, clinical 
improvements were observed when clinical trials were performed with a 
subset of asthma patients presenting with high sputum eosinophilic count (47). 
These observations further highlight the heterogeneous nature of the disease 
and the need for deeper understanding of the mechanism involved. 
1.2.1.3 Mast cells 
Mast cells develop from progenitor cells in the bone marrow. Stem cell 
factor and its receptor c-kit is a crucial signaling component in mast cell 
development. Cytokines such as IL-3, IL-4, IL-9 and IL-10 also promote the 
development and differentiation of mast cells (48).  
Mast cells were found to be present in increased numbers in the lungs of 
both allergic and non-allergic asthma patients (49). Mast cells present in the 
airways of asthma patients were more likely to have an activated phenotype 
(50). 
Mast cells express IgE binding receptors (FcεR1), which bind to the Fc 
portion of the IgE antibodies with high affinity. The Fab portion of the IgE 
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remains available to bind their specific antigens. Following antigen binding to 
the IgE and subsequent cross-linking of the cell surface IgE, mast cell 
degranulation is triggered (48).  
The granules of the mast cells contains a number of pro-inflammatory 
mediators such as histamine, tryptase, nitric oxide, proteases, leukotriene C4 
(LTC4), prostaglandin D2 and cytokines (TNFα, TNFβ, IL-1β, IL-4, IL-5, IL-
6, IL-13). These mediators can profoundly affect the permeability of the 
vascular endothelium, allowing the migration of circulating immune cells to 
migrate through the endothelium into the site of inflammation. These 
mediators contribute to the symptoms of the immediate hypersensitivity 
reaction such as coughing, sneezing, bronchospasm and mucus secretion as 
well as mediate the recruitment of other immune cells to the site (40, 51). The 
proteases in the mast cell granules such as tryptase and chymase may also 
affect the bronchial epithelium and contribute to airway remodeling (48). 
In mice, studies on the linkage between mast cells and AHR or 
eosinophilia reported contradictory observations. It is believe that when low 
allergen dosages were used, mast cells do indeed play a role in asthma as mast 
cell depleted mice showed reduced AHR and eosinophilia. However, the use 
of higher allergen dosages abrogated this effect (52). Some studies also 
indicated that mast cells could present antigen to T cells, although this is 
unlikely to be a major role for these cells (53, 54). 
1.2.1.4 Basophils 
Basophils are very closely related to mast cells, both in appearance and 
function. Like mast cells, basophils express the high affinity IgE receptor 
FCεR1 and produce many of the same inflammatory mediators such as 
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histamine, lipid mediators such as leukotrienes, cytokines such as IL-4, IL-6 
and IL-13 and chemokines (CCL3, CCL4, CCL12 and CXCL2) (55, 56).  
The development of basophils is regulated by IL-3. Basophils can be 
activated by the aggregation of the FCεR1 following the cross-linking of the 
surface IgE antibodies by the binding of multivalent antigen. The cytokines 
IL-3, IL-18 IL-33 and thymic stromal lymphopoietin (TSLP) are also capable 
of promoting basophil recruitment and activation (57-59). Basophils can also 
be induced to produce Th2 cytokines in response to protease activity (60, 61). 
Basophils were proposed to play a key role in the initiation of Th2 
inflammation following a study which showed that the depletion of basophils 
using antibodies to FCεR1 resulted in poor Th2 responses to papain (61). 
However, a later study showed that the use of antibodies against FCεR1 also 
depleted a subset of DCs that were vital to Th2 polarization (35). Studies 
using basophil-depleted mice also showed that basophils were not essential for 
the induction of Th2 responses (62). In humans, basophils were not observed 
to express HLA-DR nor co-stimulatory molecules and do not promote Th2 
responses from T cells in in vitro studies (63, 64). 
Although basophils may not be absolutely essential for the initiation of 
the allergic inflammatory response, it is clear that basophils do play a 
significant role in the pathology of allergic asthma. Basophils were found in 
increased number in the lungs of asthma patients compared to non-asthmatics 
(65). Recently, it has been suggested that basophils do contribute to Th2 
polarization of CD4 T cells (66). Certainly, the ability of the cytokine TSLP to 
recruit and activate basophils would suggest that these cells to play a role in 
allergic lung inflammation.   
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1.2.1.5 Neutrophils 
Neutrophils are the most common type of white blood cell. During the 
acute phase of an inflammatory response, neutrophils are often the first cells to 
respond. These cells are phagocytic and can quickly internalize and kill 
microbes with a combination of hydrolytic enzymes and reactive oxygen 
intermediates. Neutrophils also have the ability to degranulate and release a 
number of inflammatory mediators and antimicrobial agents such as 
myeloperoxidase, collagenase, cathepsin G and lysozyme. 
It had been observed that patients with severe asthma often have 
increased sputum neutrophil counts (67, 68).  The production of IL-8, a 
chemoattractant for neutrophils, was found to be elevated in severe asthma 
patients (69). Additionally, several studies also suggested that Th17 
inflammation might be a significant factor in severe asthma (70-72). IL-17A is 
a potent recruiter of neutrophils. 
Activated neutrophils secrete a variety of mediators that may contribute to 
AHR and airway remodeling. Elevated levels of enzymes released by 
neutrophils such as matrix metalloproteinase-9 (MMP-9) and elastase were 
found in BAL and sputum of asthmatic patients (73). These enzymes were 
believed to be involved in airway remodeling. MMP-9, in particular, 
correlated with disease severity (73). There is also correlation between the 
degree of neutrophilic inflammation with the decrease in patient lung 








Macrophages are a heterogeneous family of cells that can be found in 
most tissues and differ considerably in characteristic depending on the local 
microenvironment. Macrophages form an important part of the innate immune 
system; initiating and regulating immune responses, phagocytosis and killing 
of microbes, antigen presentation and clearance of debris and foreign matter 
from the body. 
In the lung, macrophages can generally be found in two compartments; 
the alveolar space (alveolar macrophages) and the interstitium (interstitial 
macrophages). Alveolar macrophages, unlike most macrophages, express 
CD11c but interstitial macrophages do not. However, interstitial macrophages 
express high levels of class II MHC (75). Also, alveolar macrophages 
phagocytose more effectively compared to interstitial macrophages. However, 
interstitial macrophages are more effective at inducing T cell proliferation in 
vitro (76). Interstitial macrophages were found to produce high levels of IL-10 
and inhibit the induction of Th2 responses in mice challenged by co-
administration of LPS and OVA (77). Alveolar macrophages demonstrate 
immunosuppressive effects during the effector phase of the allergic response 
but do not seem to suppress the initial sensitization response (78, 79). It has 
been demonstrated that alveolar macrophages can negatively regulate DC 
maturation and consequently, the ability of DCs to present antigen and 
activate T cells effectively (78). However, the immunosuppressive properties 
of alveolar macrophages were lost in the presence of pro-inflammatory 
cytokines such as GM-CSF or PAMPs such as LPS (77, 80). 
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Functionally, macrophages can be divided into two main subtypes, the 
M1 and M2 subtypes. M1 macrophages are induced by Th1 cytokines 
(particularly IFNγ) and stimulation via the TLRs. These cells produce Th1 
cytokines and chemokines such as TNF-α, IL-1β, IL-6, IL-12, CXCL9 and 
CXCL10. M2 macrophages are induced by IL-4 and IL-13. These cells had 
been shown to play a role in allergic airway inflammation and airway 
remodeling (81-83). 
1.2.1.7 Innate lymphoid cells 
Innate lymphoid cells (ILCs) are a relatively newly defined subset of cells. 
These cells can be divided into three groups (84). Group 1 ILCs comprise NK 
cells and other IFNγ secreting ILCs. Group 2 ILCs are ILCs that produce type 
2 cytokines. These cells had been termed natural helper cells, nuocytes or 
innate helper 2 cells in earlier publications. Finally, Group 3 ILCs were 
defined as RORγt+NKp46+ cells. Of these, the group 2 ILCs are of the most 
interest in asthma studies. In Rag-/- mice lacking both B and T cells, 
administration of IL-25 had been found to elicit IL-13 release from Group 2 
ILC cells.  The number of Group 2 ILCs was found to be increased in the 
lungs following allergen challenge of HDM sensitized mice (85). Also, Group 
2 ILCs were found to produce IL-5 and IL-13 in response to papain and were 
able to induce lung inflammation (86) 
1.2.1.8 Natural killer T (NKT) cells and γδ  T cells 
NKT cells express an invariant T cell receptor that recognizes glycolipids 
instead of peptides recognized by conventional T cells. The highly conserved 
nature of the NKT cell receptor compared to the conventional T cell receptor 
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(TCR) suggests a role as a pattern recognition receptor and that NKT cells are 
part of the innate immune response. Mice lacking NKT cells failed to develop 
AHR, suggesting a role for these cells in asthma pathogenesis. Moreover, 
administration of the NKT ligand α-galactosylceramide (α-GalCer) to the 
airways induced the production of IL-13 and TSLP by NKT cells (87). 
γδ T cells can be found at the lung epithelium and the numbers were 
observed to be higher in asthma patients. γδ T cells expressing the Vg1+ TCR 
were observed to produce IL-5 and IL13 and contribute to AHR. Meanwhile, 
γδ T cells that expressed the Vg4+ TCR appeared to suppress AHR and 
allergic airway inflammation, a role linked to their secretion of IL-17A (87). 
1.2.1.9 The airway epithelium 
For many years, the study of allergic asthma focused predominantly on 
the immune cells. Now, recent studies have drawn attention to the structural 
components of the lung and have shown that, rather than being a passive 
bystander in the inflammatory process, these components can have a profound 
influence on the nature of the allergic immune response to allergen.  
The airway epithelial cells represent the initial barrier encountered by 
infectious microbes or allergens. Epithelial cells express many PRRs that 
could detect and respond to a variety of PAMPs and DAMPs. Activation of 
epithelial cell PRRs results in the release of cytokines and chemokines and the 
recruitment of components of both the innate and adaptive immune system. 
Key to this is the activation of DCs by epithelial cells. Studies using chimeric 
mice lacking TLR4 demonstrated that triggering of TLR4 receptors on the 
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epithelial cells was sufficient to induce the recruitment and activation of DCs 
(88, 89). 
Activated airway epithelial cells secrete a large number of inflammatory 
mediators. These include the cytokine TSLP. TSLP receptors are found on 
DCs and bronchial epithelial cells and the presence of TSLP can induce DC 
activation and the production of IL-13 from epithelial cells. TSLP also 
promote the development of basophils, believed to be a source of early IL-4 
that enhances Th2 responses. Epithelial cell cultures from asthma patients 
overproduce GM-CSF, another cytokine with a key role in the promotion of 
DC activation and Th2 polarization. Activated epithelial cells also produce IL-
25 and IL-33. IL-33 activates lung DCs and promote Th2 responses in the 
lung. Group 2 ILCs respond to IL-25 and IL-33 to produce IL-5 and IL-13, 
contributing to the Th2 inflammation. Finally, epithelial cells also produce 
CCL2 and CCL20 in response to HDM. These chemokines then recruit 
monocytes and immature DCs to the lung (89). 
It is now increasingly clear that the epithelial cells are a major player in 
the development of allergic asthma. Therefore, treatment strategies targeting 
the epithelial cells may be beneficial in the control of allergic asthma. 
1.2.2 The adaptive immune system and allergic asthma 
The adaptive immune system is characterized by the ability to develop 
immunological memory following initial exposure to an antigen. Prior 
exposure to an antigen induces memory cells that would be able to mount a 
more rapid and robust immune response following subsequent encounter with 
the same antigen.  
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The adaptive immune response can be divided into two major 
components: the cell-mediated and the humoral immune response. CD4 and 
CD8 T cells are involved in the cell-mediated responses while B cells are the 
key players in the humoral response. 
The ability of the adaptive immune response to form immunological 
memory is a key focus of vaccine studies. The ability to elicit a memory 
response to an antigen is a key part of generating a long-lasting protection 
against many infectious diseases. However, in allergic responses or 
autoimmunity, the memory response is an undesirable feature that contributes 
significantly to the disease progression. 
1.2.2.1 CD4 T cells in allergic asthma 
CD4 T cells, also commonly known as T helper cells, are a major 
orchestrator of immune responses. These cells produce a variety of cytokines 
that affect the function of the other cells in the immune system, both in the 
adaptive and innate immune components of the immune system. T cells not 
only drive responses against various types of pathogens, whether intracellular 
pathogens, bacteria or parasites but they also play a key role in suppression of 
the immune response when a response is undesirable. Mossman et al (1986) 
first recognized that CD4 T cells could exist in different subsets, with differ 
dramatically in their secreted immune mediators and the nature of immune 
response elicited (90). These subsets were classified as Th1 and Th2 helper 
cells. Following this, many more subsets of T cells were identified, including 
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 Th2 cells 
In the study of allergic asthma, no discussion can be complete without 
reference to the Th2 subset of CD4 T cells. For many years, asthma was 
thought as a disease driven by the Th2 polarized CD4 T cells and many 
studies were devoted to inhibiting or reversing this response. More recently, it 
had been revealed that the blame does not only rest with these cells but with 
the complex interaction between the innate and adaptive immune response 
(87). In addition, studies also elicited roles for other subsets of T helper cells 
in the allergic inflammatory response. However, it is undeniable that Th2 CD4 
T cells and their secreted products still play a major role in the development of 
asthma.  
T helper cell differentiation is mediated by the transcription factors 
GATA3 and STAT6. Th2 CD4 T cells produce large quantities of cytokines 
that were recognized to be responsible for many features of asthma pathology 
(87, 91, 92). IL-4 is a key cytokine in the initiation and maintenance of Th2 
inflammation. This cytokine is responsible both for the polarization of the T 
cells into a Th2 phenotype as well as in the suppression of other T helper 
subsets. In addition, IL-4 also plays a key role in B cell class switching to IgE. 
IL-5 is produced in large quantities by Th2 cells, as is IL-13. IL-5 is a key 
player in eosinophil development and recruitment, a major feature of allergic 
asthma. IL-13 has been implicated in a wide range of roles in allergic airway 
inflammation. IL-13 had been shown to be a key player in mediating airway 
responses characteristic in allergic asthma such as goblet cell hyperplasia, 
AHR and airway remodeling. IL-13, along with IL-4, also plays a major role 
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in polarizing the responses of macrophages and dendritic cells to promote a 
type 2 inflammatory response.  
The presence of Th2 polarized T cells in the lungs of asthmatics has been 
shown to correlate with disease severity (93). In animal studies, antigen 
challenge following the adoptive transfer of Th2 polarized T cells specific for 
the inhaled allergen induced airway responses similar to those observed in 
allergic asthma (93-95).  However, despite many studies alluding to the central 
role of Th2 T cells in allergic asthma, therapeutic approaches targeting Th2 
mediators such as IL-4, IL-5 and IL-13 had been less successful than expected 
(96-100). This is despite promising findings in animal models that suggested 
the blocking of these cytokines might have profound effects on allergic airway 
inflammation (101-103). This highlights the difficulty of translating the results 
of animal studies to clinical applications as asthma in humans appear to be a 
far more heterogeneous disease than in animal models. The use of surrogate 
allergen like OVA in animal studies are likely to complicate matters as true 
asthma allergens are a complex mix of proteins that may induce responses not 
seen in the OVA model. Current studies are beginning to focus on asthma 
allergens and their role in the induction of allergic responses and this may 
provide greater understanding of the role of Th2 cells in disease (35, 88, 104). 
 Th1 cells 
Following the identification of the role played by Th2 cytokines in 
allergic asthma, much effort were devoted to examining the possibility of 
deviating the immune response to a Th1-type response as a Th1 response is 
believed to counter-regulate the development of a Th2 inflammatory response 
(105, 106). Th1 CD4 T cell differentiation is governed by the T box 
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transcription factor (T-bet) and STAT4 under the influence of the cytokine IL-
12. A key cytokine produced by Th1 cells is IFNγ. Generally, the Th1 
response is associated with cancer immunity and immunity to infectious 
diseases, particularly intracellular pathogens such as viruses. The Th1 
polarizing cytokine, IL-12, was shown to repress GATA-3 signaling via a 
STAT4 dependent mechanism, impairing the development of a Th2 polarized 
immune response (107). In T-bet knockout mice, spontaneous AHR and 
eosinophilia was reported, supporting the hypothesis that Th1 responses may 
negatively regulate the Th2 driven allergic asthma response (108).  
However, results from many studies suggested that the situation might not 
be as clear-cut as initially believed (109). Adoptive transfer experiments in 
rats where Th1 and Th2 cells were introduced concurrently prior to antigen 
challenge showed suppression of AHR and BAL eosinophilia (but not tissue 
eosinophilia) compared to rats that only received Th2 cells (110). Their results 
also suggested that this phenomenon might be partially mediated by IFNγ. 
However, another study using mice did not observe any changes to AHR but 
did observe reduced eosinophilia following Th1 cell transfer (111). Other 
studies also suggested that Th1 and Th2 inflammation could co-exist and even 
result in an enhanced inflammatory response (112, 113). In humans, the use of 
nebulized IFNγ did not significantly impact the symptoms of asthma (114). 
Findings of several other groups also suggested that IFNγ might be involved in 
AHR in steroid-resistant asthma (115) and may interact with pulmonary 
macrophages and mast cells to exacerbate AHR in some asthma models (116, 
117). The heterogeneity of findings with regards to the role of Th1 T cells in 
asthma suggests that the role played by these cells may be variable and 
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dependent on the nature of the disease or the nature of the allergens involved. 
It must also be indicated that a majority of the animal models used ovalbumin, 
which is not a natural allergen as well as a prime-boost protocol using 
artificial adjuvants to induce allergic responses in the mice. 
Th17 cells 
Th17 cells are characterized by the expression of IL-17 and IL-22. The 
differentiation of Th17 cells is driven by the transcription factors retinoic acid 
receptor-related orphan receptor γt (RORγt). In mice, transforming growth 
factor-β (TGF-β) and the cytokines IL-6, IL-21 and IL-23 are important for 
TH17 differentiation (87). IL-17A and IL-17F produced by Th17 cells drives 
the recruitment of neutrophils to the site of inflammation (118).  In asthmatics, 
IL-17 levels had been found to correlate with severity of disease, especially in 
the patients exhibiting neutrophiliic, steroid-resistant asthma (119). Using 
mice expressing hyperactive STAT3, a transcription factor with an important 
role in Th17 differentiation, Fogli et al (2013) demonstrated that IL-17 was 
able to drive neutrophilic lung inflammatory responses that lead to symptoms 
similar to that observed in asthma (120). Another study showed that severe 
AHR was associated with both IL-17A and IL-13 in a synergistic manner 
(121). However, this synergy may be dose-dependent as high concentrations 
of IL-17 resulted in decreased IL-13 mediated inflammatory responses (122). 
Other groups also reported an anti-inflammatory role for Th17 cells (123, 124). 
Therefore, the role of Th17 in allergic asthma remains unclear. An interesting 
observation is that exposure to endotoxin during the process of sensitization 
may divert the immune response to a Th17-mediated neutrophilic response 
(125). This may very well affect the observations made by different groups. 
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Th9 cells 
Th9 cells are the latest T cell subset to be associated with allergic asthma 
(87). The differentiation of these cells is driven by the transcription factor 
PU.1 and IL-25. Mouse studies showed that PU.1-deficient mice developed 
normal Th2 responses but demonstrated attenuated AHR and reduced cellular 
infiltration compared to wild-type mice (126). However, this field is relatively 
new and it is too early for any conclusions to be drawn on the role of Th9 cells 
in allergic asthma. 
Regulatory T cells (Tregs) 
Tregs are another subject of keen interest in the discussion on allergic 
asthma. Several subsets of Tregs exist, the naturally occurring forkhead box 
P3 (FOXP3)+CD4+CD25+ Treg and the inducible Treg (iTreg). The ability of 
Tregs to suppress the immune response lies in several different mechanism: 
they secrete inhibitory cytokines such as IL-10 and TGF-β, express inhibitory 
molecules such as they cytotoxic T lymphocyte antigen 4 (CTLA4) and 
repress the ability of antigen presenting cells to stimulate T cells by inducing 
the downregulation of class II MHC and costimulatory molecules such as 
CD80 or CD86 (87, 127).  
Adoptive transfer of Tregs abolished allergic airway inflammation and 
AHR and is effective even after initial allergenic sensitization had occurred 
(128, 129). Depletion of Tregs in C3H mice resulted in increased eosinophilia, 
AHR and IgE production as well as elevated Th2 cytokines. Moreover, DCs 
isolated from Treg depleted mice showed increase capability to stimulate T 
cell proliferation and Th2 cytokine production (130). 
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Induction of Treg responses is a key component of asthma 
immunotherapy. This involves the administration of increasing doses of the 
allergen to induce a state of immunological tolerance to that particular allergen. 
Also, treatment with corticosteroids had been found to result in increased Treg 
activity, particularly when used in combination with vitamin D3 (87, 127). 
However, there remains many unknown questions with regards to the 
conditions necessary to generate these Tregs and why is it that immunotherapy 
only successfully generate a regulatory response in some patients but not 
others. The actual mechanisms by which these cells suppress the allergic 
response also remain to be fully elucidated, although IL-10 appears to be a key 
effector in this aspect (131-136). Being able to understand these mechanisms 
would contribute greatly to the success of treatment for asthma.  
1.2.2.2 CD8 T cells in allergic asthma 
CD8 T cells are cytotoxic T cells that recognize and kill cells presenting 
the antigenic peptide in the context of class I MHC. Like CD4 T cells, CD8 T 
cells had been demonstrated to form functionally distinct subsets (137, 138). 
Predominantly, CD8 T cells are Tc1 polarized and produced large quantities 
of IFNγ. However, under the appropriate polarizing conditions, CD8 T cells 
can be induced to produce IL-4 (139). These Tc2 polarized CD8 T cells have 
been identified in biopsies from asthma patients and are believed to contribute 
to asthma pathology (140). 
In rats, the depletion of CD8 T cells using anti-CD8 antibodies resulted in 
increased AHR and increased eosinophil infiltration into the lung (141). It was 
also found that the depletion of CD8 T cells in rats prior to antigen challenge 
resulted in increased airway remodeling (142). Adoptive transfer of Tc2 
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polarized OT-I CD8 T cells induced eosinophilia and AHR in mice. In 
contrast, the transfer of Tc1 polarized OT-I CD8 T cells produced a 
neutrophilic airway inflammatory response but no AHR (143). OT-I CD8 T 
cells adoptively transferred into mice prior to OVA challenge exhibited a Tc1 
phenotype in the lung and suppressed eosinophilia and IgE production in an 
IL-12 dependent manner (144). Wong et al, 2008, demonstrated that CD8 T 
cells were able to prime CD8α+ DCs to produce IL-12 via a combination of 
secreted IFNγ and CD40-CD40L interactions (145). Using IFNγ knockout 
OT-I mice, Tang et al (2012) was able to show that the ability of CD8 T cells 
to suppress Th2 inflammation was dependent on IFNγ. Without the ability to 
produce IFNγ, CD8 T cells displayed a Tc2/Tc17 phenotype and potentiated 
allergic lung inflammation (146). A second study identified perforin as a key 
mediator in the ability of CD8 T cells to suppress allergic airway 
inflammation. In this study, IFNγ competent but perforin-deficient CD8 T 
cells were unable to suppress eosinophilia or mucus production in the OVA 
model of asthma. In this context, it was suggested that the CD8 T cells directly 
kill antigen-carrying DCs, preventing the elicitation of an immune response to 
the allergen. (147). 
However, several other studies also present contrasting observations, 
suggesting that CD8 T cells, rather than suppress allergic asthma, may actually 
contribute to disease pathology. Miyahara et al, 2004, demonstrated that CD8 
gene knockout mice developed significantly lower AHR compared to wild 
type following OVA sensitization and challenge (148). WT mice also had a 
greater degree of eosinophilia than CD8 knockout mice. This could be 
restored by the adoptive transfer of wild type CD8 T cells but not IL-13 
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deficient CD8 T cells, suggesting a role for CD8 T cell secreted IL-13. Other 
studies using OVA or cockroach antigen (CRA) showed that CD8 T cells from 
sensitized mice exhibited a Tc2 phenotype and produced Il-4, IL-5 and IL-13 
following antigen challenge (149, 150). 
Therefore, while it seems clear that CD8 T cells can play a role in the 
pathogenesis of allergic asthma, the finding are inconclusive. Conflicting 
reports suggest roles for CD8 T cells in attenuation and in exacerbation of 
allergic Th2 inflammation. Possibly, these difference in observations exist as a 
result of the differences in allergen sensitization models used by the different 
groups. It is also worth mentioning that most of these studies were performed 
on the OVA model, using a surrogate allergen that is not a natural respiratory 
allergen.  
1.2.2.3 The humoral response in allergic asthma 
B cells mediate the humoral response. Naïve B cells express IgD and IgM 
on their cell surface. Upon binding of the surface antibodies to their cognate 
antigen, B cells undergo affinity maturation and class switching to become 
plasma cells secreting high affinity antibodies designed to neutralize the 
antigen. B cell class switching to IgE  is dependent upon IL-4 and CD40-
CD40L interaction with CD4 T helper cells. To facilitate this, B cells 
internalize the antigen bound to their surface receptor and process the antigen 
for presentation on their class II MHC receptors.  
IgE production is a key feature of asthma and the antibody plays a crucial 
role in perpetuation of the allergic inflammation response. Mast cells and 
basophils express the high affinity IgE receptor FcεR1 and cross-linking of 
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these receptor by antigen binding to the IgE can induce degranulation and 
release of various inflammatory mediators by these cells (151). 
Omalizumab, a monoclonal antibody that binds free IgE and reduces IgE 
binding to its cellular receptor is currently under trial for the treatment of 
allergic asthma. Treatment with this antibody resulted in decreased airway 
eosinophilia and exacerbation frequency in some asthma patients. However, 
its effect on FEV1 and AHR appears to be minimal (152).  
1.3 Asthma allergens 
An allergen is defined as a usually harmless substance that was able to 
trigger an immune response leading to an allergic response. Exposure to the 
allergen can induce symptoms of immediate hypersensitivity such as sneezing, 
coughing, itching and rashes. Repeated exposure may trigger chronic 
inflammatory responses leading to long-term damage.  
A large number of asthma allergens had been identified. These originate 
from a wide range of sources such as animal dander, pollen, plants and insects. 
There exists a degree of cross-reactivity between related allergens. In short, 
allergens may induce IgE responses that could recognize structurally similar 
allergens from other sources (examples of which are reported in (153-155)). 
Cross reactivity may also result in a development of a completely different 
form of allergy. Bet V1, an allergen found in birch pollen, contains epitopes 
that could also be found in food plants such as celery, carrot and chestnuts 
(156, 157). Subjects with hay fever and pollen sensitivity often develop oral 
allergy symptoms after ingesting food containing cross-reactive epitopes (158). 
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1.3.1 The mite allergens 
Mites are one of the most common sources of allergens. Mites are 
grouped in the taxonomical subclass of Ascari. Domestic mites such as the 
dust mites (Dermatophagoides pteronyssinus or Dermatophagoides farinae) 
or storage mites (Blomia tropicalis) are the most common sources of mite 
allergens linked with allergic asthma. Allergy to house dust mite affects more 
than 15-20% of the total population in industrialized countries (159). 
Generally, the house dust mite (Dermatophagoides pteronyssinus) is the 
predominant source of mite allergen in temperate regions, while in tropical 
climes; sensitization to Blomia tropicalis is also common. In Singapore, 
Dermatophagoides pteronyssinus and Blomia tropicalis are the most common 
sources of mite allergens (160, 161). Allergens from Blomia tropicalis had 
been shown to have only low to moderate cross-reactivity to antibodies against 
allergens from Dermatophagoides pteronyssinus, suggesting that these mites 
should be considered separate and distinct sources of mite allergens (162). 
Mite allergens are often components of the mites themselves or their fecal 
pellets (163-165). Mites excrete their fecal pellets in balls containing food, 
debris and proteolytic enzymes bound together by mucus and covered in a 
chitinous peritrophic membrane. Many mite allergens are digestive enzymes 
such as cysteine proteases, serine proteases or amylases.  
Mite allergens can be divided into groups based on sequence homology. 
For example, Der p 1 (from Dermatophagoides pteronyssinus), Der f 1 (from 
Dermatophagoides farinae) and Eur m 1 (from Euroglyphus maynei) had 
sequence homology of about 80% and are grouped under Group 1 mite 
allergens. Group 1 allergens have been shown to function as cysteine 
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proteases. The biochemical nature of some house mite allergens is listed in 
Figure 1.2. 
 
Allergen Biological function 
Group 1 Cysteine protease (papain-like) 
Group 2 MD 2-related lipid recognition domain 
Group 3 Trypsin (serine protease) 
Group 4 α-amylase 
Group 5 unknown, moderately cross reactive with 
Group 21 
Group 6 Chymotrypsin (serine protease) 
Group 7 Lipid binding protein 
Group 8 Glutathione S-transferase 
Group 9 Collagenolytic serine protease 
Group 10 Tropomyosin 
Group 11 Paramyosin 
Group 12 Chitinase 
Group 13 Lipid transporter 
Group 14 Apolipophorin 
Group 15 Chitinase 
Group 16 Unknown 
Group 17 Unknown 
Group 18 Chitinase 
Group 20 Arginine kinase 
Group 21 unknown, moderately cross reactive with 
Group 5 
Group 22 Unknown 
Group 23 Unknown 
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1.3.2 Mite allergens and the immune system 
Mite allergens were initially identified on the basis of their ability to elicit 
IgE responses. For Dermatophagoides pteronyssinus, group 1 and group 2 
allergens account for approximately 50% of IgE binding in allergic patients 
while Der p 4,5, and 7 account for a further 30% (167). The other groups 
showed relatively low IgE binding capacity. For Blomia tropicalis, IgE 
responses were predominantly directed against Blo t 5 (21%) and its paralogue 
Blot 21 (36.2%) as well as Blo t 7 (18.1%) (168, 169).  
Mite allergens are not passive antigens but had been demonstrated to 
actively elicit innate immune responses. A key part of the ability of mite 
allergens to activate the immune system lies with the protease activity of some 
mite allergens. Der p 1, a group 1 cysteine protease allergen from 
Dermatophagoides pteronyssinus, is particularly well studied. Der p 1 had 
been shown to disrupt the lung epithelial barrier function via the proteolytic 
cleavage of tight junctions (170). This facilitates the permeability of the 
bronchial epithelium and possibly allows access to the DCs in the 
subepithelial tissues. Der p 1 (and Der f 1) were also shown to inactivate lung 
surfactant proteins A and D (171). In vitro studies had demonstrated the ability 
of Der p 1 to cleave a number of biologically significant molecules such as 
CD40, CD25 and DC-SIGN which could modify the immune response in 
favor of a Th2 inflammatory response (159). Importantly, protease activated 
receptors (PARs) can be activated by the cleavage of their N terminus by 
serine proteases. PAR-2 activation by Der p 3 and Der p 9 lead to the secretion 
of GM-CSF, eotaxin, IL-6 and IL-8 from cultured epithelial cells. Der p 1, too, 
was shown to induce IL-6 and IL-8 release from airway epithelial cells, 
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although the involvement of PAR-2 in this case is less clear (159). Proteases 
were also observed to elicit TSLP production from airway epithelial cells 
(172). TSLP is a key player in the induction of a Th2 inflammatory response. 
Other than the lung, mite allergens have also been shown to activate the NOD-
like receptor family, pyrin domain containing-3 (NLRP3) inflammasome in 
keratinocytes. HDM extract was found to activate caspase-1 and induced IL-
1b and IL-18 release from keratinocytes. This effect was shown to be 
dependent on cysteine protease activity (173). 
Chitin, a component of the mite exoskeleton and the fecal membrane 
could also stimulate the immune system via TLR2 (174). Der p 15 and Der p 
18 are chitinases and their close association with the PAMP may contribute to 
their allergenicity. 
The ability of Der p 2 to influence TLR4 signaling added a whole new 
dimension to our understanding of the ability of mite allergens to induce 
allergic airway inflammation (175). Inhalation of antigens such as OVA, 
without the additional signaling through PRRs, would normally result in 
tolerance (26). The ability of Der p 2 to induce signaling through TLR4 
contributes to the ability of mite allergens to bypass tolerogenic mechanisms 
that normally predominate in the lung. 
However, it must be said that many of these studies with regards to the 
interaction between allergens and the immune cells were carried out in vitro. 
In vivo studies of the interactions between allergens and the immune system 
are limited by the availability of tools. The lack of reagents such as MHC 
tetramers or TCR transgenic mice meant that OVA specific responses were 
still commonly used as readout. For example, Moldaver et al, 2014 used 
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OVA-specific responses as a read-out following Der p 1 peptide 
immunotherapy (176). This engenders a complex prime-boost protocol that 
mixed multiple administrations of OVA, HDM and Der p 1 peptides. The 
complexity of such protocols and the indirect read-outs may indirectly affect 
the outcome.  
Compared to HDM, even less is known about the Blomia tropicalis 
allergens. Unlike Dermatophagoides pteronyssinus, the major allergens for 
Blomia tropicalis are not the group 1 or group 2 allergens but rather Blo t 5 
and its paralogue Blo t 21. The role of the Blomia tropicalis allergens in the 
elicitation of allergic airway inflammation is not well understood. Considering 
the importance of Blomia tropicalis as a major source of asthma allergens in 
the tropical regions, there is a need for more and better tools for which to 
study the responses to these allergens.  
Clearly, mite allergens differ significantly from the model allergen 
ovalbumin. Mite allergens possess the ability to elicit and modify the immune 
response to favor a Th2 allergic inflammatory response and understanding the 
nature of these allergens is key to understanding the development of asthma. 
1.4 Aims of the study 
Work done in our laboratory and by other groups indicated that there may 
be a role played by CD8 T cells in allergic asthma inflammation. In our hands, 
OVA specific CD8 T cells were able to attenuate the allergic inflammatory 
response in a IFNγ mediated manner.  
However, most in vivo studies of allergic asthma were still performed in 
the OVA sensitization and challenge model. While observations had shown 
that this model produced an inflammatory response similar to that observed in 
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human asthma, this model does not take into account the nature of the asthma 
allergen itself. What is increasingly clear is that asthma allergens are distinctly 
different in nature from ovalbumin. Through a combination of protease 
activity and molecular mimicry, house dust mite allergens were able to bypass 
the tolerogenic mechanisms of the lung and directly influence a Th2 
inflammatory response. The ability of natural allergens to modify the innate 
immune response allude to the possibility that the observations made in the 
OVA model of asthma may not be entirely applicable to asthma induced by 
these allergens. Therefore, there is a need for an asthma model based on real 
aeroallergens.  
There is a lack of tools to study T cells in allergic asthma inflammation in 
the HDM model. In the OVA model, the use of TCR transgenic mice like OT-
I and OT-II greatly facilitated studies of the role of T cells in allergic 
inflammation. To facilitate a greater understanding in the role of CD8 T cells 
in asthma, we believe that tools such as TCR transgenic mice and class I MHC 
tetramers are invaluable. TCR transgenic mice are a valuable source of T cells 
for adoptive transfer studies and can be crossed to produce strains with useful 
features such as T cells specific for mite allergens with IFNγ-/- phenotype. 
Class I MHC tetramers would greatly facilitate the tracking of allergen 
specific CD8 T cells during allergic airway inflammation. Unlike functional 
assays such as intracellular cytokine staining, class I MHC tetramers are able 
to stain both responding and non-responding cells and are less prone to 
underestimate the number of cells present. 
In this project, we propose the generation of a TCR transgenic mouse 
with CD8 T cells recognizing house dust mite allergens. There exists only a 
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single known murine class I MHC epitope for house dust mite; the 
FGISNYCQI epitope from Der p 1 (177). Using a DNA immunization 
strategy, we were able to induce a CD8 T cell response to this peptide. These 
T cells were then cultured in vitro to clonality. The TCR genes were identified 
and cloned into cassette vector for microinjection to generate CD8 T cell 
transgenic mice with TCR specificity for Der p 1. In addition, we also carried 
out some preliminary adoptive transfer experiments to explore the role played 
by these CD8 T cells in allergic asthma inflammation. To assist in tracking 
these cells, we produced class I MHC tetramers capable of staining CD8 T 
cells specific for Der p 1. 
We also explored the possibility of producing TCR transgenic mice with 
CD8 T cells recognizing other mite allergens. We screened for class I MHC 
epitopes in Blo t 5 and Der p 2. Unfortunately, we did not identify any class I 
MHC epitopes for these allergens.  
As the allergens from Blomia tropicalis are very much less studied than 
those from Dermatophagoides pteronyssinus, we proceeded to map and 
characterize class II MHC epitopes from a major Blomia tropicalis allergen, 
Blo t 5. We were able to identify novel epitopes in two mouse strains 
(C57BL/6 and BALB/C). We also showed that the T cells recognizing these 
epitopes were able to elicit an allergic airway inflammation following allergen 
exposure. 
Specific aims: 
1. Map T cell epitopes for Blo t 5 and Der p 2 
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2. Characterize the pulmonary T cell response to inhaled allergen (Blo t 
5) and explore the possibility of using synthetic peptides encoding T 
cell epitopes as a form of immunotherapy. 
3. Characterize and clone TCR genes of Der p 1-specific CD8 T cells for 
the production of TCR transgenic mice 
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Chapter 2. Materials and Methods 
 
 
2.1  Media and buffers 
2.1.1 PBS buffer 
PBS is purchased from 1st BASE (Singapore) as a 10x stock that contains 
137mM NaCl, 2.7mM KCl and 10mM phosphate buffer at pH7.4. 1x working 
solution of PBS is made by diluting the stock with 9 parts distilled water.  
2.1.2 MACS buffer 
MACS buffer contains 2% FBS and 5mM EDTA in 1x sterile PBS. The 
pH of the buffer was adjusted to fall within pH 7.2-7.4. The buffer is stored at 
4°C. 
2.1.3 FACS buffer 
 FACS buffer consists of 1x PBS supplemented with 1% FBS and 5mM 
EDTA. As the buffer is stored and used under non-sterile conditions, 0.05% 
sodium azide was added as a preservative. The pH of the buffer was adjusted 
to fall within pH 7.2-7.4. Although this concentration of sodium azide is not 
known to be toxic to cells, it may inhibit the metabolic functions of cells and 
hence FACS buffer cannot be substituted in place of MACS buffer during the 
process of cell isolation or preparation should the cells be used in a 
downstream functional assay or for culture. The buffer is stored at 4°C. 
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2.1.4 Red Blood cell  (RBC) lysis solution 
A 10x stock of the RBC lysis solution is made by dissolving the following 
in 100ml of water: 
a) Ammonium chloride        8.3g 
b) Sodium Bicarbonate         0.84g 
c) EDTA                               0.03g 
The pH of the RBC lysis solution is adjusted to pH7.2-7.4, adjusted to a final 
volume of 100ml and sterilized by filtering through a 0.22µm membrane. The 
working 1x concentration of the RBC lysis solution can be made by diluting 1 
part of the 10x stock solution with 9 parts of sterile distilled water. 
2.1.5 Complete RPMI for cell culture 
Complete RPMI consists of RPMI-1640 with L-glutamine from (Gibco, Life 
Technologies, Singapore) supplemented with the following: 
a) 10% v/v heat inactivated FBS (Biowest, Sciencewerke Pte. Ltd., 
Singapore). Heat inactivation degrades complement proteins that 
may interfere with immunological assays and is performed by 
heating the serum at 56°C for 30min with periodic (every 5-10min) 
agitation to distribute the heat throughout the serum.  
b) 1% v/v non-essential amino acids (Sigma-Aldrich, Singapore) from 
100x stock solution 
c) 1mM sodium pyruvate (Sigma-Aldrich, Singapore) 
d) 100 IU/ml penicillin and 0.1mg/ml streptomycin (Sigma-Aldrich, 
Singapore); 
e) 50µM β-mercaptoethanol (Sigma-Aldrich, Singapore). 
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The complete RPMI medium can be stored at 4°C for up to a month. 
2.1.6 Buffers for ELISA 
ELISA wash buffer: 1x PBS with 0.5% v/v Tween-20. pH was adjusted to 
7.2-7.4. 
ELISA blocking buffer: 1x PBS supplemented with 1% v/v BSA. 
2.1.7 LB broth 
LB broth, Miller (Novagen, Millipore, Singapore) contains 5g yeast extract, 
10g peptone from casein and 10g sodium chloride per liter. 10g of the 
granulated LB broth medium were dissolved in 400ml water and autoclaved to 
sterilize. Antibiotics, if required, were added after allowing the broth to cool 
sufficiently. For LB broth with ampicillin (LB-Amp), 100µg/ml of ampicillin 
was added. For LB broth with kanamycin (LB-Kan), 50µg/ml of kanamycin 
was added. 
2.1.8 LB agar 
10g of LB broth medium and 6g of Bacto agar (BD, Singapore) were 
dissolved in 400ml water and autoclaved to sterilize. Antibiotics were added 
after the agar was allowed to cool sufficiently, but before the agar begins to set.  
2.1.9 CaCl2 solution for preparation of competent cells 
Contains 60mM CaCl2, 15% glycerol and 10mM piperazine-N,N’-bis(2-
hydroxypropanesulfonic acid (PIPES). Adjust pH to 7 and filter sterilize.  
2.1.10 SDS-PAGE gel electrophoresis buffers 
4x resolving gel buffer: 91g Tris was dissolved in water and the pH adjusted 
to 8.8. Top up with water to 480ml and add 20ml of 4% SDS (1st BASE, 
Singapore). 
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4x stacking gel buffer: 6.05g Tris was dissolved in water and adjusted to 
pH6.8. Top up with water to 96ml and add 4ml of 10% SDS. 
4x SDS-PAGE sample buffer: Contains 40% glycerol, 240mM Tris/HCL 
pH6.8, 8% SDS, 0.04% bromophenol blue and 5% β-mercaptoethanol. Top up 
with water and store in aliquots at -20°C. 
5x SDS/Glycine electrophoresis running buffer: Dissolve 15.1g Tris, 72g 
glycine and 5g SDS in 1L of water. 
Coomassie brilliant blue stain: Stain contains 0.5g Coomassie brilliant blue 
R-250, 40% methanol and 10% acetic acid in 1L. Top up with water. 
2.1.11 Buffers for protein purification from E.coli 
Solution buffer: Contains 50mM Tris-HCL, 25% sucrose, 1mM EDTA and 
0.1% sodium azide in final volume. Adjust pH to 8 and top up with water. 
Lysis buffer: Contains 50mM Tris-HCL, 100mM sodium chloride, 1% Triton 
X-100 and 1mM sodium EDTA. Adjust pH to 8 and top up with water. 
Washing buffer: Contains 50mM Tris-HCL, 100mM sodium chloride, 1mM 
sodium EDTA and 0.1% sodium azide. Adjust pH to 8 and top up with water. 
Washing buffer with Triton: Add 0.5% Triton X-100 to washing buffer 
components above. Adjust pH to 8 and top up with water. 
Inclusion body solubilization buffer: Contains 8M urea, 25mM MES, 10mM 
EDTA and 0.1mM DTT. Adjust pH to 6 and top up with water.  
2.1.12 Buffers for protein refolding and purification 
Refolding buffer: Contains 100mM Tris, 400mM L-arginine-HCL and 2mM 
EDTA. Adjust pH to 8 and top up with water. 
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Injection buffer: Contains 3M guanidine-HCL, 10mM sodium acetate and 
10mM EDTA. Adjust pH to 4.2 and top up with water. 
Tris buffer: Contains 20mM Tris-HCL and 50mM sodium chloride. Adjust 
pH to 8 and top up with water. 
2.2  List of antibodies used 
Target Host Clone Conjugate Source 
CD3e Rat 17A2 eFlour450 eBioscience 
Hamster 145-
2C11 
AF488 BD Pharmingen 
CD4 Rat RM4-5 PB BD Pharmingen 
Rat RM4-5 PE BD Pharmingen 
CD8α Rat  53-6.7 APC eBioscience 
Rat  53-6.7 PE-Cy7 eBioscience 
Rat  53-6.7 AF488 eBioscience 
CD11c Hamster N418 PerCP-Cy5.5 eBioscience 
CD16/32 Rat 2.4G2 None Biolegend 
CD44 Rat IM7 APC BD Pharmingen 






FITC BD Pharmingen 
IFN-γ Rat XMG1.2 AF647 BD Pharmingen 
Rat  XMG1.2 PE BD Pharmingen 
Rat  XMG1.2 FITC BD Pharmingen 
IL-2 Rat JES6-
5H4 
FITC BD Pharmingen 
IL-4 Rat 11B11 BV421 Biolegend 
IL-5 Rat TRFK5 APC BD Pharmingen 
IL-10 Rat JES5-
16E3 




Ly6G Rat 1A8 AF647 Biolegend 
Siglet F Rat E50-
2440 
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2.3  Mice 
Wild type C57BL/6 and BALB/c mice used in these studies were 
purchased from the Centre for Animal Resources (CARE), an animal breeding 
facility under the management of the National University of Singapore (NUS). 
Mice are housed under specific pathogen-free conditions in the NUS Centre 
for Comparative Medicine. All experiments are conducted in accordance with 
the institutional guidelines and with approval from the NUS Institutional 
Animal Care and Use Committee (IACUC) under the protocol number 029/09.  
2.4  Molecular biology protocols 
2.4.1 Preparation of chemically competent E.coli  
Three strains of E.coli were used in this study. E.coli DH5α, which contains 
an endA1 mutation that inactivates an intracellular endonuclease, was 
generally used for most purposes, especially in the expansion of plasmids for 
purification. E.coli BL21(DE3) is used for protein expression. During 
subcloning using TOPO 2.1 TA cloning vectors, E.coli TOP 10 cells were 
used as these would permit selection of insert-containing vectors by 
blue/white colony selection on 5-bromo-4-chloro-3-indoyl-β -D-
galactopyranosidase (X-gal) containing plates. The transformation procedure 
is identical for all 3 strains used. 
a) E.coli cells were inoculated into 50ml of B medium without antibiotics.  
b) The culture was grown overnight at 37°C with shaking. 
c) 4ml of the overnight culture was inoculated into 400ml of LB in a 2-liter 
baffled flask.  
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d) The culture was grown at 37°C with shaking until the density reaches 
OD600=0.4. 
e) The culture was then aliquoted into 50ml volumes in pre-chilled sterile 
50ml polypropylene centrifuge tubes and chilled on ice for 10 min. Cells 
must be kept chilled for the subsequent steps. 
f) Cells were pelleted at 1600g/7min/4°C without brakes. 
g) The pellet was gently resuspended in 10ml ice cold CaCl2 solution.  
h) Cells were pelleted at 1600g/7min/4°C without brakes. 
i) The pellet was then resuspended gently in 10ml ice-cold CaCl2 solution.  
j) The cell suspension was kept on ice for 30min. 
k) Cells were pelleted at 1100g/5min/4°C without brakes. 
l) Bacteria pellet was resuspended in 2ml ice-cold CaCl2 solution. Leave 
pellet on ice for 2 hours. 
m) 100µl aliquots of competent cells were distributed into pre-chilled sterile 
1.7ml microfuge tubes and frozen immediately at -80°C. Each aliquot can 
only be thawed once and will lose competency if refrozen. 
2.4.2 Transformation of E.coli  
a) Competent cells were thawed on ice. 
b) 50-100ng of plasmid DNA were added to 50µl of thawed competent cell 
and mixed gently. Do not vortex. 
c) Plasmid DNA was incubated on ice with competent cells for 30min. 
d) Competent cells were next subjected to a heat shock for 45seconds at 42°C 
in a water bath. Cells were then returned to the ice immediately and left for 
5 minutes. 
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e) 550µl LB medium without antibiotics was added to competent cells and 
cultured for 30min at 37°C with shaking. 
f)  Cells were centrifuged at 4000g/2min/room temperature (RT) and the 
most of the supernatant discarded. 
g) Plate bacteria onto LB agar plates with the appropriate selective antibiotic 
and incubate overnight at 37°C. 
2.4.3 General PCR protocol 
For PCR gene cloning, we used the expand High Fidelity system from 
Roche, Singapore. This contains a blend of Taq DNA polymerase with another 
DNA polymerase with proofreading activity for greater fidelity. This reduces 
the possibility of PCR induced mutations in the product. 
a) The final PCR mix contains the following: 
• 10x PCR buffer with 15mM MgCl2 – 1 x  
• 10mM dNTP mix – 200µM of each dNTP 
• DMSO – 5%  
• Forward primer – 300nM 
• Reverse primer – 300nM 
• Template – 1-10ng 
• Taq polymerase (added last) – 2.6 units/reaction 
• Water – to make up to 50µl 
b) The PCR cycle used was as follows 
a. 94°C for 2min 
b. 25-28 cycles of 
i. 94°C for 15sec 
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ii. 55-60°C for 30sec (depending on primer annealing 
temperature) 
iii. 72°C for 45-60sec (depending on product length based on 
the manufacturer recommendations). 
c. 72°C for 7min 
d. 4°C hold 
For colony screening to identify bacterial colony containing the plasmid with 
the gene of interest, we used the Promega GoTaq Green Mastermix (Promega, 
Singapore). The reagent contains Taq polymerase, dNTPs and optimally 
adjusted buffers pre-mixed in a ready-to-use solution, which also allows for 
direct loading into agarose gels. 
a) First, a colony of bacteria was picked from the selective agar plate using a 
sterile yellow pipette tip. 
b) The bacterial colony was emulsified into 5µl of sterile distilled water and 
the tip was next transferred into 5ml of LB with selection antibiotic for 
culture. PCR positive colonies will then be subject to plasmid miniprep to 
extract the plasmid containing the gene of interest. An aliquot of the 
bacterial culture can be frozen down with 10% DMSO at -80°C as stock 
for future cultures. 
c) The final PCR mix contains the following: 
• 2x GoTaq Green Mastermix – 1 x  
• Forward primer – 300nM 
• Reverse primer – 300nM 
• Bacterial emulsion in water - 5µl 
• Water – to make up the desired final volume 
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d) The PCR cycle is as follows 
a. 94°C for 2min 
b. 25-28 cycles of 
i. 94°C for 15sec 
ii. 55-60°C for 30sec (depending on primer annealing 
temperature) 
iii. 72°C for 60sec  
c. 72°C for 5min 
d. 4°C hold 
2.4.4 Agarose gel extraction 
The QIAquick Gel extraction kit (Promega, Singapore) was used to extract 
DNA of interest following agarose gel electrophoresis. The procedure was 
carried out in accordance to the manufacturer’s instruction. 
2.4.5 Subcloning into TOPO vector by TA cloning 
Subcloning of PCR product into the pCR2.1-TOPO (Life Technologies, 
Singapore) vector allows for the expansion of the PCR product as well as 
verification of fidelity by sequencing prior to cloning into the final vector. 
Restriction enzyme digestion of genes subcloned into an intermediate vector 
such as the TOPO vector is also more efficient that direct digestion of PCR 
products. 
a) E.coli TOP10 chemically competent cells were thawed on ice. 
b) The TOPO TA cloning reaction mixture was assembled as follows: 
• Gel extracted PCR product – 4µl  
• Salt solution – 1µl 
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• TOPO vector – 1µl 
c)  The mixture was incubated at room temperature for 5min. 
d) 3µl of TOPO TA cloning reaction was mixed with the chemically 
competent E.coli TOP10. 
e) Cells were kept on ice for 30min. 
f) Competent cells were next subjected to a heat shock for 45seconds at 42°C 
in a water bath. Cells were then returned to the ice immediately and left for 
5 minutes. 
g) 550µl LB medium without antibiotics was added to competent cells and 
cultured for 30min at 37°C with shaking. 
h) Agar plate containing either kanamycin 50µg/ml or ampicillin 100µg/ml 
was dried and 40µl of 50mg/ml X-gal solution in dimethylformamide was 
spread onto each plate and allowed to absorb onto plate. 
i) Cells were pelleted at 4000g/2min/RT and most of the supernatant 
discarded. 
j) The bacteria were plated onto agar plate using a glass spreader. 
k) Plates were incubated at 37ºC overnight. 
 
Successful transformation was indicated by survival on kanamycin or 
ampicillin (pCR-TOPO 2.1 vector has resistance genes to both antibiotics). 
Blue-white selection using x-gal allows for selection of bacteria that had been 
transformed by a plasmid containing the inserted gene (disruption of the β -
galactosidase gene by insertion of gene of interest resulting in white/light blue 
instead of dark blue colonies). 
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2.4.6 Plasmid miniprep 
Plasmid DNA was extracted using the QIAprep spin miniprep kit (Qiagen, 
Singapore). The procedure was carried out in accordance to the 
manufacturer’s instruction. 
• Modifications for low copy number plasmids such as pTα and pTβ. 
• In step (a), a 10ml of overnight culture in LB medium was 
made instead of 5ml. 
• The volume of buffers P1, P2 and P3 used was doubled. 
• The entire volume of the lysate from the 10ml bacterial culture 
was loaded onto a single QIAprep column. If the volume of the 
plasmid containing lysate is more than 800µl, repeat the 
plasmid binding step (g-h).  
• For large plasmids (>10kb) such as pTα and pTβ, the distilled water was 
pre-warmed to 70ºC prior to elution to improve the yield. 
2.4.7 Restriction enzyme digest 
Restriction enzymes used in this study: 
Restriction enzyme Source Restriction site 
Bam HI New England 
Biolabs (NEB) 
GGATCC 
BspHI NEB TCATGA 
HindIII NEB AAGCTT 
KpnI NEB GGTACC 
NcoI NEB CCATGG 
NotI NEB GCGGCCGC 
SacII NEB CCGCGG 
SalI Promega GTCGAC 
XhoI NEB CTCGAG 
XmaI NEB CCCGGG 
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For a restriction enzyme double digest, the appropriate buffer was chosen as 
per manufacturer’s recommendations.  
a) Each reaction contains: 
• 10x restriction enzyme buffer – 1x  
• 100x BSA solution – 1x  
• Restriction enzymes – 1µl  (100-200 units)  
• Plasmid DNA – 1-10µg  
• Water – to make up to 50µl final volume 
b) Reaction was incubated at 37ºC for 2 hours. 
c) The reaction was terminated by heat inactivation at 65ºC for 20min. 
For SalI and XhoI, due to the lack of a compatible buffer, sequential digests 
were carried out instead of a single double digest reaction. Following 
digestion with the first restriction enzyme, the plasmid DNA was purified 
using the QIAprep PCR purification kit prior to digestion with the second 
enzyme. This was to remove the first enzyme and the salts present in the first 
buffer that may affect the second reaction, leading to star activity. 
2.4.8 PCR purification 
The QIAquick PCR purification kit (Qiagen, Singapore) was used to 
purify product from a PCR reaction prior to sequencing. This removes primers, 
nucleotides, polymerases and salts that may affect any downstream reactions. 
Also, the kit was used during a sequential restriction digest to clean up 
plasmid DNA following the first digest. The procedure was carried out in 
accordance to the manufacturer’s instruction. 
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2.4.9 Ligation into plasmid vector 
DNA ligase catalyzes the formation of a phosphodiester bond between 
the 3’ hydroxyl and 5’ phosphate of adjacent DNA residues. This allows the 
joining of the gene of interest with the vector of choice following restriction 
enzyme digest to produce compatible ends.  
As a general rule, the ratio of insert to plasmid used is 3:1 although a 
higher ratio had been used on occasions when the ligation efficiency was 
found to be low. 
a) The ligation reaction contains the following: 
• 10x T4 DNA ligase buffer – 1x 
• Plasmid – 100ng 
• Insert – variable (depending on size) 
• T4 DNA ligase (Promega, Singapore) – 0.5µl 
• Water  - to make up 10µl final volume 
b) The ligation mix was incubated at 16ºC overnight. 
c) The mix was transformed into chemically competent E.coli DH5α cells as 
described previously and transformants were selected using the 
appropriate antibiotic. 
d) The colonies were screened by PCR with the appropriate primers to 
identify colonies carrying the gene of interest. 
2.4.10 RNA extraction and purification 
Messenger RNA (mRNA) from T cells was extracted for use in the 5’ 
RACE assay to identify the TCR chain usage of the T cell line. Extraction was 
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carried out using the RNeasy mini kit (Qiagen, Singapore). The procedure was 
carried out in accordance to the manufacturer’s instruction. 
Care must be taken to avoid RNase contamination that could degrade the 
mRNA. Also, do not freeze cell pellets for later extractions, as RNA content 
will degrade. Extraction should be carried out immediately for optimum 
mRNA quality.  
2.4.11 Reverse transcription of mRNA 
Reverse transcription reaction was performed using the Quantitect Reverse 
Transcription kit (Qiagen, Singapore). The procedure was carried out in 
accordance to the manufacturer’s instruction. 
2.4.12 5’ RACE reaction 
PCR amplification of a target gene requires the use of two sequence-specific 
primers that bind to the 5’ and 3’ ends of the target gene. However, this is not 
useful should the 5’ end of the sequence to be studied is unknown. Such is the 
case with TCR genes, where a variety of variable chains render it difficult if 
not impossible to prime the 5’ end of the gene. Gene specific primers were 
designed to prime the constant region of the TCR chain for the first strand 
cDNA synthesis reaction.. The enzyme terminal deoxynucleotidyl transferase 
(TdT) is used to add a homopolymeric tail to 3’ end of the first strand cDNA. 
Following this, a PCR reaction can be performed using a nested primer for the 
TCR C-region with an adapter primer recognizing the homopolymeric tail. 
First strand cDNA synthesis 
a) In 0.5ml tube or pCR tube (if using thermocycler). 
• Gene specific primer 1 – 10ng 
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• Sample RNA – 2µg 
• DEPC-treated water – up to final volume of 15.5µl. 
b) The reaction was incubated at 70°C for 10min to denature RNA. 
c) The reaction was then kept on ice for 1min. 
d) The first strand synthesis reaction was assembled in the following order: 
• 10x PCR buffer – 2.5µl 
• 25mM MgCl2 – 2.5µl 
• 10mµ dNTP mix – 1µl 
• 0.1M DTT – 2.5µl 
e) The reaction was incubated at 42°C for 1min. 
f) 1µl Superscript II RT was added. 
g) The reaction was incubated at 42°C for 50min. 
h) The reaction was terminated at 70°C for 15min. 
i) The reaction was incubated at 37°C. 
j) 1µl of RNase mix was added and mixed gently but thoroughly. 
k) The reaction was incubated at 37°C for 30min then transferred to ice. 
l) Procedure may be stopped here and sample kept at -20°C. 
cDNA purification by S.N.A.P column 
a) 120µl of room temperature binding solution was added to the first strand 
reaction. 
b) The mix was loaded into a SNAP column. 
c) The column was centrifuged at 13,000g/20s/RT. 
d) 400µl of cold 1x Wash buffer was added to the spin cartridge. 
e) The column was centrifuged at 13,000g/20s/RT. 
f) Wash was repeated 3 more times. 
  
	   CHAPTER	  2:	  MATERIALS	  AND	  METHODS	   	  	   	  
54 
g) Next, the cartridge was washed twice with cold 70% ethanol.  
h) After removing the ethanol for the last time, the column was centrifuged at 
13,000g for 1min to remove traces of ethanol. 
i) The spin cartridge was then transferred to a new recovery tube. 
j) 50µl of distilled water preheated to 65°C was added to the column 
membrane. 
k) cDNA was eluted by centrifugation at 13,000g/20s/RT. 
TdT tailing of cDNA 
a) The following reaction mix was prepared: 
• DEPC treated water – 6.5µl 
• 5X tailing buffer – 5µl 
• 2mM dCTP – 2.5µl 
• SNAP purified cDNA – 10µl 
b) The reaction was incubated at 94°C for 2-3min. 
c) The reaction was chilled on ice for 1min. 
d) 1µl of the TdT mix was added. 
e) Reaction was incubated at 37°C for 10min. 
f) The reaction was heat inactivated at 65°C for 10min. 
PCR of dC-tailed cDNA 
a) Thermocycler block was first equilibrated to 94°C, 
b) The following reaction mixture was prepared on ice: 
• Sterilized, distilled water – 31.5µl 
• 10x PCR buffer – 5µl 
• 25mM MgCl2 – 3µl 
• 10mM dNTP mix – 1µl 
• Nested Gene specific primer 2 (10µM) – 2µl 
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• Abridged anchor primer (10µM) – 2µl 
• dC-tailed cDNA – 5µl 
c) 0.5µl Taq DNA polymerase (5u/ml) was added just before mixing. 
d) The PCR cycle is as follow: 
a. 94°C for 2min 
b. 30-35 cycles of: 
i. 94°C for 1min 
ii. 55°C for 30sec 
iii. 72°C for 1min 
c. 72°C for 7min 
d. 4°C hold 
2.5  Protein expression and purification protocols 
2.5.1 SDS-PAGE gel electrophoresis 
o Stacking gel consists of: 
• 4x stacking gel buffer – 1x 
• 30% acrylamide/0.8% bisacrylamide – 4.5% 
• Water – as required 
• 10% (w/v) ammonium persulfate (APS) – 0.1% 
• N,N,N,N-tetramethylethylenediamine (TEMED) – 0.001% 
(added last) 
o Acrylamide content of resolving gel is variable depending on the size of 
the proteins assayed (12-15% used usually). The formulation is as follows: 
• 4x resolving gel buffer – 1x  
• 30% acrylamide/0.8% bisacrylamide – 12-15% 
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• Water – as required 
• APS – 0.05% 
• TEMED – 0.00075% 
a) Protein samples were mixed with 4x SDS-PAGE sample buffer and heated 
at 100°C for 3min before loading into wells. 
b) SDS-PAGE gel electrophoresis performed using the Mini PROTEAN tetra 
cell system (Bio-Rad, Singapore). 
c) Gels were stained with Coomassie brilliant blue stain and destained in 
water. 
2.5.2 Production of class I MHC tetramers 
The protocols below are identical for the expression and purification of both 
heavy and light chain proteins of the class I MHC. The heavy and light chain 
proteins were expressed in bacteria and refolded with a UV-labile peptide to 
produce class I MHC monomers (178-180). 
Induction of protein expression 
a) A single stab of bacteria stock containing the plasmid encoding the protein 
of interest was inoculated into 40ml of LB medium with the appropriate 
selection antibiotic.  
b) Culture was grown overnight at 37°C with shaking. 
c) 10ml of overnight starter culture was inoculated into 1L of LB medium 
with the selection antibiotic. 
d) Culture was grown at 37°C with shaking until OD600nm reading reaches 0.5. 
e) 1mM IPTG was added and the culture incubated for another 3 hours at 
37°C with shaking. 
f) Bacteria was pelleted by centrifugation at 4000g/30min/4°C. 
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g) Pellet was washed once with PBS and pelleted again at 4000g/30min/4°C. 
h) Pellet can be stored at -80°C. 
Isolation of class I MHC inclusion bodies 
a) Protein samples should be kept on ice or at 4°C at all times during 
purification process. 
b) Bacteria pellet was solubilized in 13ml solution buffer containing 
cOmplete EDTA-free Protease Inhibitor (Roche, Singapore) and 200µl 1M 
DTT. 
c) 1µl 1M MgCl2, 50µl 10mg/ml DNAse I, 100µl 50mg/ml lysozyme was 
added. 
d) The mixture was left on ice for 30min. 
e) 13ml of lysis buffer was added and the mixture incubated on ice for at 
least 15min. 
f) 10mM EDTA was added. 
g) The bacterial lysate was sonicated until the DNA clumps are broken up.  
h) The lysate was centrifuged at 15,000g/30min/4°C. 
i) The pellet was resupended in 10ml wash buffer with Triton and 1mM DTT 
and sonicated. 
j) The lysate was centrifuged at 15,000g/30min/4°C. 
k) The pellet was resupended in 10ml wash buffer without Triton and 1mM 
DTT and sonicated. 
l) The lysate was centrifuged at 15,000g/30min/4°C. 
m) The pellet was resuspended in inclusion body solubilization buffer and 
sonicated to break up the pellet. 
  
	   CHAPTER	  2:	  MATERIALS	  AND	  METHODS	   	  	   	  
58 
n) The inclusion body mixture was incubated overnight at 4°C with rocking 
to ensure complete solubilization of pellet. 
o) The lysate was centrifuged at 15,000g/30min/4°C. 
p) Supernatant containing the solubilized inclusion body proteins was 
collected. 
q) Protein concentration was measured with Bradford assay and the 
solubilized inclusion body proteins distributed into aliquots sufficient for a 
single protein refolding reaction.   
Refolding of class I MHC monomers 
a) Protein refolding should be carried out at 4°C at all times. 
b) The following was prepared: 
• Class I MHC heavy chains – 18.6mg 
• β2M (light chain) – 13.4mg 
• Chilled 200ml refolding buffer containing: 
— cOmplete Protease Inhibitor (Roche,Singapore) – 1 tablet 
— Oxidized glutathione (Sigma-Aldrich, Singapore) – 0.5mM 
— Reduced glutathione (Sigma-Aldrich, Singapore) – 5mM  
— Peptide – 12mg  
c) The heavy and light chains were divided into 3 separate aliquots and 500µl 
of injection buffer added to each. Store at -30°C. 
d) One portion of heavy and light chains were each injected into refolding 
buffer while gently agitated using a magnetic stirrer. Bubble formation 
should be avoided as this may increase protein aggregation. 
e) Heavy and light chain additions were repeated on following days.  
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f) One day after the final addition of heavy and light chains, precipitates 
were removed by centrifugation at 4000g/30min/4°C. 
g) The refolded class I MHC monomers were dialyzed into 20mM Tris buffer 
(pH8) without NaCl. NaCl with affect the efficiency of the downstream 
biotinylation reaction. 
Biotinylation of class I MHC monomers 
a) The following reaction mixture was assembled: 
• 50mM bicine (pH8.3) 
• 10mM ATP 
• 100mM MgOAc 
• 50µM d-biotin 
• 10nmol of up to 40µM class I MHC monomers to be 
biotinylated 
• 2.5µg biotin ligase enzyme  
b) The biotinylation reaction was allowed to proceed overnight at 4°C with 
gentle mixing. 
Purification of class I MHC monomers 
a) Biotinylated class I MHC monomers was dialyzed into 20mM Tris buffer 
(pH8) with 50mM NaCl. 
b) Class I MHC monomers were purified using a HiLoad 16/60 gel filtration 
column on an AKTA FPLC system (GE Life Sciences, Singapore). 
Tetramerization of class I MHC monomers 
Biotinylated class I MHC monomers can be tetramerized with a 
streptavidin moiety conjugated to a flourochrome for use in flow cytometry. 
The final ratio of monomer to streptavidin should be 4:1 as addition of too 
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much streptavidin could produce trimers or dimers with much lower avidity 
and hence result in suboptimal staining. Streptavidin should be added to class I 
MHC monomers in 5 separate additions an hour apart in order to allow for 
complete tetramerization. 
2.5.3 Production of recombinant Blo t 5 
Bacterial expression of Blo t 5 protein 
 The protocol for the expression of Blo t 5 in E.coli BL21 is identical to 
that for class I MHC proteins. 
Lysis of bacteria 
a) Protein samples should be kept on ice or at 4°C at all times during 
purification process. 
b) Bacteria pellet was solubilized in 13ml solution buffer containing 
cOmplete EDTA-free Protease Inhibitor (Roche, Singapore) and 200µl 1M 
DTT. 
c) 1µl 1M MgCl2, 50µl 10mg/ml DNAse I, 100µl 50mg/ml lysozyme were 
added. 
d) The mixture was left on ice for 30min. 
e) 13ml of lysis buffer was added and the mixture incubated on ice for at 
least 15min. 
f) 10mM EDTA was added. 
g) The bacterial lysate was sonicated until the DNA clumps are broken up.  
h) The lysate was centrifuged at 15,000g/30min/4°C. 
i) Unlike class I MHC proteins, Blo t 5 does not form inclusion bodies and 
are hence found in the bacterial lysate. 
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Ammonium sulfate precipitation of Blo t 5 protein from whole bacteria 
lysate 
Bacterial lysate contains many contaminating proteins and therefore it is not 
recommended to run the lysate immediately on FPLC purification columns. 
The lysate can be cleaned up by precipitating the proteins using increasing 
concentrations of ammonium sulfate and identifying the fraction containing 
the Blo t 5 protein. 
a) Sequentially precipitate the proteins from the whole bacteria lysate by 
adding increasing concentrations of saturated ammonium sulfate.  
b) 250µl saturated ammonium sulfate was added to 1ml of the cell lysate and 
mixed quickly to obtain 20 % saturation. Lysate was rotated at 4ºC for 
30min. The lysate was the centrifuged at 16,000g/15min/4ºC. 
c) The supernatant was transferred into a fresh 2ml microfuge tube. The 
pellet was resuspended in 500µl 50mM Tris pH8. Store at 4ºC. 
d) Steps (b) and (c) were repeated for to subject the lysate to incrementally 
higher saturations of ammonium sulfate, proceeding stepwise from 20% to 
40% then 50% and 60%. 
e) The fraction at 60% saturation gives the cleanest yield of Blo t 5. Usually, 
the samples from 50% and 60% saturation would be used in further 
purification steps. 
f) Fractions intended for use in downstream purification must be dialyzed in 
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Purification of recombinant Blo t 5 protein 
a) Fractions containing the Blo t 5 protein can be purified further using anion 
exchange chromatography. 
• Column: MonoQ 5/50GL 
• Running buffer: 50mM Tris (pH8) 
• Elution buffer: 50mM Tris (pH8) with 1M NaCl 
b) A linear gradient of 0-15% Buffer B was used to elute Blo t 5 protein from 
the column. 
c) The fractions corresponding to chromatogram peaks were analyzed on 
SDS-PAGE.  
d) A second round of purification based on size exclusion chromatography 
was carried out using a HiLoad 16/60 gel filtration column. 
e) The fractions corresponding to chromatogram peaks were analyzed on 
SDS-PAGE.  
f) Purified recombinant Blo t 5 proteins were aliquoted and stored at -20ºC 
until required. 
2.6 Cell isolation protocols 
2.6.1 Processing of splenic and lymph node cells 
a) Spleen or lymph nodes were disrupted by mashing and pushing the cells 
through a 70µm cell strainer to obtain a single cell suspension. 
b) Cells were pelleted at 450g/5min/4ºC.  
c) Cell pellet was washed once with cold MACS buffer. 
  
	   CHAPTER	  2:	  MATERIALS	  AND	  METHODS	   	  	   	  
63 
d) The cell pellet  was resuspended in MACS buffer and layered onto Ficoll-
Paque (GE Healthcare Life Sciences, Singapore) and centrifuged at 
600g/20min/RT without brakes. 
e) Cells found at the interface were collected and washed twice with cold 
MACS buffer. 
f) Cells can now be used for culture or assays such as ELISPOT or further 
purified by magnetic separation. 
2.6.2 Isolation of CD8 cells by magnetic separation 
a) Cells from the spleen or lymph nodes processed as described previously 
were mixed with 4µl anti-CD8α conjugated MACS beads per ten million 
cells (Miltenyi Biotec, Singapore). 
b) Cells were incubated at 4ºC for 30min with occasional agitation to 
resuspend the cells. 
c) Cells were washed once with cold MACS buffer and resuspended in 1ml 
MACS buffer. 
d) Cell suspension was loaded into an LS column (Miltenyi Biotec, 
Singapore) fitted onto a MACS separator magnet (Miltenyi Biotec, 
Singapore). The column was washed thrice with 3ml MACS buffer. Non-
magnetically labeled cells would be washed out of the column while 
magnetically labeled cells remain bound. 
e) The column was removed from the MACS separator magnet and the cells 
were eluted with 3ml of cRPMI medium using the plunger provided. 
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2.7 Cell culture 
2.7.1 T cell line production and maintenance 
Protocol for establishing a CD8 T cell line. 
a) The splenocytes from an immunized mouse were processed as described 
previously. 
b) Cells were resuspended in cRPMI medium. 
c) 100nM of antigenic peptide was added to the cell suspension. 
d) 2ml of the cell suspension were plated to each well of a 24-well cell 
culture plate.  
e) Cells were cultured at 37ºC with 5% CO2 for 6-7 days with constant 
monitoring. 
Restimulation and feeding of T cell line. 
a) Splenocytes were processed as described previously. 
b) 4µl anti-CD90.2 magnetic beads were added per 10 million cells. 
c) Cells were incubated at 4ºC for 30min with occasional agitation to 
resuspend the cells. 
d) Cells were washed once with cold MACS buffer and resuspended in 1ml 
MACS buffer. 
e) Cell suspension was loaded onto an LS column (Miltenyi Biotec, 
Singapore). The column was washed thrice with 3ml MACS buffer. 
f) The flowthrough, which contains T cell depleted splenocytes, was 
collected. 
g) Cells were pelleted and resuspended in cRPMI. 
h) The feeder cells were then irradiated at 3000rads. 
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i) The cells were washed once and resuspended in cRPMI. 
j) Cells were pulsed for 30min at 37ºC with 1µM antigenic peptide. 
k) Cells were washed and resuspended to 1x106 cells/ml in cRPMI. 
l) T cells from the T cell line were washed once and resuspended in pre-
warmed cRPMI to 1x106 cells/ml. 
m) 1ml of feeder cells and T cells were added to each well of a 24-well 
plate.10u/ml recombinant IL-2, 5ng/ml IL-7 and 5ng/ml IL-15 (Peprotech, 
USA) were also added to each well. 
n) Cells were cultured at 37ºC with 5% CO2 for 6-7 days with constant 
monitoring. Fresh IL-2 (10u/ml) was added every 2 days. 
2.7.2 Bone-marrow derived Dendritic Cells 
a) The femurs and tibia were excised from mice. 
b) The bone marrow cells were flushed out of the femur and tibia using 
cRPMI. 
c) A single cell suspension was produced by passing the cells through a cell 
strainer. Cells were centrifuged at 280g/10min/RT. 
d) 2ml red blood cell lysis solution was added to the pellet and allowed to 
stand for 1 minute at room temperature. cRPMI was then added and the 
cell suspension centrifuged at 280g/10min/RT. 
e) The bone marrow cells were washed twice with cRPMI. 
f) The bone marrow cells were resuspended to 1 x106 cells/ml in complete 
RPMI with 20ng/ml GM-CSF and plated at 2ml per well of a 12-well plate. 
g) The BMDC culture medium was replaced every 2 days with fresh medium 
with GM-CSF.  
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h) BMDCs can be harvested by Day 6-7 by gently pipetting medium over the 
adherent stroma to dislodge the aggregates of DCs. 
i) The dislodged cells were collected and centrifuged at 280g/10min/RT. 
Cells were resuspended in cRPMI (without GMCSF) to 1x106 cells/ml and 
cultured for 24 hours in 6-well cell culture plates. 
j) The non-adherent cells were collected. These are the non-proliferating, 
non-adherent maturing DCs. Macrophages would remain adherent. DCs 
may be initially adherent but would detach by 12-20hr. 
k) Staining: CD11c, MHC II and CD86. Mature DCs should show high MHC 
II and CD86 expression. 
2.8 Protocols for evaluation of cell functionality 
2.8.1 IFN-γ  ELISPOT 
The ELISPOT assay protocol used is adapted from protocols provided with 
the IFN-γ ELISPOT kit (BD, Singapore). 
Day 1: Coating of plates (STERILE). 
a) 15µl of 35% ethanol was dispensed into each well of a MutiScreenHTS-IP 
filter plate (Millipore, Singapore) to activate the PVDF membranes.  
b) The plate was washed 6 times with sterile water.  
c) Coating Antibody (BD,Singapore) diluted in sterile PBS was added 
according to manufacturer specifications.  
d) The plate was incubated overnight at 4ºC.  
Day 2: Loading of cells (STERILE) 
a) The plate was washed 6 times with sterile PBS. 
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b) The PVDF membranes were blocked by adding 100µl of cRPMI per well 
and incubating for at least 30 minutes. 
c) The cells and stimulus (peptides or mitogen) were added into each well. 
2x106 cells were added to each well. Final volume: 200µl.  
d) Plates were incubated at 37ºC / 5% CO2 overnight (about 20 hours). 
Ensure that plate is not moved during incubation as this may result in the 
shifting of the cells. 
Day 3: Developing of plate (NON STERILE) 
a) ELISPOT plate was washed 6 times with 200µl/well PBS. 
b) Detection Antibodies (BD,Singapore) were added according to 
manufacturer’s specification. 
c) Plate was incubated at room temperature for 2 hours. 
d) ELISPOT plate was washed 6 times with 200µl/well PBS. 
e) Streptavidin-AP (Mabtech, USA) was added according to manufacturer’s 
specification. 
f) Plate was incubated at room temperature for 1 hour. 
g) BCIP/NBT substrate (Mabtech, USA) was pre-warmed and filtered with 
41micron filter membrane before use. Keep in dark. 
h) ELISPOT plate was washed 6 times with 200µl/well PBS. 
i) 50µl/well BCIP/NBT substrate was added and the plate incubated at room 
temperature in dark.  
j) Following adequate spot development, the plate was washed with tap 
water. 
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2.8.2 ELISA 
Measurements of cytokines such as IL-4, IL-5, IL-10, IL-13, IL-17A and 
IFN-γ were performed using commercially available DuoSet ELISA kits 
(R&D Systems, USA). The procedure was carried out in accordance to the 
manufacturer’s instruction.  
2.8.3 3H-thymidine proliferation assay 
Assay preparation 
a) Cells with the appropriate antigen or mitogenic stimulus were cultured in a 
96-well cell culture plate for 48-72 hours (depending on proliferation rate) 
at 37ºC with 5% CO2. 
 
3H-thymidine pulse 
a) 1µCi of 3H-thymidine (Perkin-Elmer, Singapore) diluted in cRPMI were 
added to each well. 
b) Cells were incubated at 37ºC with 5% CO2. for approximately 16-18 hours. 
Harvest and measurement of proliferation 
a) Cells were harvested into a Unifilter plate (Perkin-Elmer,Singapore) using 
a cell harvester. 
b) 20µl of scintillation liquid (Perkin-Elmer,Singapore) was added to each 
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2.8.4 Chromium-51 release assay  
Preparation of target cells 
a) EL-4 cells are used as target cells in this assay. Cells should be freshly 
passaged and in good condition to minimize background. 
b) Target cells were washed once with warm cRPMI. 
c) 200µl of Cr51 radionuclide (1mCi/ml) were mixed with the cells. 
d) The cells were incubated with the radionuclide for 1 hour at 37ºC with 5% 
CO2. 
e) Target cells were washed twice with warm cRPMI and resuspended in 
cRPMI. 
f) Target cells with pulsed with the appropriate peptides for 30min at 37ºC 
with 5% CO2. 
g) Target cells were washed twice with warm cRPMI and resuspended in 
cRPMI to 5 x 104 cells/ml. 
Assay setup 
a) Target cells were cultured with effector cells at several effector:target 
ratios. 
b) Cells were incubated for 4-6 hours at 37ºC with 5% CO2. 
Harvesting and measurement of cytotoxicity 
a) 50µl of supernatant was harvested from each well into the corresponding 
well of a 96-well LumaPlate (Perkin-Elmer, Singapore). 
b) The LumaPlate was dried and read using a TopCount scintillation counter. 
c) Cytotoxic activity is calculated as follows: 
Cytotoxic activity =  (sample lysis – spontaneous lysis) 
                
                                                    (total lysis – spontaneous lysis 
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2.9 Flow cytometry 
2.9.1 Cell surface marker staining for flow cytometry 
a) Cells for FACs staining were pelleted by centrifugation at 400g/5min/4ºC 
in FACS tubes. The supernatant was discarded. 
b) The cell pellet was disrupted and Fc block antibodies (anti-CD16/CD32) 
were added at 0.1µg per million cells and incubated for 5min to prevent 
non-specific binding of antibodies to Fc receptors found on some cells. 
c) Fluorophore conjugated antibodies were then added (the quantity varied 
from 0.1-0.5µg per million cells depending on the intensity of antibody 
staining). Cells were then incubated at 4ºC in dark for 30min. 
d) Cells were washed twice in FACS buffer and fixed in 0.5ml 1% PFA. 
2.9.2 Intracellular cytokine staining for flow cytometry 
Stimulation of cytokine production 
a) Cells were cultured with either antigenic peptides pulsed APCs or a 
mitogen (phorbol myristate acetate, PMA at 10ng/ml with ionomycin at 
400ng/ml). 1:1000 fold dilution of Brefeldin A (BD Pharmingen, 
Singapore) and Golgi stop (containing monensin) (BD Pharmingen, 
Singapore) were added. Cells were cultured at 37ºC with 5% CO2 for 6 
hours. 
Surface staining of cells were carried out as described previously in 2.9.1. 
 
 
Permeabiilization and intracellular staining 
a) Cells were resuspended in 0.2ml fixation and permeabilization buffer 
(eBioscience, Singapore) and incubated at 4ºC for 1 hour. 
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b) Cells were washed twice with permeabilization buffer (eBioscience, 
Singapore). 
c) Flourophore conjugated antibodies against intracellular targets were then 
added at 1µg per million cells. 
d) Cells were stained at 4ºC for 1 hour. 
e) Cells were washed twice with permeabilization buffer. 
f) Cells were resuspended in 1% PFA and kept at 4ºC until analyzed. 
2.9.3 Peptide exchange and class I MHC tetramer staining 
Class I MHC tetramers were refolded with the UV-labile SV9-P7 
peptide. Cleavage of this peptide by UV irradiation in the presence of another 
peptide capable of binding to and stabilizing the class I MHC protein can 
produce class I MHC tetramers of a different specificity. This can then be used 
for staining of antigen specific CD8 T cells.  
a) For every 1µg class I MHC tetramer to be exchanged, 10ng of peptide to 
be exchanged was added. The peptides were mixed in gently on ice. 
b) The mixture was then exposed to UV irradiation at a wavelength longer or 
equal to 365nm. The use of lower wavelength UV radiation is not 
recommended, as it may be detrimental to the structure of the class I MHC 
protein. 
c) Following UV irradiation, the mixture was left on ice for 1 hour to allow 
for peptide exchange. 
d) The mixture was then centrifuged at 16,000g/10min/4ºC to pellet any 
precipitate that may contribute to background staining. 
e) For tetramer staining of CD8 T cells, 1µg of the class I MHC tetramer per 
million cells was used. 
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2.10   Intradermal immunization of mice with plasmid DNA by skin 
tattoo 
a) Mice were anaesthetized by intraperitoneal injection with a cocktail 
containing ketamine (7.5% v/v) and medetomidine (10% v/v) in normal 
saline. 
b) The fur of the left hind leg of the mice was removed by shaving followed 
by application of hair removal cream (VEET).  
c) 10µl of the plasmid DNA (2mg/ml) was applied to the site. 
d) Using an 11RL tattoo needle, the skin was tattooed at approximately 
100Hz with a needle depth of approximately 0.5mm for 20 seconds. 
e) Mice were revived with atipamezole (2% v/v) in saline.  
2.11    Murine model of asthma 
2.11.1 Intranasal sensitization or challenge of mice 
a) Mice were anaesthetized with isoflourane (2.5% in oxygen) in an 
induction chamber connected to an isofluorane vaporizer and scavenger. 
Ensure that mice were rendered inactive, with slow and even breathing. 
b) 20-50µl of allergen in endotoxin-free PBS was administered to the nares 
of the nostrils. 
c) Mice will recover consciousness rapidly following removal from exposure 
to isoflourane. 
2.11.2 Bronchoalveolar lavage analysis 
a) Mice were sacrificed by carbon dioxide asphyxiation.  
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b) Using a 21G needle threaded with a length of polyethylene tubing 
(Intramedic, BD, Singapore), the trachea was cannulated and the lungs 
flushed with 2 applications of 0.5ml MACS buffer. 
c) Cells were pelleted by centrifugation at 450g/5min/4ºC. 
d) Cells were resuspended in 100µl RBC lysis buffer and left to stand at 
room temperature for 1 min. 
e) MACS buffer was added to stop the lysis reaction and the cells pelleted at 
450g/5min/4ºC. 
f) Cell number was determined by counting with a haemocytometer. 
g) 0.1µl Fc block antibodies (anti CD16/32) were added to block non-specific 
staining by flourochrome labeled antibodies. 






i) Cells were stained for 30min at 4ºC and then washed twice with FACS 
buffer. 
j) The cells were then resuspended by raking and fixed with 1% PFA. 
2.11.3 Analysis of lung cells 
a) Mice were sacrificed by carbon dioxide asphyxiation.  
b) Lungs were excised and the esophagus and trachea removed. 
  
	   CHAPTER	  2:	  MATERIALS	  AND	  METHODS	   	  	   	  
74 
c) Lungs were immersed in 1 x Liberase TL (Roche Applied Science, 
Singapore) and macerated into fine pieces to aid digestion. 
d) The lungs fragments were allowed to digest at 37ºC for 45min. To assist in 
disrupting the lung tissue, the suspension was resuspended repeatedly and 
vigorously with a Pasteur pipette after 20min. 
e) The digested lung tissues were then passed through a 70µm cell strainer to 
obtain a single cell suspension. 
f) Cells were pelleted at 450g/5min/4ºC. 
g) Cells were then resuspended in 3ml of Optiprep  (Sigma-Aldrich, 
Singapore) (specific gravity = 1.064) and then the cell suspension was 
layered on top of 5ml of Ficoll-Paque (GE Healthcare Life Sciences, 
Singapore). 2ml of FBS was then layered above the cell suspension and 
the preparation was centrifuged at 600g/20min/RT without brakes. 
h) Dendritic cells can be found in the layer above the Optiprep, while 
lymphocytes were generally found at the interface between the Optiprep 
layer and the Ficoll-Paque. Red blood cells and granulocytes were 
generally pelleted at the bottom. 
i) The desired cells were harvested and washed twice in MACS buffer. 
2.11.4 Culture of lung-draining mediastinal lymph node (MLN) 
cells 
a) Mice were sacrificed by carbon dioxide asphyxiation.  
b) MLNs were excised and stored in MACS buffer. 
c) Single cell suspension was produced by mashing MLN cells through a 70 
micron mesh. 
d) Cells were pelleted at 450g/5min/4ºC. 
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e) Cells were resuspended in 100µl RBC lysis buffer and left to stand at 
room temperature for 1 min. 
f) MACS buffer was added to stop the lysis reaction and the cells pelleted at 
450g/5min/4ºC. 
g) Cells were washed twice in MACS buffer and resuspended in cRPMI. 
h) Cell number was determined by counting with a haemocytometer. 
i) MLN cells were cultured at density of 2x106 cells per well in a 48 well 
plate for 3 days. 
2.11.5 Lung histology 
Preparation of lung tissues 
a) Mice were sacrificed by carbon dioxide asphyxiation. 
b) An incision was made at the left atrium of the heart to allow blood and 
perfusion fluid to drain. 
c) The lung was perfused with 20ml PBS until the lungs turns pale white. 
d) The trachea was cannulated and 0.7ml of 4% PFA was injected into the 
lung to fix the tissues. 
e) The perfused lung was stored in 4% PFA for 2-5 days. 
Processing and sectioning of lung tissue 
a) The lung tissues were processed using a Leica benchtop tissue processor 
(TP1020). The process was as described below: 
• 75% ethanol – 1 hour 
• 80% ethanol  - 1hour 
• 90% ethanol – 1hour 
• 100% ethanol – 1.5 hours 
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• 100% ethanol – 1.5 hours 
• 100% ethanol – 1.5 hours 
• Histoclear (Sigma-Aldrich, Singapore) – 2 hours 
• Histoclear – 2 hours 
• Histoclear – 2 hours 
• Paraffin – 2.5 hours 
• Paraffin – 2.5 hours 
b) Lung tissue was transferred to embedding mold and embedded in paraffin 
wax. 
c) Embedded lung tissue was sectioned into 3.5-5mm thick sections for 
staining. 
Periodic acid-Schiff staining 
a) Lung sections on slides were deparaffinized and rehydrated as follow: 
• Histoclear – 10min 
• 100% ethanol – 2min 
• 100% ethanol – 2min 
• 90% ethanol – 2min 
• 70% ethanol – 2min 
• Distilled water – 1min 
b) Lung sections were then oxidized in periodic acid (SIngma-Aldrich, 
Singapore) for 5min. 
c) Slides were then washed twice in distilled water (3 min per wash). 
d) Slides were placed into Schiff’s reagent (Sigma-Aldrich, Singapore)for 
15min. 
e) Slides were washed in Scott’s tap water for 5min. 
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f) Lung sections were then counter-stained in haematoxylin (Sigma-Aldrich, 
Singapore) for 1.5min. 
g) Slides were then washed in Scott’s tap water for 1min. 
h) Slides were dehydrated and cleared as follow: 
• 70% ethanol – 1min 
• 90% ethanol -1min 
• 100% ethanol -1min 
• Histoclear – 1min 
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Chapter 3. Expression and purification of recombinant Blo t 5 
 
 
3.1  Introduction 
Blo t 5 is a 14kDa protein from the storage mite, Blomia tropicalis. 
Recombinant Blo t 5 protein had been extensively used for serum reactivity 
assays and ELISA assays to measure the presence of mite allergens. 
Expression of recombinant Blo t 5 protein were described in several 
systems, ranging from prokaryotic (E. coli) to yeasts (Pichia pastoris) and 
Chinese Hamster Ovary (CHO) cells (181-183). 
Due to the high costs of procuring enough protein for immunization 
studies, in-house synthesis of the protein was preferable. We opted for a 
bacterial expression system using E.coli BL21 as the system was well 
established in our laboratory and able to generate large quantity of the 
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3.2 The Blo t 5 gene 
Figure 3.1 shows the mRNA sequence of the gene encoding the Blo t 5 
protein (GenBank accession number U59102). The Blo t 5 sequence is 
predicted to contain a putative signal peptide that would direct the secretion 
of the protein through the acidic secretory vesicles (184). Signal peptide 
prediction program, SignalP 4.1, predicts that the signal peptide cleavage 
would occur between amino acid residues 17 and 18 (Figure 3.2). We 
designed 2 constructs, with and without the signal peptide sequence (with a 
start codon introduced in front of the truncated gene). These constructs 
were first codon optimized for expression in the E.coli bacteria by the 
proprietary OptimumGene™ algorithm (Genescript, USA). These genes 
























Figure 3.2 SignalP 4.1 prediction of signal peptide cleavage in Blo t 5. 
Signal peptide is predicted to extend from residues 1-17 and cleavage occurs 
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3.3 Cloning of the Blo t 5 gene into pET 28 expression vector 
Both the Blo t 5 protein (Blo t 5) and the Blo t 5 protein with signal peptide 
included (Blo t 5+signal) were cloned into pET28 expression vectors 
(Novagen, USA). Primers designed to incorporate the appropriate restriction 
sites into the PCR products for cloning into pET28 (Figure 3.3). The Blo t 5 
gene constructs were first subcloned into TOPO 2.1 TA cloning vector and 
sequenced for fidelity before cloning into the pET28 expression vector. 
The Blo t 5 (without signal peptide) gene and the pET28 vector were 
digested with Nco I and Bam HI respectively. For the Blo t 5+signall gene, the 
restriction enzyme Bsp HI, which produced Nco I compatible ends, was used 
instead.  
 Following ligation and transformation into E.coli DH5α, 
colonies were screened by PCR. Positive colonies were sequenced for 
verification. E.coli DH5α with the pET 28-Blo t 5 or pET-28-tBlo t 5 were 
expanded and the plasmids purified using plasmid miniprep kits (Qiagen) and 
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(b) Blo t 5 
 
 
Figure 3.3 Blo t 5+signal and Blo t 5 gene constructs in pET28 plasmid. 
Priming sites shown in red. The predicted signal peptide is indicated in green. 
The Blo t 5 construct has the signal peptide removed and a start codon (ATG) 
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3.4  Expression of recombinant Blo t 5 in E. coli BL 21 
The expression of the Blo t 5 or  Blo t 5+signal was tested in a small 
scale protein expression assay (Figure 3.4). E.coli BL 21 bacteria 
transformed with either pET28-Blo t 5 or pET28-Blo t 5+signal, were 
grown to log phase in LB broth supplemented with kanamycin. Protein 
expression was induced by the addition of IPTG. Following 3 hours of 
induction, OD600nm was measured and the bacteria loaded onto an SDS-
PAGE gel. The OD600nm readings were used to normalize the number of 
bacteria loaded for better comparison of induction efficacy. Expression of 
both Blo t 5 and Blo t 5+signal were induced following the addition of 
IPTG. However, the induction of the truncated protein appeared to be more 
robust than for that of the full-length protein. Therefore, we reason that the 
yield of the Blo t 5 protein without the signal peptide would be superior 
compared to a similar preparation using the protein with the signal peptide 
included. In addition, as the signal peptide was cleaved during the secretion 
process, it is unlikely that the signal peptide would be present during 
asthma sensitization by Blo t 5 and therefore the T cell epitopes present in 
the signal peptide sequence, if any, would be irrelevant. Therefore, we 
proceeded with large-scale production of recombinant Blo t 5 using the 
construct encoding the Blo t 5 gene construct. 
 
  




Figure 3.4 Overview of the process for the expression of Blo t 5 and Blo t 
5+signal in E.coli BL21 and the expression levels of both constructs 
following IPTG induction. E.coli BL21 transformed with either pET28-Blo t 
5 or pET28-Blo t 5+signal was induced to express the recombinant protein by 
addition of IPTG at log-phase of growth. Samples were collected pre- and 
post-induction and ran on 15% SDS-PAGE gels. The full-length Blo t 5 
protein is approximately 14kDa in size. Absorbance measurements made at 
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3.5  Purification of recombinant tBlo t 5 
E.coli BL21 transformed with pET28-Blo t 5 were grown in 1L cultures 
and induced to express recombinant Blo t 5 protein by the addition of IPTG 
at log phase. The bacteria was then pelleted by centrifugation and lysed by 
a combination of detergent lysis and sonication. Rather than being in 
insoluble inclusion bodies as expected for most highly expressed proteins 
in E.coli, we observed that the recombinant protein was instead present in 
the soluble fraction of the bacteria lysate.  
Due to the presence of large amount of contaminating proteins in the 
bacterial lysate, we decided that it was not advisable to immediately apply 
the lysate onto a chromatography column. The presence of these 
contaminating proteins would likely affect the efficiency of the 
chromatographic separation.  
Precipitation by ammonium sulfate is based on the principle that, at 
high salt concentrations, the natural tendency of protein not to aggregate 
together is overcome by the neutralization of the surface charges on these 
proteins. As the protein aggregate, they form larger complexes that are 
increasingly easy to precipitate by centrifugation. As different proteins 
would begin to aggregate at different salt concentrations, it is possible to 
fractionate different proteins at different salt concentrations. Here, we 
applied a gradient of ammonium sulfate salt at varying degrees of 
saturations. Recombinant Blo t 5 protein, seen as a 14kDa band on SDS-
PAGE, could be observed to precipitate at different salt saturations (Figure 
3.5). However, by progressively precipitating the proteins in the bacterial 
lysate, we could observe that most of the contaminating proteins were 
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removed at 60% ammonium sulfate concentration, leaving a much cleaner 
preparation of recombinant protein that could then be subjected to further 
purification. As an additional benefit, we could also resuspend the 
precipitated protein in a much smaller volume, hence concentrating the 
protein for the next stage of purification. 
We next applied the ammonium sulfate precipitation purified fraction 
onto a MonoQ 5/50GL anion exchange column (GE Life Sciences) (Figure 
3.6a). This separated the proteins in the lysate on the basis of their surface 
charges. Peaks corresponding to proteins eluted at different ionic strengths 
were collected and analyzed on SDS-PAGE. A band corresponding to 
approximately14kDa, the expected size of the recombinant Blo t 5 protein 
was observed in the second peak (Figure 3.6b). 
Finally, the fraction containing the recombinant Blo t 5 protein was 
applied to a HiLoad 16/60 Superdex 75 gel filtrations column for 
separation on the basis of size (Figure 3.7a). A single major peak was 
recorded and analysis on SDS-PAGE indicated that the protein present in 
the fraction corresponded to the expected size of the recombinant Blo t 5 
(Figure 3.7b). Group 5 mite allergens had been shown to polymerize under 
acidic conditions (184, 185). However, under the denaturing conditions of 
the SDS-PAGE gel electrophoresis, this was not observed. As the intention 
was to use this protein to induce a T cell response, which requires linear 
epitopes, we did not proceed to analyze the conformation of the protein in 
comparison to the native Blot 5 (for example using circular dichroism). It 
would be recommended to do so should conformation be of importance, for 
example in identification of antibody epitopes. 
  




Figure 3.5 Ammonium sulfate purification of bacterial lysate containing 
recombinant Blo t 5 protein. Proteins contained in the bacterial lysate were 
precipitated at different salt concentrations and analyzed on a SDS-PAGE gel. 
For comparison, samples from pre-induction and post-induction fractions as 
well as the bacterial lysate (pre ammonium sulfate precipitation) were also 

























Figure 3.6 Anion exchange chromatography and SDS-PAGE gel analysis. 
FPLC trace of anion exchange chromatography of the bacterial lysate on a 
MonoQ 5/50GL column following ammonium sulfate precipitation (a). The 
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Figure 3.7 Size exclusion chromatography and SDS-PAGE analysis of 
fractions. (a) FPLC chromatograph of size exclusion purification by gel 
filtration on a HiLoad 16/60 Superdex 75 column. The fractions from the 
major peak was analyzed on SDS-PAGE (b).
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The development of class I MHC tetramers by Altman et al allowed 
for the visualization of antigen-specific T cells (186). Due to the rapid 
dissociation rate of peptide-MHC monomers from the T cell receptor, 
effective staining of antigen-specific T cells was not possible. Multimerization 
of the peptide-MHC complexes increased their avidity for the T cell receptor, 
reducing the dissociation time and allowing their use to stain antigen specific 
T cells. This technology facilitates study of antigen specific T cells, even at 
low frequencies and has the advantage over function-based assays that the T 
cells do not need to be activated beforehand which may underestimate the 
numbers of antigen specific cells due the inability of these methods to detect 
non-responding cells. 
Class I MHC molecules require the presence of the cognate peptide to 
form a stable complex. Hence, production of class I MHC tetramers can be 
laborious process as refolding needs to be repeated for every antigenic peptide.  
In 2006, Toebes et al described a novel method of producing conditional 
ligands that could be used to produce class I MHC complexes which could be 
cleaved in the presence of UV light. This allows for the exchange of the 
original peptide containing a UV-labile moiety with another peptide to 
produce class I MHC complexes of the desired specificity (179). This allows 
for rapid production of multiple class I MHC complexes for different targets 
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in a shorter time and can greatly facilitate the process of epitope mapping (178, 
179, 187-189). 
Here, we expressed and refolded class I MHC proteins for H-2Kb and H-
2Db using a UV-labile peptide (SV9-P7) and showed that the tetramers could 
be exchanged with the desired peptide, producing class I MHC tetramers of 
the desired specificity. These tetramers would next be used in tetramer-guided 
epitope mapping studies as well as to identify antigen specific CD8 T cells. 
4.1 Expression and purification of class I MHC proteins 
The production of class I MHC tetramers involves several steps. The 
class I MHC heavy chains and b2-microglobulin proteins were first expressed 
in bacteria and the proteins purified. The heavy and light chains were then 
refolded in the presence of the UV cleavable peptide to form class I MHC 
complexes, which were then purified (178, 180, 190). The class I MHC 
complexes were then biotinylated to allow for tetramerization using 
fluorophore-labeled streptavidin.  
The procedure for expressing and refolding class I peptide MHC had 
first been described in 1992 by Garboczi et al (191). The H-2Db and H-2Kb 
heavy chains as well as the b2M light chain expression vectors, based on the 
pET24a(+) vectors, were provided by Dr Gijsbert M. Grotenbreg (178). For 
the heavy chain expression vector, the vector was modified with a BirA 
substrate peptide (BSP) immediately downstream of the BamHI in the 
multiple cloning site. 
H-2Kb, H-2Db and b2M expression vectors were separately 
transformed into E. coli BL21 (DE3). Protein expression was driven by the T7 
polymerase, which is under the control of the lac promoter in the DE3 lambda 
  
	   CHAPTER	  4:	  PRODUCTION	  OF	  CLASS	  I	  MHC	  TETRAMERS	   	  	   	  
92 
lysogen and hence is induced by the addition of lactose or isopropyl-b-D-
thiogalactopyranoside (IPTG). Expression of β2M can be visualized on SDS-
PAGE gel electrophoresis by the presence of a 12kDa band following the 
addition of IPTG (Figure 4.2a). Class I MHC heavy chains (H-2Kb or H-2Db) 
can be seen as bands approximately 35kDa in size following IPTG induction 
of protein expression (Figure 4.2b). Inclusion bodies purified from the 
bacterial pellet were resuspended in 8M urea, aliquotted and stored at -80°C 
until required.  Solubilized inclusion bodies of H-2Db or H-2Kb heavy chains 
were refolded by rapid dilution in the presence of a modified SV9-P7 peptide 
(FAPGNYPAL) that binds to both H-2Db and H-2Kb. The proline at position 7 
of the SV9-P7 peptide was replaced by a 3-amino-3-(2-nitro) phenyl-
propanoic acid (ANP) residue which is sensitive to UV cleavage (178). The 
peptides used were synthesized in-house by the laboratory of Dr. Gijsbert 
Grotenbreg. 
Refolded class I MHC monomers were biotinylated at the BSP site 
with the BirA enzyme to allow for tetramerization by streptavidin. The 
biotinylation status of the class I MHC heavy chain can be elucidated by a 
Western blot assay using horseradish-peroxidase conjugated streptavidin. 
Class I MHC monomers were purified by size exclusion chromatography 
using a S75 gel filtration column (Figure 4.3a). The presence of class I MHC 
monomers was determined by assaying fractions obtained from the expected 
peaks on SDS-PAGE gel. The presence of properly refolded class I MHC 
monomers can be visualized on the gel as a ~35kDa heavy chain and a 12kDa 
light chain band (Figure 4.3b). Purified class I MHC monomers can be frozen 
at -80°C until required. 
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Class I MHC tetramers were produced by attaching 4 biotinylated class I 
MHC monomers to a streptavidin moiety conjugated to a fluorochrome, 
usually R-Phycoerythrin (R-PE).  
 
 
Figure 4.1 Steps involved in the production of class I MHC tetramers 
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Figure 4.2 Large-scale expression of class I MHC subunits 
Expression of b2M (a) and class I MHC heavy chains (b) were induced by 
IPTG and the expression of the protein checked by SDS-PAGE. Molecular 
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Figure 4.3 S75 gel filtration chromatography for purification of class I 
MHC monomers. Fractions were collected from all major peaks and analyzed 
by SDS-PAGE gel electrophoresis. Peak 2 was shown to contain refolded 
class I MHC. H-2Db purification is shown in (a). Major peaks observed are as 
defined: 1 = aggregated proteins; 2 = H-2Db monomers; 3 = BirA biotin ligase 
from biotinylation reaction; 4 = free b2M; 5 = unbound peptides. (b) SDS-
PAGE gel electrophoresis of fractions from the peak containing class I MHC 
monomers. Lanes 1, 2 and 3 refer to the fractions collected from the various 
points of the chromatographic peak. Varying levels of biotinylation can result 
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4.2  Testing the functionality of UV cleavable class I MHC tetramers 
Refolded class I MHC tetramers can be exchanged for the ligand of interest 
following UV cleavage of the UV-labile peptide initially used in the refolding 
process (Figure 4.4). This grants the flexibility to produce a variety of class I 
MHC tetramers without the need for refolding and is especially useful when 
only small quantities of each specificity are needed, as would be the case with 
epitope identification or detection of antigen specific T cells. 
Class I MHC tetramers that were produced were next tested for their 
ability to be exchanged for the peptides of interest and the ability of the 
peptide exchanged class I MHC tetramers to bind the relevant T cells was 
tested. H-2Kb tetramers were UV exchanged with the SIINFEKL peptide and 
used to stain splenocytes from the OT-I mice which are engineered to possess 
T cell receptors specifically recognizing SIINFEKL with H-2Kb (Figure 4.5a). 
For H-2Db tetramers, we used splenocytes from mice previously infected with 
PR8 influenza. Specific staining of T cells specific for the influenza NP366-374 
peptide (ASNENMETM) was detected by flow cytometry (Figure 4.5b). In 
both cases, class I MHC tetramers that were not UV exchanged or exchanged 
for an irrelevant peptide were not able to stain the antigen specific T cells. 
 In summary, we had successfully expressed and refolded class I MHC 
proteins for two mouse alleles, H-2Kb and H-2Db. Both these class I MHC 
proteins were refolded with UV-labile peptide ligands. We next carried out a 
peptide exchange reaction by exposing the tetramers to UV radiation 
(>365nm) in the presence of a rescue peptide. The peptide-exchanged 
tetramers were able to stain specifically the antigen specific T cells 
recognizing a particular peptide-MHC combination. Therefore, we showed 
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that the class I MHC tetramers produced here could be ligand-exchanged to 





Figure 4.4 UV-mediated peptide exchange for class I MHC tetramers 
Exposure of the class I MHC refolded with the UV-labile peptide to UV light 
cleaves the peptide at the ANP residue. Binding of a compatible peptide to the 
now vacant peptide-binding groove rescues the complex and produced class I 
MHC of a new specificity.  
  






Figure 4.5 Functinoality of refolded UV-cleavable class I MHC tetramers 
Splenocytes from (a) OT-I mice and (b) PR8 influenza infected mice were 
stained with Kb-SIINFEKL or Db-ASNENMETM class I MHC tetramers 
respectively. Plots shown were gated on viable, CD8 positive staining cells. 
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Asthma is a complex multifactorial disease of the lung that involves an 
intertwined network of interactions between different immune cells.  One of 
the key players in the development of asthma are the T cells. Particularly well 
studied is the role of CD4 T cells. These T cells, particularly the Th2 subset, 
play a major role in asthma pathogenesis due to the production of a number of 
immune mediators such as IL-4, IL-5, IL-6, IL-9, IL-13 and IL-31. The 
involvement of other CD4 T cell subsets such as Th17 or Th1 are less clear, 
with some studies showing their role in both exacerbation and also 
amelioration of the asthma phenotype. The studies of the role played by CD8 
T cells too were inconclusive. Some studies showed that CD8 T cells could 
exacerbate asthma while many other groups had data to the contrary, with 
CD8 T cells shown to play a beneficial role by reducing eosinophilia and IgE 
production. 
Most murine studies of the role of T cells in asthma pathogenesis used 
the ovalbumin model. This is a convenient model, with well characterized T 
cell epitopes and a variety of useful tools available, such as MHC tetramers 
and TCR transgenic mice recognizing either class I or class II MHC presented 
epitopes of the OVA protein. However, this ignores the fact that OVA is not a 
true asthma allergen and true asthma allergens can possess qualities not 
associated with OVA such as protease activity and molecular mimicry of 
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inflammatory mediators. These qualities could modify the T cells responses in 
ways not observed in the OVA model. Asthma allergens are a complex mix of 
different proteins of different nature that combine to produce the symptoms. 
This is particularly important in the induction phase of asthma as the OVA 
model requires a rigorous prime-boost protocol using artificial adjuvants to 
induce a T cell response prior to nasal exposure to OVA and the development 
of asthma-like pathology. This makes it difficult to study the induction phase 
where the interactions between the different components of the innate and 
adaptive immune system occur. For true asthma allergens, the ability to 
monitor the development of allergic airway inflammation would greatly 
benefit our understanding of the complex interplay between the innate 
immunity, the adaptive immunity and the allergens themselves. As T cells 
play a central role in the development of Th2 inflammation, the ability to 
pinpoint and track these allergen specific T cells would be invaluable. A key 
step towards this would be the identification of epitopes recognized by these 
cells. Several studies on house dust mite specific T cells had identified a 
number of epitopes recognized by T cells (177, 192-194). However, these 
studies depend on in vitro expansion of T cells from immunized mice prior to 
screening and this approach could potentially lead to amplification of T cells 
of certain specificities while suppressing others, leading to a biased result. 
Using more sensitive assays like the ELISPOT assay allow for the direct ex 
vivo measurement of T cell responses that better commensurate with the in 
vivo responses to the allergen.  
A major focus of asthma therapy involves the redirection of the 
immune system to reduce or even abolish the allergic inflammatory responses 
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towards allergens. Specific Immunotherapy (SIT) had been shown to reduce 
the allergic responses in some patients and many studies pointed towards the 
induction of regulatory T and B cell responses, the production of anti-
inflammatory cytokines such as IL-10 as well as switching of allergen specific 
antibodies towards the production of IgG4 antibodies (131, 132, 136, 195). 
Peptide immunotherapy, too, had been applied successfully to induce Treg and 
IL-10 dependent suppression of the allergic inflammatory responses to some 
allergens (135, 176, 196, 197). However, the mechanism of action remains 
poorly understood and the triggering mechanism behind the switch from 
allergic inflammation to a tolerogenic response remain poorly understood. 
Given the difficulty of studying such responses in humans, animal models 
would play a crucial in studies to elucidate these mechanisms. As such, 
identifying the epitopes recognized by allergen specific T cells would allow 
better tracking of T cell responses and how the therapeutic approaches alter 
these responses. However, this is currently hampered by the limited number of 
epitopes identified, particularly for less studies allergens such as Blomia 
tropicalis. 
In our laboratory, we are interested in asthma induced by mite 
allergens, specifically allergens from the house dust mite Dermatophagoides 
pteronyssinus and the storage mite Blomia tropicalis. The latter, a major 
source of mite allergen in the tropics, is particularly poorly studied. In this 
study, we aim to identify T cell epitopes from a major Blomia tropicalis 
allergen, Blo t 5. We are also interested in mapping any class I MHC epitopes 
present in Blo t 5 or Der p 2 from the house dust mite. To that end, we 
explored the possibility of eliciting CD4 and CD8 T cells responses against 
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mite allergen proteins using a plasmid DNA immunization strategy. Mite 
allergen specific T cells were then identified by ELISPOT. We also screened 
for CD8 T cells using an alternative strategy with peptide-exchanged class I 
MHC tetramers and epitope prediction algorithms (178, 179, 187, 189, 198). 
Next, we studied the recruitment of allergen specific T cells to the lung 
following intranasal allergen challenge and the phenotype of these T cells in 
the allergic lung. Finally, we explored the possibility of using synthetic 
peptides encoding these epitopes as a form of peptide immunotherapy. As 
murine epitopes for Blo t 5 had yet to be identified, it would be of interest to 
explore the possibility that these therapeutic approaches could be used for 
treatment of Blomia tropicalis induced asthma. This could potentially allow us 
to identify the mechanisms behind this therapeutic approach and modify them 
to improve treatment efficacy in the future. 
5.2 DNA immunization constructs 
We explored several immunization strategies to identify one that could 
generate the optimum CD8 T cell response including the use of whole protein 
with adjuvants such as Complete Freund’s Adjuvant and a combined adjuvant, 
CASAC (199). However, the use of endogenous proteins as immunogens 
means that the CD8 T cell responses are heavily dependent on cross-
presentation by dendritic cells. We found that the use of a plasmid DNA 
vaccine not only efficiently induced CD8 T cell responses but also CD4 T cell 
responses to the same antigen. The use of a plasmid DNA as immunogen also 
has the benefit of greater flexibility. It is far easier to generate a plasmid DNA 
encoding a particular protein than to purchase the recombinant protein (costly) 
or to express the recombinant protein in-house (time-consuming). It was also 
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easier to modify the target protein. For example, a SIINFEKL epitope 
(OVA257-264) can be tagged to the Blo t 5 protein to check that the plasmid 
DNA vaccination could indeed result in the expression and proper processing 
of the protein for antigen presentation, as evidenced by the detection of 
SIINFEKL specific CD8 T cells with Kb-SIINFEKL class I MHC tetramers 
following immunization with the plasmid DNA. 
For the plasmid encoding Blo t 5, we used the sequence of the 
truncated Blo t 5 as used during in the expression of the recombinant protein 
in Chapter 3. We included flanking HindIII (5’) and BamHI (3’) sites for 
cloning as well as a Kozak initiation sequence (GCCACC) to facilitate the 
initiation of ribosomal translation. The gene sequence was codon optimized 
for expression in mice and synthesized by Genescript, USA (Figure 5.1).  
As with Blo t 5, the Der p 2 gene sequence (GenBank ascension 
number AF276329), was modified to contain the desired restriction site and 
Kozak initiation sequence. The gene was then codon optimized for murine 
expression by the proprietary OptimumGeneTM algorithm and synthesized by 
Genescript (USA) to the desired specification (Figure 5.2). 
The genes were cloned into the pVAX1 vector (Life Technologies, 
Singapore). The pVAX1 expression vector was originally derived from 
pcDNA3.1. However, the vector was modified in accordance with the 
requirements of the FDA Center for Biologics Evaluation and Research which 
stipulated a number of guidelines for plasmid DNA that could possibly be 
used in human vaccination studies. The pVAX1 plasmid was pared of 
sequences not necessary for replication in E.coli or for the expression of the 
protein in mammalian cells. This is to reduce the possibility of chromosomal 
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integration. The ampicillin resistance gene found in pcDNA3.1 was replaced 
by the kanamycin resistance gene as aminoglycoside antibiotics were believed 
to be less likely to elicit allergic responses in humans. As the restriction sites 
were already designed into the contruct, the Blo t 5 or Der p 2 gene could be 
easily cloned into the pVAX vector by restriction digest using BamHI and 
HindIII followed by ligation with T4 DNA ligase. 
We also produced two additional constructs engineered at the 3’ end of 
the gene to include a known H-2Kb restricted CD8 T cell epitopes 
(SIINFEKL) (Figure 5.3a). The primers were designed to include 3 amino 
acids found at both the flanking 3’ and 5’ ends of the epitopes in the native 
protein (OVA). This is to ensure that the proteosomal cleavage or TAP 
transporter recognition sites would be preserved. Also, we included native 
sequences flanking the restriction sites. A list of the primers used can be found 
in Figure 5.3b. We used PCR cloning to produce the modified Blo t 5 or Der p 
2 genes with the additional CD8 epitope. The PCR product was then 
subcloned into a TA cloning vector and digested with BamHI and HindIII to 
produce sticky ends. Ligation with similarly digested pVAX1 vector with T4 
DNA ligase follows. The colonies were screened by PCR to determine the 
presence of the gene and sequenced to check for fidelity. An example, with 























































Figure 5.2 Murine optimized Der p 2 gene with restriction sites and 
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Primer name Primer sequence (5’è3’) 
Blo t 5 - forward ATGAAGTTCGCCATCGTGCTGATT 
Blo t 5 - reverse TCACTGTGTCTGGATATCTTTCAC 
Blo t 5/SIINFEKL - reverse CGAATTCGGATCCTCACCATTCAGTCAG
TTTTTCAAAGTTGATTATACTCTCAAGCT
GCTGTGTCTGGATATCTTTC 
Der p 2 - forward ATGATGTATAAGATTCTCTGCCTCTC 
Der p 2 - reverse TTAATCTCTAATCTTAGCGTGAGTAGCA 





Figure 5.3 Gene constructs produced for immunization studies and list of 
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Figure 5.4 PCR cloning of Der p 2-SIINFEKL into pVAX1 (a) Agarose gel 
electrophoresis of Der p 2 (control), Der p 2 using Der p 2–forward primers 
and the appropriate reverse primers. (b) Restriction digest of Der p 2-
SIINFEKL PCR product TA cloned into TOPO. As control, a digest of Der p 
2 in pcDNA3.1 was performed. The Blo 5 digest was for another experiment 
(+ indicated digestion with BamHI and HindII; - indicated incubation in the 
absence of enzymes).  (c) Colony screening following ligation of Der p 2-
SIINFEKL with pVAX1 by PCR using Der p 2-forward and Der p 2-reverse 
primers.  
  
	   CHAPTER	  5:	  MAPPING	  OF	  MITE	  ALLERGEN	  T	  CELL	  EPITOPES	   	  	   	  
109 
5.3 DNA vaccination of mice 
Plasmid DNA is commonly delivered by intramuscular injections. 
However, Bins et al, in 2005, demonstrated an alternative method that could 
deliver plasmid DNA by skin tattoo and induce a robust CD8 T cell response 
(200). We hence decided to explore the possibility of delivering the plasmid 
DNA using a tattoo device. This has the benefit of requiring less plasmid 
DNA per immunization and may be more consistent than intramuscular 
delivery. Briefly, the mice were shaved and the mice tattooed with a rotary 
tattoo device at approximately 100Hz. This produces a number of small 
perforations on the skin, which allows for the delivery of the plasmid DNA 
into the dermal layer. The tattooing also produces a local inflammation that 
could boosts the immune response to the plasmid DNA. The tattooing seems 
to be well tolerated and mice immunized in this manner were not observed to 
show any adverse effect or loss of mobility. 
We began by testing the delivery system using the pVAX1 plasmid 
encoding Blo t 5 with the SIINFEKL inserted into the C-terminus of the 
protein. Mice were tattooed with 20µg of plasmid DNA on days 0, 3 and 6. T 
cell responses were measured using the IFNγ ELISPOT assay (Figure 5.5a). 
Mice were screened for SIINFEKL specific T cell responses on days 7, 10, 14 
and 22. We observed that the CD8 response peaked on days 10-14 and 
declined by day 22 (Figure 5.5b). The presence of CD8 T cells specific for the 
SIINFEKL peptide was confirmed by tetramer staining (Figure 5.5c). We 
observed a tetramer positive population of CD8 T cells that made up 
approximately 1% of the total CD8 T cell population in the spleen. Tetramer 
positive CD8 T cell population was not observed in mock-immunized mice 
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that only received the empty pVAX plasmid. Gating on this tetramer positive 
population showed that a majority of the cells are CD44high and CD62Llow, 
unlike the majority of the spleen CD8 T cells. This phenotype corresponds to 
T cells that had been recently activated and indicates that these T cells had 
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Figure 5.5 Plasmid DNA immunization of mice by skin tattoo. Splenocytes 
were assayed using the IFNγ ELISPOT assay. (a) Splenocytes from mice 
immunized with the plasmid vector encoding Blo t 5-SIINFEKL produced 
IFNγ in response to SIINFEKL but not splenocytes from mock-immunized 
mice. (b) T cell responses measured using IFNγ ELISPOT were observed to 
peak at days 10-14. (c) Kb-SIINFEKL tetramer staining of splenocytes from 
immunized or mock-immunized (pVAX1) mice at day 14. Tetramer positive 
cells exhibited an activated phenotype (CD44high CD62Llow). 
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5.4 Epitope mapping studies  
We designed and ordered a panel of 15-mer peptides (overlapping by 
10 amino acids) that span the Blo t 5 (Figure 5.6) and Der p 2 protein (Figure 
5.7).  The peptides were synthesized and purified to >85% purity by 
Genescript, USA. The peptide panel includes peptides mapped to the signal 
peptide region which was truncated from the pVAX-truncBT5 construct. We 
had included these peptides in the order as we were still in the process of 
evaluating the efficacy of the truncated protein in eliciting a T cell response in 
vivo. We decided to include these peptides in the screen as a negative control 
as no T cell responses should be observed for these peptides. 
We proceeded to vaccinate C57BL/6 and BALB/c mice with the 
pVAX-Blo t 5 and pVAX-Der p 2 plasmid constructs. We tattooed the mice at 
days 0,3 and 6 and culled different batches of mice on day 14. Spleen and the 
draining lymph nodes (popliteal and inguinal) were harvested and assayed 
with the IFNγ ELISPOT assay using the overlapping 15-mer peptides. We 
opted for the ELISPOT assay as a screening method due to the superior 
sensitivity of the assay compared to other methods such as intracellular 
cytokine staining or assays for cell proliferation. An overview is shown in 
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Peptide Position Sequence 
Bt5#1 1-15 MKFAIVLIACFAASV 
Bt5#2 6-20 VLIACFAASVLAQEH 
Bt5#3 11-25 FAASVLAQEHKPKKD 
Bt5#4 16-30 LAQEHKPKKDDFRNE 
Bt5#5 21-35 KPKKDDFRNEFDHLL 
Bt5#6 26-40 DFRNEFDHLLIEQAN 
Bt5#7 31-45 FDHLLIEQANHAIEK 
Bt5#8 36-50 IEQANHAIEKGEHQL 
Bt5#9 41-55 HAIEKGEHQLLYLQH 
Bt5#10 46-60 GEHQLLYLQHQLDEL 
Bt5#11 51-65 LYLQHQLDELNENKS 
Bt5#12 56-70 QLDELNENKSKELQE 
Bt5#13 61-75 NENKSKELQEKIIRE 
Bt5#14 66-80 KELQEKIIRELDVVC 
Bt5#15 71-85 KIIRELDVVCAMIEG 
Bt5#16 76-90 LDVVCAMIEGAQGAL 
Bt5#17 81-95 AMIEGAQGALERELK 
Bt5#18 86-100 AQGALERELKRTDLN 
Bt5#19 91-105 ERELKRTDLNILERF 
Bt5#20 96-110 RTDLNILERFNYEEA 
Bt5#21 101-115 ILERFNYEEAQTLSK 
Bt5#22 106-120 NYEEAQTLSKILLKD 
Bt5#23 111-125 QTLSKILLKDLKETE 
Bt5#24 116-130 ILLKDLKETEQKVKD 
Bt5#25 121-134 LKETEQKVKDIQTQ 
 
Figure 5.6 List of peptides used in mapping epitopes of the Bo t 5 protein. 
Peptides are 15 amino acids in length (except Bt5#25 which a 14-mer) and 
overlap by 10 amino acids. Peptides at position 1-17 encode the signal peptide 
and are cleaved off the final product prior to export. The signal peptide is not 
encoded in the plasmid DNA used for immunization and hence peptide #1 is 





















Peptide Position Sequence 
Dp2#1 1-15 MMYKILCLSLLVAAV 
Dp2#2 6-20 LCLSLLVAAVARDQV 
Dp2#3 11-25 LVAAVARDQVDVKDC 
Dp2#4 16-30 ARDQVDVKDCANHEI 
Dp2#5 21-35 DVKDCANHEIKKVLV 
Dp2#6 26-40 ANHEIKKVLVPGCHG 
Dp2#7 31-45 KKVLVPGCHGSEPCI 
Dp2#8 36-50 PGCHGSEPCIIHRGK 
Dp2#9 41-55 SEPCIIHRGKPFQLE 
Dp2#10 46-60 IHRGKPFQLEAVFEA 
Dp2#11 51-65 PFQLEAVFEANQNTK 
Dp2#12 56-70 AVFEANQNTKTAKIE 
Dp2#13 61-75 NQNTKTAKIEIKASI 
Dp2#14 66-80 TAKIEIKASIDGLEV 
Dp2#15 71-85 IKASIDGLEVDVPGI 
Dp2#16 76-90 DGLEVDVPGIDPNAC 
Dp2#17 81-95 DVPGIDPNACHYMKC 
Dp2#18 86-100 DPNACHYMKCPLVKG 
Dp2#19 91-105 HYMKCPLVKGQQYDI 
Dp2#20 96-110 PLVKGQQYDIKYTWN 
Dp2#21 101-115 QQYDIKYTWNVPKIA 
Dp2#22 106-120 KYTWNVPKIAPKSEN 
Dp2#23 111-125 VPKIAPKSENVVVTV 
Dp2#24 116-130 PKSENVVVTVKVMGD 
Dp2#25 121-135 VVVTVKVMGDDGVLA 
Dp2#26 126-140 KVMGDDGVLACAIAT 
Dp2#27 131-146 DGVLACAIATHAKIRD 
 
Figure 5.7 List of peptides used in mapping epitopes of the house dust 
mite protein, Der p 2. Peptides are 15 amino acids in length (except Dp2#27, 
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Figure 5.8 Overview of the epitope mapping process. Mice were 
immunized intradermally by skin tattoo as described in (a). C57BL/6 and 
BALB/c mice were immunized intradermally with plasmid constructs 
encoding Der p 2 protein from the house dust mite, Dermatophagoides 
pteronyssinus, and Blo t 5 from the storage mite, Blomia Tropicalis. Epitope 
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5.1.1 Mapping of Blo t 5 epitopes 
We identified three 15-mer peptides that could elicit an IFNγ response 
from splenocytes harvested from immunized C57BL/6 mice (Figure 5.9a). The 
other peptides failed to elicit any measureable responses above the baseline 
(DMSO only). The peptides containing epitopes recognized by T cells were 
Bt5#16 (LDVVCAMIEGAQGAL), Bt5#21 (ILERFNYEEAQTLSK) and 
Bt5#22 (NYEEAQTLSKILLKD). Due to the 10 amino acids overlap between 
Bt5#21 and Bt5#22, it is highly possible that the epitope exists in the 
overlapping region of the two peptides. 
We next sought to identify the source of the T cell responding to the Blo t 
5 epitopes. Using MACS magnetic cell separation, we depleted either CD4 or 
CD8 T cells from the splenocytes of immunized mice and repeated the 
ELISPOT assay using the epitope-containing peptides (Figure 5.9b). 
Depletion of CD8 T cells did not affect the response against Bt5#16, Bt5#21 
or Bt5#22. However, depletion of CD4 T cells completely abolished any 
measurable IFNγ secretion from the splenocytes. Therefore, we concluded that 
the peptides Bt5#16, Bt5#21 and Bt5#22 contain class II MHC binding 
epitopes that can elicit a CD4 T cell response in C57BL/6 mice. 
The same experiment was repeated in the BALB/c mouse model. 
Similarly BALB/c mice were immunized intradermally by skin tattoo with 
plasmid DNA encoding Blo t 5. The splenocytes were then assayed by 
ELISPOT assay for IFNγ production in response to the same panel of 
overlapping peptides. We identified two peptides, Bt5#15 
(KIIRELDVVCAMIEG ) and Bt5#16 (LDVVCAMIEGAQGAL), that could 
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elicit IFNγ production from splenocytes harvested from the immunized mice 
(Figure 5.10a). Due to the 10 amino acid overlap, we predict that the actual 
epitope falls within the overlapping region. Depletion of CD4 T cells prior to 
ELISPOT analysis abrogated the production of IFNγ while CD8 T cell 
depletion failed to do so (Figure 5.10b). Thusly, we can conclude that the 
epitope identified is presented by class II MHC and is recognized by T helper 
cells. 
No CD8 T cell responses were observed in either C57BL/6 or BALB/c 
mice. Although we detected SIINFEKL specific T cells when the mice were 
immunized with the pVAX-Blo t 5-SIINFEKL construct, it remains possible 
that our assay failed to detect a CD8 T cell response. To confirm that a CD8 T 
cell response was indeed absent, we proceed to assay for possible Blo t 5 
specific CD8 T cells using an alternative method.  
Tetramer guided epitope mapping is a relatively new method that was 
brought about following the recent discovery of UV-labile conditional ligands 
for class I MHC that allowed for the rapid and efficient generation of class I 
MHC multimers of different specificities (179). Epitope mapping studies 
utilizing this method had identified new epitopes in a number of models 
including influenza, hepatitis B, dengue, Chlamydia trachomatis, murine 
Gammaherpesvirus 68 and Toxoplasma gondii (178, 179, 187-189). Briefly, 
possible class I MHC epitopes were predicted using consensus epitope 
prediction program available on http://jura.wi.mit.edu/bioc/grotenbreg/ (178). 
This program combines four scoring-matrix prediction algorithms to identify 
possible class I MHC binding peptides. Each prediction algorithm would be 
employed to predict the likelihood of a particular peptide to bind to the class I 
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MHC. This would be reflected in the score. The peptides would then be 
ranked according to their scores. A concensus score, based on the ranking 
provided by all of the four prediction algorithms, would be assigned to each 
peptide sequence. The highest ranking peptide would be the most likely to 
bind to the class I MHC. A panel of screening peptides was synthesized for the 
top 20 peptides predicted to bind either H-2Db or H-2Kb (Figure 5.11). We 
also analyzed a known epitope, SIINFEKL, and compared the score with that 
of our predicted epitopes. It can be seen that SIINFEKL scored higher than 
any of the Blo t 5 peptides predicted to bind H-2Kb (the higher the score, the 
higher the likelihood to bind to the class I MHC). 
Class I MHC tetramers refolded with UV-labile conditional ligands were 
subjected to UV exposure in the presence of a screening peptide. Should the 
new peptide be compatible, the peptide will now replace the cleaved 
conditional ligand peptide in the class I MHC peptide binding groove, 
stabilizing the protein and producing a class I MHC tetramer of a new 
specificity. In this manner, we exchanged H-2Db or H-2Kb class I MHC 
tetramers with the 20 peptides predicted to be possible epitopes. Following 
peptide exchange, the class I MHC tetramer was used to stain splenocytes 
from mice immunized with pVAX-Blo t 5 plasmid. Splenocytes were then 
analyzed by flow cytometry. However, we did not observe any staining for the 
40 peptides examined (Figure 5.12). OT-I T cells were used as positive control 
and H-2Kb class I MHC tetramers exchanged with SIINFEKL were indeed 
able to stain these cells. For H-2Db, we used class I MHC tetramers exchanged 
with ASNENMETM to stain splenocytes from PR8 influenza infected mice as 
a positive staining control. Therefore, we conclude that there indeed were no 
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CD8 T cell responses against Blo t 5 and that the ELISPOT screen did not 
miss any possible CD8 T cell responses. 
 
Figure 5.9 Mapping of Blo t 5 epitopes in C57BL/6 mice. Mice were 
immunized by intradermal administration of plasmid DNA encoding Blo t 5. 
(a) Splenocytes were then assayed using ELISPOT for IFNγ production 
against a panel of overlapping 15-mer peptides derived from Blo t 5. The 
results shown are tabulated from the data obtained from 3 separate 
experiments. (b) Splenocytes were depleted of CD4 or CD8 T cells by 
magnetic separation prior to IFNγ ELISPOT assay with the 15-mer peptides. 
The results shown are tabulated from 2 separate experiments. Each circle 
represents a single mouse tested and the grey bar represents the average spot 
forming units. 
  




Figure 5.10 Mapping of Blo t 5 epitopes in BALB/c mice. Mice were 
immunized by intradermal administration of plasmid DNA encoding Blo t 5. 
(a) Splenocytes were then assayed using ELISPOT for IFNγ production 
against a panel of overlapping 15-mer peptides derived from Blo t 5. The 
results shown are tabulated from the data obtained from 3 separate 
experiments. (b) Splenocytes were depleted of CD4 or CD8 T cells by 
magnetic separation prior to IFNγ ELISPOT assay with the 15-mer peptides. 
The results shown are tabulated from the data obtained from 3 separate 
experiments. Each circle represents a single mouse tested and the grey bar 
represents the average spot forming units. 
 
  













1 LLYLQHQL 50-7 -0.02 -0.744 -0.278 -4.189 
2 IACFAASV 8-16 -0.124 -0.602 -0.399 -0.19 
3 ACFAASVL 9-17 -0.162 -0.346 -0.272 -3.186 
4 FRNEFDHL 27-34 0.009 -0.302 0.04 -3.584 
5 AQTLSKIL 110-117 0.017 0.229 0.12 -2.398 
6 IEGAQGAL 83-90 -0.034 -0.293 1.982 -2.398 
7 IIRELDVV 72-79 0.029 -0.35 0.638 1.15 
8 LQHQLDEL 53-60 0.101 0.15 0.454 -2.398 
9 HQLLYLQH 48-55 0.421 -0.402 -0.156 -0.875 
10 QTLSKILL 111-118 -0.053 -0.293 0.807 -0.095 
11 IVLIACFA 5-12 0.21 -0.863 -0.384 -0.095 
12 EAQTLSKI 109-116 0.074 0.495 0.867 -2.657 
13 LIACFAAS 7-14 0.354 -0.987 1.18 -2.675 
14 KRTDLNIL 95-102 0.157 0.538 0.313 -1.281 
15 SKILLKDL 114-121 0.162 -0.052 0.824 -1.194 
16 RELKRTDL 92-99 0.008 -0.137 1.897 -0.372 
17 MKFAIVLI 1-7 -0.015 -0.079 1.365 -0.588 
18 EKGEHQLL 44-51 0.257 1.144 0.848 -1.281 
19 ASVLAQEH 13-20 0.378 -0.427 0.256 2.208 
20 ERFNYEEA 103-110 0.551 0.313 -0.002 -2.58 












1 FAIVLIACF 3-11 -0.201 0.349 -0.847 -0.012 
2 IACFAASVL 8-16 0.403 0.007 -0.583 -1.456 
3 YLQHQLDEL 52-60 -0.097 2.484 -0.688 -1.38 
4 QLLYLQHQL 49-57 -0.012 1.427 -0.449 -1.778 
5 RELDVVCAM 74-82 -0.007 0.409 1.712 -1.778 
6 AQGALEREL 86-94 -0.277 0.827 -0.001 -1.342 
7 AQTLSKILL 110-118 -0.054 0.932 -0.826 -1.342 
8 KGEHQLLYL 45-53 -0.095 1.738 0.123 -0.795 
9 EAQTLSKIL 109-117 -0.137 1.163 1.671 -1.415 
10 FNYEEAQTL 105-113 0.071 0.817 0.789 -1.421 
11 AMIEGAQGA 81-89 0.387 0.573 -0.152 -0.711 
12 FRNEFDHLL 27-35 0.083 1.661 0.738 -1.421 
13 KSKELQEKI 64-72 -0.147 1.297 0.789 -0.971 
14 LSKILLKDL 113-121 0.141 1.753 0.566 -0.971 
15 LQEKIIREL 68-76 -0.016 1.495 0.453 -0.681 
16 KIIRELDVV 71-79 0.104 0.691 1.2 -0.556 
17 IVLIACFAA 5-13 0.639 0.629 -0.613 -0.518 
18 LIEQANHAI 35-43 0.329 0.678 1.277 -0.681 
19 EEAQTLSKI 108-116 0.208 1.331 4.286 -1.459 
20 ELKRTDLNI 93-101 0.288 1.174 2.306 -0.778 
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Figure 5.11 Top 20 peptides predicted to bind H-2Db and H-2Kb. 
Peptides were ranked based on their scores from 4 class I MHC binding 
prediction algorithms, ARB(201), SMM(202), Udaka et al(203) and 
BIMAS(204). The consensus rank is the average of the ranking assigned by 
the 4 different algorithms and represent the likelihood of the peptide binding 
to the class I MHC molecules. These ranks do not take into account the 
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Figure 5.12 Tetramer guided epitope mapping. Class I MHC tetramers 
exchanged with predicted peptides were used to stain splenocytes from mice 
immunized with plasmid encoding Blo t 5. Positive controls: OT-I splenocytes 
with Kb-SIINFEKL in (a) and splenocytes from PRB influenza infected mice 
with Db-ASNENMETM in (b). Negative control peptides are SiYRYYGL and 
SAVSNLFYV respectively. These peptides bind to their respective class I 
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5.1.2 Mapping of Der p 2 epitopes 
 
We next proceeded to map Der p 2 epitopes recognized by T cells in a 
similar manner as was carried out for Blo t 5. We immunized C57BL/6 mice 
with a plasmid encoding Der p 2 (pVAX-Der p 2). T cell response was 
measured using the IFNγ ELISPOT assay. 
In C57BL/6 mice, T cells responses were measured against four 15-mer 
peptides (Dp2#11, Dp2#21, Dp2#22 and Dp2#27) (Figure 5.13a). For three of 
these peptides, the response was CD4 mediated, as depletion of CD4 T cells 
clearly abolished the production of IFNγ in response to these peptides. 
However, we observed IFNγ production against Dp2#11 following depletion 
of either CD4 or CD8 T cells (Figure 5.13b). However, after efforts to fine 
map and better characterize this putative epitope, we concluded that the 
observed response was possibly due to a contaminating agent in the peptides. 
We synthesized a new batch of the Dp2#11 peptide and we do not detect any 
T cell responses against this peptide (Figure 5.13c). 
Only a single 15-mer peptide induced a response from splenocytes from 
pVAX-Derp2 immunized BALB/C mice (Figure 5.14a). The response 
observed was weaker than observed in the other groups. Depletion of CD4 T 
cells abolished the response to the peptide (Figure 5.14b). 
  







	   CHAPTER	  5:	  MAPPING	  OF	  MITE	  ALLERGEN	  T	  CELL	  EPITOPES	   	  	   	  
126 
Figure 5.13 Mapping of Der p 2 epitopes in C57BL/6 mice. Mice were 
immunized by intradermal administration of plasmid DNA encoding Der p 2. 
(a) Splenocytes were then assayed using ELISPOT for IFNγ production 
against a panel of overlapping 15-mer peptides derived from Der p 2. The 
results shown are tabulated from the data obtained from 3 separate 
experiments. (b) Splenocytes were depleted of CD4 or CD8 T cells by 
magnetic separation prior to IFNγ ELISPOT assay with the 15-mer peptides. 
The results shown are tabulated from the data obtained from 2 separate 
experiments. Each circle represents a single mouse tested and the grey bar 

















Figure 5.14 Mapping of Der p 2 epitopes in BALB/c mice. Mice were 
immunized by intradermal administration of plasmid DNA encoding Der p 2. 
(a) Splenocytes were then assayed using ELISPOT for IFNγ production 
against a panel of overlapping 15-mer peptides derived from Der p 2. The 
results shown are tabulated from the data obtained from 2 separate 
experiments. (b) Splenocytes were depleted of CD4 or CD8 T cells by 
magnetic separation prior to IFNγ ELISPOT assay with the 15-mer peptides. 
The results shown are tabulated from the data obtained from 2 separate 
experiments. Each circle represents a single mouse tested and the grey bar 
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5.5 Further characterization of Blo t 5 epitopes 
We had identified a number of epitopes for Blo t 5 and Der p 2 in 
C57BL6 and BALB/c mice. The Blo t 5 epitopes are especially of interest as 
no studies thus far has identified a major epitope for this allergen protein. 
Therefore, for the first time, we are able to study the T cell responses against 
this protein. In the C57BL/6 mice, we identified 3 peptides that could elicit a 
CD4 T cell response.  In peptide Bt5#21 and Bt5#22, the T cells probably 
recognize an epitope found in the overlap region between the two peptides. It 
is our aim next to characterize the T cell response to these epitopes in the 
allergic asthma murine model. 
Commonly, DNA immunization is believed to elicit a strong Th1 type 
T cell response. However, depending on the nature of the construct and the 
route of vaccination, it is possible that a mix of Th1 and Th2 responses be 
induced instead (205). Therefore, the responses measured using IFNγ 
ELISPOT assay may severely underestimate the strength of the responses to 
each peptide. We assayed the responses of Blo t 5 specific T cells using the 
ELISPOT assays for IFNγ or IL-4. Intradermal immunization with the pVAX 
vector encoding Blo t 5 without the signal peptide induced a strong Th1 
response, with over 90% of the antigen specific T cells producing IFNγ rather 
than IL-4 (Figure 5.15). However, we do observe a small population of IL-4 
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Figure 5.15 IFNγ  producing T cells recognizing Blo t 5 epitopes in 
C57BL/6 mice following plasmid DNA immunization. T cells were assayed 
for IFNγ or IL-4 production by ELISPOT. Predominantly, Blo t 5 specific T 
cells generated by pVAX-truncBlo t 5 immunization produced IFNγ (>90%) 
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 Next, we immunized the mice intradermally with pVAX-truncBlo t 5 
as previously described. Mice were then challenged intranasally with 
recombinant Blo t 5 protein on days 14, 16 and 18 before being culled on day 
21 (Figure 5.16a). Mice that were mock immunized with PBS were not 
observed to mount a response against the Blo t 5 challenge. However, we 
observed marked immune cell infiltration in the lung lavage samples of mice 
that had been immunized prior to the intranasal challenge. There was marked 
eosinophilia in the lung lavage, a key indication of the development of allergic 
asthma (Figure 5.16b and 5.16c). We next cultured cells from the draining 
posterior mediastinal lymph nodes with either Blo t 5 or the peptides Bt5#16, 
Bt5#21 or Bt5#22. Cells in the control wells were cultured with ovalbumin. 
Following 3 days of culture, cytokine production was measured by ELISA. 
When cells were cultured with recombinant Blo t 5 protein, we observed a 
significant quantity of Th2 cytokines such as IL-5, IL-10 and IL-13. However, 
IL-4 levels were too low to be detected. In our laboratory, we frequently do 
not detect IL-4 in the cell culture supernatants as the cells themselves could 
take up the cytokine. We also observed significant levels of IFNγ. A similar 
cytokine profile was detected when the lymph node cells were cultured with 
the peptide Bt#16. However, we observed significantly lower levels of all 
cytokines when the lymph node cells were cultured with Bt5#21 or Bt5#22. 
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Figure 5.16 T cells induced by intradermal plasmid DNA immunization 
were able to induce lung inflammation following antigen exposure. (a) 
C57BL/6 mice were immunized with plasmid DNA encoding Blo t 5 without 
the signal peptide (pVAX-truncBlo t 5) and then challenged with recombinant 
Blo t 5 protein. Analysis of immune cell population in BAL; depicted by (a) % 
total cells and (b) cell numbers. Control mice were immunized with PBS and 
then challenged with Blo t 5 intranasally. Each circle is representative of a 
single mouse. The bar represents the average reading of all the mice in the 
experimental group. (d) Cytokine production by draining lymph node cells 
cultured for 3 days with Blo t 5 or the indicated 15-mer peptides were 
analyzed by ELISA. The results are tabulated from 2 experiments (n=3 per 
experiment). For (d), the MLN cells from 3 mice were combined due to the 
low number of cells in each MLN. 
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 The cells from the draining lymph node cultures were also harvested 
and stained for intracellular cytokine production (Figure 5.17). A proportion 
of the T cells cultured in the presence of the Blo t 5 protein were observed to 
produce IL-5 and IL-13. Weak levels of IL-4 expression were observed in 
some cells. Generally, IL-4 levels are difficult to detect due to the low levels 
of secretion. We also do not observe any IL-10 production in these cells.  For 
most cases, T cells were found to produce IL-5 and IL-13 in conjunction. 
However, we also observed a population of T cells producing IFNγ and IL-
17A, although we saw no overlaps between these populations. The number of 
cells producing IFNγ was especially significant, with greater than 10% of the 
T cells responding to Blo t 5 producing this cytokine.  
 When the lymph node cells were restimulated with peptides instead of 
whole protein, we observed some interesting variability in the T cell responses 
to different peptides. T cells recognizing Bt5#16 appeared to be the 
predominant population in the lymph nodes. Some of these T cells respond to 
the peptide by producing IL-5 and IL-13. However, we also observed that a 
significant fraction of these cells produced IFNγ instead, similar to that 
observed with responses to the whole protein. In fact, few T cells responding 
to Bt5#21 and Bt5#22 produced IFNγ, and those that did, produced only small 
quantities of the cytokine as can be seen by the weak MFI of the staining.  
Hence, we could draw the conclusion that the T cells that produced IFNγ in 
response to Blo t 5 protein are very likely to be the population with specificity 
for Bt5#16. Meanwhile, we observed a clear population of T cells that 
secreted Il-17A in the cells restimulated with peptides Bt5#21 and Bt5#22. 
However, we do not observe this in the Bt5#16 specific T cell population. 
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These observations suggest a clear variability in T cell responses against 










































Figure 5.17 Intracellular cytokine staining of draining lymph node cells. 
Mediastinal lymph node cells were stimulated with ovalbumin (as control), 
recombinant Blo t 5 protein or peptides for 3 days before intracellular cytokine 
staining was performed. Cells were stained with LIVE/DEAD Aqua stain 
(Invitrogen, Singapore) and gated on live cells. Cells were stained for (a) IL-4, 
IL-5 and IL-13 or (b) IFNγ, IL-10 and IL-17A. The above figures are 
representative of results observed from two separate experiments. 
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 The administration of antigenic peptides had been shown to induce a 
regulatory T cell response that could attenuate the allergic response (135, 176, 
196, 197, 206). We conducted a pilot study to ascertain if the epitopes 
identified here could be used for this purpose. Intranasal administration of 
recombinant Blo t 5 protein was unable to induce airway inflammatory 
responses. The administration of bone marrow-derived dendritic cells 
(BMDCs) pulsed with antigen had been successfully used to prime allergic 
airway responses to the antigen (207). Mice were sensitized by intranasal 
administration of 1 million BMDCs that had been pulsed overnight with 10µg 
of recombinant Blo t 5 protein. Two weeks following sensitization, mice were 
immunized with 1µg of Bt5#16 and BT5#21 peptides. The peptides (in PBS) 
were injected (not tattooed) intradermally without the use of any adjuvants. 
Mice were then challenged with recombinant Blo t 5 and sacrificed on Day 35 
(Figure 5.18a). We observed a statistically significant decrease in eosinophilia 
in mice that had received the peptides compared to the control mice (Figure 
5.18b). Additionally, we also observed a decrease in IL-5 and IL-13 levels in 
the MLN cultures of mice that had received the Blo t 5 peptides (Figure 5.18c).  
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Figure 5.18 Peptide immunotherapy of Blo t 5 sensitized and challenged 
mice. (a) Mice were sensitized and challenged in accordance to the protocol 
described. Peptides were injected intradermally on Day 14. Test mice were 
immunized intradermally with a mix of Blo t 5 peptides #16, #21 and #22 
(1µg each). Control mice received OVA323-339, an irrelevant peptide. (b) BAL 
immune cell infiltrate were measured by flow cytometry and tabulated as % of 
total cells (b) or cell number (c). Each point represent a single mouse and the 
mean reading indicated by the line. (d) Cytokine ELISA measurements for 
culture medium of draining lymph node cells cultured with 10µg/ml HDM 
extract for 3 days. The bar indicates the average of reading for all the 
individual mice. Measurements between different experimental groups were 
compared using the Mann-Whitney test. Statistically significant measurements 
were indicated by *, ** or *** depending on the degree of significance and the 
p value indicated.  Unless otherwise indicated, measured values showed no 
statistical significance between different study groups. Cytokine levels below 
assay detection limit are labeled “nd”. 
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5.6 Discussion 
In the course of this study, we identified a total of 9 peptides that contain 
epitopes recognized by T cells directed against the allergen proteins Blo t 5 
and Der p 2 (Figure 5.19).  
A number of murine Der p 2 epitopes had been identified in previous 
studies. These are summarized in Figure 5.20. Wu et al, in 2002, described a 
major T cell epitope at position 21-35 (which corresponds to position 38-52 in 
our study due to the fact that our construct contains the signal peptide while 
the protein used in their study does not) (194). However, we did not observe a 
T cell response at this position, nor at position 88-102, which the group also 
identified as containing a T cell epitope. However, our results correlated more 
closely with Hoyne et al, 1993 (208). They described H-2b restricted T cell 
responses to a peptide spanning position 104-121 of the Der p 2 protein, which 
correlated with the responses we observed with Dp2#21 and Dp2#22. 
Additionally, they also described an epitope present at position 121-146, 
which again agreed with our results for Dp2#27. Finally, we also observed a T 
cell response in BALB/c mice against Der p 2 peptide 61-75 (Dp2#13). Hoyne 
et al also reported a response in their H-2d restricted mice against the amino 
acids at position 53-67 of the Der p 2 protein. Also, they described the 
response in the H-2d mice as being particularly weak compared to mice of the 
other haplotype, a phenomenon we also observed. However, we did not 
observe a T cell response with peptides spanning position 28-42. We believe 
that the differences observed could be due to the differences in assay methods. 
Both Hoyne et al and Wu et al measured T cell responses using the 3H-
thymidine proliferation assay. T cells were cultured for 4 days in the presence 
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of peptides and irradiated feeder cells. This could result in the expansion of T 
cells recognizing minor epitopes. With the ELISPOT assay, we are able to 
assay the T cell responses immediately ex vivo. While this may result in the 
possibility of missing rare epitopes, we believe that this gives a better snap 
shot of the major T cell responses in the mice. 
According to the Immune Epitope Database, there are no murine T cell 
epitopes identified for any of the Blomia tropicalis proteins. However, a T cell 
line recognizing a Blomia tropicalis epitope was recently described (209).  We 
were unable to detect any responses against this epitope in our study. As the T 
cell line had been cultured in the presence of Blo t 5 for a year, it is possible 
that the process expanded T cells recognizing a minor epitope of Blo t 5. 
HDM allergens are a common cause of allergies in both temperate and tropical 
regions and are relatively well studied. However, in the tropics, Blomia 
tropicalis is an equally important source of allergens. However, Blomia 
tropicalis allergens remains relatively poorly understood and studies on this 
subject are still lacking With the identification of the new CD4 T cell epitopes, 














Blo t 5 
Strain Name Position Sequence 
C57BL/6 Bt5#16 76-90 LDVVCAMIEGAQGAL 
C57BL/6 Bt5#21 101-115 ILERFNYEEAQTLSK 
C57BL/6 Bt5#22 106-120 NYEEAQTLSKILLKD 
BALB/c Bt5#15 71-85 KIIRELDVVCAMIEG 




Der p 2 
Strain Name Position Sequence 
C57BL/6 Dp2#21 101-115 QQYDIKYTWNVPKIA 
C57BL/6 Dp2#22 106-120 KYTWNVPKIAPKSEN 
C57BL/6 Dp2#27 131-146 DGVLACAIATHAKIRD 
BALB/c Dp2#13 61-75 NQNTKTAKIEIKASI 
 
Figure 5.19 Summary of T cell epitopes identified in this study. In total, 9 
peptides were found to contain epitopes recognized by CD4 T cells directed 
against mite allergen proteins (a) Blo t 5 and (b) Der p 2. No CD8 T cell 
epitopes were identified.  
 









88-102 NACHYMKCPLVKGQQ (194) 
B10 (H-2b) 28-42 HEIKKVLVPGCHGSEPCIIHRGKPF (208) 
B10 (H-2b) 
B10.BR(H-2k) 
104-121 DIKYTWNVPKIAPKSENV (208) 
B10 (H-2b) 121-146 VVTKVMGDDGVLACAIATHAKIRD (208) 
B10.BR (H-2k) 53-67 QLEAVFEANQNTKTA (208) 
B10.BR (H-2k) 104-121 DIKYTWNVPKIAPKSENV (208) 
B10.D2 (H-2d) 53-77 QLEAVFEANQNTKTAKIEIKASIDG (208) 
Figure 5.20 Murine Der p 2 T cell epitopes identified in other studies. 
A list of Der p 2 epitopes identified in earlier studies. The position of the 
amino acids in these epitopes were adjusted to match the numbering of the Der 
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Several studies had identified a number of epitopes on Blo t 5 that 
could be recognized by antibodies directed against the protein. The murine B 
cell epitope, from the monoclonal 4A7 antibody, was mapped by nuclear 
magnetic resonance (NMR) studies (210). The antibody was shown to bind in 
a conformation-specific manner to two epitopes, LNENK (residues 60-65) and 
KIIR (residues 71-74). The numbering of these residues was changed from the 
original numbering used in the manuscript to reflect the context of the 
peptides used in this experiment. This is due to the fact that groups working on 
this protein used slightly different constructs in their assays and hence the 
assigned positions of the amino acids could differ from the nomenclature used 
in our study. These residues do not fall within the T cell epitopes identified in 
this study, with the exception of the BALB/c epitope in Bt5#15, which 
overlaps with the second 4A7 antibody epitope. Information on human 
antibody binding sites are more prevalent. Chan et al (2008) analyzed the 
solution structure of the Blo t 5 protein by NMR (185). They identified four 
major IgE binding epitope residues, Glu93, Asp98, Glu103 and Glu108. These 
residues were found to be highly solvent exposed and were localized at or 
around the loop region connecting the α2 and α3 helices of the molecule. 
Mutation of any of these residues produced a significant reduction in IgE 
binding in 50% or more patient sera. Using overlapping peptides, the authors 
highlighted a putative major linear IgE epitope between the residues 93-108 
(ELKRTDLNILERFNYE). Another study in 2003 analyzed the responses of 
131 patients to Blo t 5 (211). Their observations showed that 75% of Blo t 5 
sensitive patients were allergic to a fragment derived from Blo t 5 amino acids 
86-133. This is the same region in which Bt5#21 and Bt5#22 are located. 
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Finally, we also found overlaps between the T cell epitopes identified in this 
study with linear IgE binding epitopes reported by Caraballo et al in 1998 
(212). One of the epitopes, LDVVCAMIEGAQCALER, completely 
overlapped Bt5#16 (an epitope we identified in both C57BL/6 and BALB/c 
mice) while two other epitopes TNLNILERFNYEEAQT and 
EEAQTLSSKILLKDLKE overlapped with Bt5#21 and Bt5#22.  
Therefore, it would seem that the T cell epitopes identified in this 
study overlapped with linear IgE recognition epitopes identified in sera of Blo 
t 5 sensitive patients. Bt5#21 and Bt5#22 were located in a region of the 
protein that was shown to be highly solvent exposed and hence available for 
antibody binding. Also, inhibition ELISA studies showed that IgG from mice 
immunized with Blo t 5 was able to block the binding of IgE antibodies from 
human sera (185). This suggests that murine antibodies could recognize 
epitopes found in the same region as linear epitopes recognized by human 
antibodies. This implies that the CD4 T cell epitopes in this region could 
possibly overlap with recognition sites of murine antibodies as well. 
It had been suggested that antibody binding could affect the processing 
and presentation of epitopes recognized by T cells. Many studies have shown 
that antibody binding could either improve or suppress the presentation of 
particular epitopes to the cognate T cells (213-216). Antibody binding to the 
epitope containing region is postulated to affect epitope processing by 
protecting the epitope from proteolysis or reduce presentation by interfering 
with the loading of the peptide onto class II MHC. However, it is unclear if 
such a mechanism is involved in IgE-binding to T cell epitope containing 
regions in allergic asthma. 
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We next showed that CD4 T cells specific for the C57BL/6 Blo t 5 
epitopes identified in this study were recruited into the lung following 
intranasal Blo t 5 challenge and produced Th2 cytokines and mediated 
eosinophilic infiltration into the airways. In the lungs, CD4 T cells recognizing 
Bt5#16 responded more strongly than T cells recognizing Bt5#21 or Bt5#22. 
This was clearly different from the response in the periphery. We do not 
observe this difference following intradermal immunization with pVAX-trunc 
Blo t 5 (Figure 5.9). It would suggest that these differences might be specific 
to the lung. This has implications in vaccine studies as T cell epitopes that 
generated a robust response in the periphery may very well induce a very 
different response in the lung. Furthermore, our observations suggest that the 
assignment of roles to Th2 T cells as asthma inducers and Th1 T cells as 
potential repressors of the allergic asthma responses may be too simple an 
assumption. Here, we clearly observed a robust production of IFNγ concurrent 
with the production of Th2 cytokines such as IL-5, IL-10 and IL-13, 
suggesting that the production of these cytokines are not mutually exclusive. 
Moreover, the mice developed clear eosinophilia despite the presence of 
strongly IFNγ secreting cells. 
Finally, we demonstrated that the intradermal delivery of these 
peptides (without the presence of any adjuvant) could induce a regulatory 
response that dampened the airway inflammatory responses. This correlated 
with the findings of several other studies (135, 176, 196, 197, 206). Due to a 
shortage of mice following a change in supplier to CARE, NUS, we were only 
able to assign 4 animals to each group (control peptide and Blo t 5 peptides). 
With more mice available, we plan to further optimize the sensitization and 
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challenge protocol as well as the peptide immunotherapy procedure. However, 
the preliminary results clearly demonstrated a possibility for the use of these 
peptides to attenuate the response against Blo t 5. 
To summarize, we managed to identify a number of Blo t 5 and Der p 
2 epitopes in this study. The Der p 2 epitopes we identified matched well with 
epitopes previously identified using other methods and demonstrated that our 
DNA immunization and ELISPOT screening approach can be reliably used for 
the mapping. This method has the benefit of being more flexible as the gene 
encoding the protein of interest could be easily cloned into the vaccination 
vector. Additionally, plasmid DNA immunization reliably induced CD8 T cell 
responses as well, a weakness of protein-based immunization methods. We 
identified a number of novel Blo t 5 epitopes using this method and 
demonstrated that the T cells recognizing these epitopes were recruited to the 
lungs following antigen challenge and were able to induce allergic lung 
responses as characterized by the infiltration of eosinophils into the lung and 
the production of Th2 cytokines. Finally, we showed that these peptides could 
be used to induce a regulatory response that attenuated the allergic airway 
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Unlike CD4 T cells, the role played by CD8 T cells in allergic asthma is 
less clear, with several studies identifying contradictory roles for CD8 T cells. 
Some studies pointed to CD8 T cells exacerbating the asthma phenotype. CD8 
knockout mice sensitized and challenged with OVA demonstrated decreased 
AHR and eosinophlic infiltration (217). Cells from the lung draining lymph 
nodes of the CD8 knockout mice also exhibited decreased IL-13 production 
following antigenic stimulation in vitro or in vivo (217). Identification of the 
Tc2 subset of CD8 T cells that could infiltrate into the asthmatic lung and 
secrete high levels of type 2 cytokines such as IL-4, IL-5 and IL-13 further 
supported this hypothesis (150, 218, 219). However, other studies in both rats 
and mice pointed to a role for CD8 T cells in suppressing IgE responses in 
allergic asthma (220-222). CD8 T cells had also been shown to upregulate 
IL12 production using a combination of IFN-γ production and CD40-CD40L 
interactions (145). Additionally, in vivo studies suggested a possible role for 
both IFN-γ and perforin mediated mechanisms in regulating airway responses 
to allergen proteins (146, 147). In both studies, a marked decline in 
eosinophilic infiltration was observed. IL-4, IL-5 and IL-13 levels were 
markedly lower in perforin-competent mice that had been immunized to 
generate a CD8 T cell response prior to airway challenge with OVA (147). 
Several studies have explored the possibility of an asthma vaccine by inducing 
an allergen specific CD8 T cell response (223, 224). 
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However, it is worth mentioning that the studies involving CD8 T cell 
responses in asthma have been performed in the OVA asthma model. The lack 
of suitable tools for studies in models using true asthma allergens are probably 
a major factor in these choices. Researchers working on the OVA model have 
the benefit of a wide array of tools from which to perform their studies. Kb-
SIINFEKL class I MHC multimers, directed against a major OVA epitope, is 
available commercially and allow for the detection and tracking of OVA 
specific CD8 T cells. The OT-I TCR transgenic mouse is an enormously 
useful tool and had been used to great effect in many of the studies described 
above. The mice provide a ready source of antigen specific CD8 T cells for 
use in in vitro and in vivo adoptive transfer studies. These mice could also be 
readily crossed to produce derivation such as the IFNγ knockout OT-I strain 
(146) to study the role of different effector molecules.  
However, it is increasingly clear that asthma allergens differ quite 
significantly from OVA. Asthma allergens such as house dust mite proteins 
consist not of a single protein but rather a heterogeneous mix of proteins with 
different characteristics (225, 226). These proteins had been shown to 
demonstrate a variety of biological activities not associated with OVA. Group 
1 house dust mite allergens possess cysteine protease activity similar to the 
enzyme papain (227). Studies of Der p 1 have demonstrated the ability of the 
protein to affect the permeability of the bronchial epithelium by disrupting 
tight junctions (228). Der p 1 had also been shown to induce pro-inflammatory 
mediators such as IL-6, IL-8, eotaxin, GM-CSF and some chemokines, 
possibly through the activation of protease-activated receptors such as PAR-2 
(229-232). Group 3, 6 and 9 mite proteins have been shown to have serine 
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protease activity. Group 2 house dust mite allergen, specifically Der p 2, is 
structurally homologous to MD-2, an LPS binding protein that plays a key role 
in the TLR4 signaling pathway and was able to facilitate TLR4 signaling 
(175). These properties of mite allergens, and indeed other allergens, cannot 
be seen in the OVA model of asthma. Hence, there exists a major gap in our 
knowledge regarding the role played by CD8 T cells in the lung responses to 
an actual asthma allergen. 
We believe that the availability of tools such as class I MHC tetramers 
and TCR transgenic mice specifically recognizing epitopes from mite allergen 
will be very useful for furthering the knowledge in the role of CD8 T cells in 
allergic asthma. A CD8 T cell epitope for Der p 1 had been identified 
previously (177). We aim to generate a CD8 T cell response in mice against 
this epitope and expand the antigen specific cells in vitro. Following this, the 
T cell receptor genes will be characterized using 5’ RACE and gene 
sequencing. The α and β chains of the Der p 1 specific TCR would then be 
cloned into pTαcass and pTβcass cassette vectors (233). These vectors have been 
used to generate TCR transgenic mice. We will also produced class I MHC 
tetramers capable to staining Der p 1 specific CD8 T cells, allowing us to track 
the Finally, we set up an acute allergic asthma model using house dust mite 
extract and examined the role played by Der p 1 specific CD8 T cells in 
responses to the allergen during the early stages of asthma development. 
6.2 Immunization of mice 
To induce a CD8 T cell response against the Der p 1 epitope, we used the 
intradermal plasmid DNA immunization strategy as used in Chapter 5. As 
CD8 responses can be augmented by the presence of CD4 T cell help, the 
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inclusion of the tetanus toxoid fragment C (TTFC) containing T helper cell 
epitopes can help boost the CD8 T cell response. Professor Ton Schumacher 
of the Netherlands Cancer Institute (NKI) kindly provided the d1TTFC-NP 
DNA vaccine plasmid (200). This vector contains the TTFC gene (amino 
acids 831-1315) preceding the sequence encoding the influenza NP366-374 
epitope in a pcDNA3.1 plasmid backbone. The TTFC sequence was 
engineered to remove any CD8 T cell epitopes. For our purpose, we 
engineered the Der p 1 epitope into the 3’ end of the TTFC sequence (Figure 
6.1a). We designed primers for the 5’ and 3’ end of the TTFC gene, prior to 
the NP sequence (Figure 6.1b). In the reverse primer (TTFCDp1-reverse), we 
included the nucleotide sequence encoding the Der p 1 epitope (FGISNYCQI). 
Also included are HindIII (5’) and NotI (3’) restriction sites for cloning into 
the pVAX1 vector. The PCR product was subcloned into TOPO2.1 TA 
cloning vector as an intermediate step. Double restriction digest with HindIII 
and NotI was carried out for the TOPO-TTFC-FGISNYCQI and the pVAX1 
vector. The fragments were then ligated with T4 DNA ligase and transformed 
into E.coli DH5α. Colonies were selected on LB-kanamycin agar and 
screened by colony PCR. Positive colonies were verified for fidelity by 
sequencing. 
Mice were immunized intradermally on days 0,3 and 6 by skin tattoo with 
a rotary tattoo device as previously described. On day 14, mice were culled 
and the splenocytes assayed for antigen specific CD8 T cells by IFNγ 
ELISPOT. We also screened the splenocytes using Db-FGISNYCQI tetramers. 
These tetramers were produced through UV-mediated ligand exchange using 
H-2Db class I MHC monomers refolded with the SV9-P7 peptide. As a control, 
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mice were also immunized with the pVAX1 vector without the TTFC-
FGISNYCQI sequence inserted. We observed IFNγ producing cells when 
splenocytes from pVAX-TTFC-FGISNYCQI immunized mice were cultured 
with the FGISNYCQI peptide but not with the control peptide 
(ASNENMETM) (Figure 6.2a). Mice that were immunized with the control 
plasmid did not respond to either peptide. Similarly, Db-FGISNYCQI tetramer 
staining was only observed with mice immunized with pVAX-TTFC-
FGISNYCQI (Figure 6.2b). Therefore, we could conclude that the 
immunization method used was effective in generating a CD8 T cell response 
against the Der p1 epitope. Also, for the first time, class I MHC tetramers 
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CMV promoter TTFC FGISNYCQI 
(a) 
(b)  
Primer name Primer sequence (5’ è 3’) 
TTFCDp1 - forward CTTAAGCTTGCCACCATGGCCAAGAACCT  






Figure 6.1 Gene construct for immunization of mice. (a) The pVAX-TTFC 
plasmid consists of the pVAX1 plasmid backbone with the tetanus toxoid 
fragment C (TTFC) inserted. The class I MHC binding motif from Der p 1 
(FGISNYCQI) was inserted immediately downstream of the TTFC sequence. 
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(b) Primers used for PCR cloning. The Der p 1 epitope was inserted by PCR 
(c) and the PCR product subcloned into TOPO2.1. The entire TTFC-
FGISNYCQI construct was digested with HindIII and BamHI (d) and ligated 
into similarly digested pVAX1 plasmid. The presence of the desired insert was 

















Figure 6.2 Immunization of mice with pVAX-TTFH-FGISNYCQI. Mice 
were immunized intradermally by skin tattoo. Splenocytes of immunized mice 
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6.3 Generation of a Der p 1 specific CD8 T-cell line. 
Splenocytes from immunized mice were cultured with the FGISNYCQI 
peptide for 7 days. Following this, the cells were restimulated with irradiated 
splenocytes (CD90 depleted) as feeders and supplemented with IL-2, IL-7 and 
IL-15. The restimulation cycle was carried out every 7 days. T cells were 
screened by tetramer staining. Following 4 restimulation cycles, the T cell line 
consisted almost entirely (96.9%) of antigen specific CD8 T cells (Figure 
6.3a). To control for specificity of staining, frozen and thawed aliquots of OT-
I mouse splenocytes were used. These cells were not stained by the Db-
FGISNYCQI tetramers. We also stained cells from the cell line with Db-
ASNENMETM class I MHC tetramers as a background control. All samples 
were stained with LIVE/DEAD stain to differentiate the live cells from the 
dead cells. Generally, dead cells do bind the tetramers and contribute to a 
higher background staining that may lead to artefacts.  
To confirm the specificity and functionality of these cells, we next carried 
out a chromium-51 cytotoxicity assay. The CD8 T cells were incubated with 
EL4 cells pulsed with the cognate (FGISNYCQI) peptide or a control peptide 
(ASNENMETM). Specific killing was observed only with FGISNYCQI 
pulsed target cells (Figure 6.3b). 
The Der p 1 specific CD8 T cell line was also analyzed by intracellular 
cytokine staining (Figure 6.3c). Briefly, we incubated the CD8 T cells with 
irradiated feeder cells and the FGISNYCQI peptide (or ASNENMETM as 
control). Following this, the cells were surface stained and fixed and 
permeabilized before cytokine staining. The CD8 T cells were observed to 
respond specifically to the FGISNYCQI peptide and produced predominantly 
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IFNγ, (78.8%) although some were also observed to produce TNFα (17.8%). 
No Tc2 cytokine (IL-4 or IL-5) production was observed.  
We also screened the T cells with the mouse Vβ TCR screening panel 
(BD Pharmingen, Singapore). This is a panel of monoclonal antibodies 
recognizing some of the murine TCR Vb regions (Vb 
2,3,4,5.1,5.2,6,7,8.1,8.2,8.3,9,10b,11,12,13,14 and 17a). However, none of 
these antibodies were able to stain the Der p 1 specific T cells, suggesting that 
the TCR did not use any of the Vβ chains tested. 
Aliquots of the Der p1 specific CD8 T cell line were frozen in liquid 








Figure 6.3 Establishment of a Der p 1 specific T cell line. Splenocytes from 
mice immunized with plasmid DNA encoding the Der p 1 epitope were 
cultured with the peptide in vitro. (a) Following 4 cycles of restimulation, 
tetramer staining with Db-FGISNYCQI showed that a majority of the cells in 
culture were specific for Der p 1. As control, OT-I cells were stained with the 
same tetramer. The cell line was also stained with a tetramer against an 
irrelevant Db  restricted epitope (ASNENMETM) . (b) Chromium release assay. 
EL4 cells were pulsed with FGISNYCQI or a control peptide, ASNENMETM. 
(c) Intracellular cytokine staining of Der p 1 specific T cell line. Cells were 
restimulated for 6hr with FGISNYCQI or ASNENMETM in the presence of 
brefeldin A and monensin before staining. 
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6.4 Characterization of T cell receptor gene 
The mouse T cell receptor gene loci contain a large number of genes 
encoding a huge number of possible combinations. The mouse T cell receptor 
α (TRA) region contains a potential repertoire of 73-84 functional variable 
chain (TRAV) genes, 38 joining (TRAJ) genes and a single constant region 
gene (TRAC) (234). The murine TCR β (TRB) region in the genome contains 
21-22 functional variable chain genes (TRBV), 2 diversity genes (TRBD), 11 
joining (TRBJ) genes and 2 constant region (TRBC) genes. A productively 
recombined TCR gene consists of single VJC chains for TCR α and VDJC 
chains for TCR β.Therefore, identification of TCR chain usage cannot be 
easily performed by PCR as the possible primer combinations for the V region 
are numerous. Should the V region gene usage be known, it could be possible 
to design primers that could prime the relevant V region. However, screening 
with the mouse Vβ TCR screening panel (BD Pharmingen, Singapore) did not 
yield any positive results. The most common method used to characterize the 
TCR gene usage is by 5’ Rapid Amplification of cDNA Ends (5’-RACE). In 
this method, the enzyme terminal deoxynucleotidyl transferase (TdT) is used 
to add a homopolymeric (dCTP) tail to the 3’ end of the cDNA. This allows 
the use of primers designed to bind the dCTP-tail as a forward primer for PCR 
amplification. Briefly, the mRNA extracted from the T cell line was purified 
and converted to cDNA by reverse transcription (the mRNA for TCR α and 
TCR β is shown schematically in Figure 6.4a). This was followed by the 
addition of the dCTP tail by TdT and purification to remove cDNA without 
the dCTP tail. This was followed by PCR using a primer for the dCTP tail 
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(abridged anchor primer) and a reverse primer specific for the constant region. 
The PCR product was TA cloned into TOPO2.1 TA cloning vector and 
sequenced to identify the TCR gene. This is summarized in Figure 6.4b. The 
sequence obtained can be compared to the sequences of known TCR genes on 
the database found in the International ImMunoGeneTics information systems 
website (http://ww.imgt.org)(235). As it is common to encounter fragments 
and sequences for unproductively combined TCR genes, we picked and 
sequenced close to 20 colonies for each TCR chain. The database searches 
returned two productive TCR chain combination for the TCR α. 11 out of 18 
colonies yielded the same TCR sequence (TRAV7-5*01/TRAJ26*01) with 
only a single colony returning a productive TCR combination of 
TRAV16N*01/TRAJ34*02. The TRAV7 family correlates to the AV1 family 
of TCR α chains under the older classification system by Arden et al, 1995 
(236). Sequencing results returned a single productive combination of TCR β 
genes, TRBV5*01/TRBD1*01/TRBJ2-3*01/TRBC2. The TRBV5 gene 
correlates to the Vb1 TCR in the “old” classification system by Wilson et 
al,1988 and 1S1 under the classification system by Arden et al, 1995 (237, 
238). The murine Vβ screening panel used previously did not contain antibody 
for Vβ1 and hence was unable to stain this TCR during the screening process. 
The limited usage of TCRs indicated that the Der p 1 specific CD8 T cell line 
had been grown close to clonality. The TCR gene usage is shown in Figure 
6.6a and the complete sequences are shown in Figure 6.6b (TCR α) and 
Figure 6.6c (TCR β). Generally, the TCR chain consists of a leader sequence 
consisting of the L-PART1 and L-PART2, which are separated by an intron in 
the genomic sequences but spliced together following transcription. There 
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exist 3 complementarity-determining regions (CDRs) that are believed to be 
the major players in antigenic recognition. The CDR1 and CDR2 regions are 
generally associated with the recognition of specific MHC molecules while 
the CDR3 region is the major player in recognition of the antigenic peptide 
bound to the presenting MHC molecule. This is, however, an 
oversimplification, as the CDR1 and CDR2 regions are also believed to play a 
major role in shaping the conformation of the CDR3 loop to allow for the 
binding to a peptide-MHC. The hypervariability of the CDR3 region is central 
to the antigen-specific properties of the TCR. The joining of the V and J 
regions (or V-D-J for TCR β) is imprecise and there exists significant 
variability in the loop length and amino acid sequence in this region. It is this 












Figure 6.4 Molecular characterization of TCR chains. (a) graphical 
representation of the structure of the TCR mRNA. (b) overview of the 5’ 
RACE procedure to amplify the TCR chain cDNA from the mRNA. The 
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Figure 6.5 Primers used in 5' RACE characterization of TCR chains. 
 
(a) 
 TCR α TCR β 
V gene TRAV7-5*01 TRBV5*01 
D gene - TRBD1*01 
J gene TRAJ26*01 TRBJ2-3*01 
C gene TRAC TRBC2 
CDR3 region CAVRNNYAQGLTF CASSHRQGGAETLYF 
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(c) TCR β 
 
 
Figure 6.6 T cell receptor chains of the Der p 1 specific T cell line. (a) TCR 
chain usage of the Der p 1 specific T cell line. cDNA sequences of (b) TCR α 
and (c) TCR β chains with the relevant segments marked in accordance to the 
IMGT nomenclature. Shown are the leader sequences (L-PART1 and L-







L-P... 2  L-PART 2
Leader
TACTCGACGTCCGAAGAGGAGATACAAAGGGATACAGAACACCTTTGTCGTGAGTACttgtgattttaatgagtcagtggttctatagattaggacccttctcgtttatt3'
M S C R L L L Y V S L C L V E T A L M N T K I T Q S P R Y L I L G R A N K1
 110
gtctttggaatgtgagcaacatctgggacataatgctatgtactggtataaacagagcgctgagaagccgccagagctcatgtttctctacaatcttaaacagttgattc5'
FR1-IMGT CDR1-IMGT FR2-IMGT CDR2-IMGT  FR3-IMGT
TRBV5*01 F
cagaaaccttacactcgttgtagaccctgtattacgatacatgaccatatttgtctcgcgactcttcggcggtctcgagtacaaagagatgttagaatttgtcaactaag3'
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6.5 Cloning of T cell receptor gene into cassette vectors 
TCR transgenic mice can be generated by microinjection of linearized 
DNA fragments into fertilized eggs. These DNA fragments contain the gene 
encoding the rearranged TCR gene of the desired specificity as well as 
upstream and downstream untranslated regions that contain various splicing 
and regulatory elements. Generally, expression of a functionally rearranged 
TCR inhibits further rearrangement of genome encoded TCR loci, allowing 
for the exclusive expression of the transgene encoded TCR on a majority of 
the T cells (a phenomenon known as allelic exclusion). However, it has been 
reported that the transgenic β chain generally provided good allelic exclusion 
while transgenic TCR α chains are generally less effective at maintaining 
allelic exclusion (reviewed in (239)). 
For the purpose of producing the TCR transgenic mice with CD8 T cells 
specific for the house dust mite protein, Der p 1, we employed the strategy 
employed by Kouskoff et al, 1995. This method employs two gene cassettes, 
pTαcass and pTβcass to produce the necessary gene construct, inclusive of 
regulatory elements that are required to express the desired rearranged TCR. 
Both gene cassettes were originally derived from the DNA initially used to 
produce the H-Y specific TCR transgenic mice (240, 241). The authors 
included the 5’ flanking region upstream of the Vα region of the H-Y TCRα, 
reasoning that all the essential regulatory and promoter motifs should be 
present. They also included all the sequences downstream of the 3’-most Jα 
segment (Jα2). This is due to the fact that TCR rearrangements resulting in the 
loss of sequences upstream of the Jα2 region still produced TCRs that were 
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efficiently transcribed. Unique restriction sites were also introduced to allow 
for more convenient cloning of the TCR genes into the cassette vector. 
Similarly the pTβcass vector contained the region upstream of the Vβ5.1 
(TRBV 12-2) TCR chain with all the required regulatory regions as well as the 
sequences just upstream of the Jβ2.6 (TRBJ2-6) segment till the Cβ exons. 
Additional unique restriction sites were also introduced.  
Both the TCR sequences derived from genomic DNA or mRNA could be 
cloned into these cassettes to produce constructs that could productively 
express the desired TCR. However, there exist two intron sequences found in 
the genomic DNA. Firstly, an intron divides the leader region into L-PART 1 
and L-PART 2, as mentioned above (Figure 6.6b and Figure 6.6c). It is not 
certain if this intron sequence could influence the expression of the TCR. 
Additionally, there exists a splice site at the J-C intron that is not found in the 
mRNA. While this splice sequence can be added by PCR, we decided that the 
use of genomic DNA represents the most promising approach to produce a 
functional gene construct.  
Genomic DNA was extracted from the Der p 1 specific T cell line as a 
template. PCR primers were designed to amplify the TCR genes from the 5’ 
UTR upstream of the leader sequence till the 3’ UTR downstream of the of the 
J region (Figure 6.7). This includes the splicing sites at the J-C intron. We 
introduced several mutations in the primer to produce the desired restriction 
sites for cloning. For TCRα, we introduced an Xma I site at the 5’ end and a 
Not I site at the 3’ end (Figure 6.8a). For TCRβ, the restriction sites used in 
Kouskoff et al 1995 were Sac II and Xho I. However, we located an Xho I site 
within the TCR gene, thus precluding the use of this restriction enzyme in our 
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cloning process. However, Sal I produce a sticky end compatible with that 
produced by Xho I allowing for the ligation of the TCR gene with the cassette 
vector cut with Xho I. Therefore, we introduced a Sal I site in the forward 
primer for the 5’ UTR. We also introduced a Sac II site in the reverse primer 
for the 3’ UTR just downstream of the splice site. Figure 6.8b shows the final 
genomic TCR β sequence cloned out from the genomic DNA. The PCR 
products containing the TCR chain genes were subcloned into the TOPO2.1 
TA cloning vector. 
 Firstly we verified the integrity of the pTαcass and pTβcass vectors. Both 
vectors are very large (~20kb) and susceptible to shearing. We received the 
plasmids from Prof Chua Kaw Yan (Department of Pediatrics, National 
University of Singapore) with permission from the creator, Professor Dianne 
Mathis. We transformed the vectors into E.coli DH5α for expansion and 
screened the resulting colonies to check for the integrity of the plasmids. We 
observed several colonies that yielded plasmid DNA smaller than the expected 
size, suggesting that the plasmid may have been sheared and re-ligated into a 
smaller plasmid. We selected several colonies that produced plasmids of the 
correct sizes. To further verify the integrity of the plasmids, we digested the 
plasmid DNA with restriction enzymes and analyzed the ensuing restriction 
fragments.  
For pTαcass, we digested the plasmid with Sal I or BamHI. We verified 
that the restriction fragment sizes do indeed correlate with the expected 
restriction digest products from pTαcass (Figure 6.9a and Figure 6.9b). We also 
performed a double digest with Xma I and Not I to remove the TCR gene 
originally present in the cloning site into which we would insert the TCR a 
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chain from the Der p 1 specific T cells. We also proceeded to digest the 
TOPO2.1 vector containing the TCR a gene with Xma I and Not I to produce 
fragments with compatible sticky ends in the pTαcass vector. We next ligated 
the cut plasmid with the TCR α chain DNA with T4 DNA ligase and 
transformed the ligation product into E.coli DH5α. Colonies were screened by 
PCR. As the plasmids were too large to be sequenced directly, we sequenced 
the PCR product using nested primers to determine that the correct sequence 
was indeed inserted. In addition, we performed another RE digest using Sal I 
or BamHI to verify that the plasmid remains intact. We also performed double 
digests with Cla I + Xma I or Cla I + Not I to verify that the insert is in the 
correct orientation. A larger fragment should be obtained with the Cla I + Not 
I digest. 
For the pTβcass plasmid, we verified the integrity of the plasmid by single 
digests with BamHI or EcoRI (Figure 6.10a and Figure 6.10b). Again, we 
removed the original TCR β chain with a Sac II + Xho I double digest. We 
also performed a single digest with Sal I followed by a second digest with Sac 
II to obtain compatible sticky ends on the Der p 1 specific TCR β gene. This is 
due to the fact that Sal I and Sac II enzymes are do not share compatible 
conditions for a double digest to be performed. The TCR β gene was ligated 
into the pTβcass vector with T4 DNA ligase. Colonies were screened by PCR 
and the PCR products sequenced using nested primers to verify the fidelity of 
the insert. The integrity of the plasmid was verified BamHI or EcoRI single 
digests. We also performed a double digest with Xho I and Sac II. However, 
as the Xho I site does not exist on the newly ligated plasmid, we should not 
observe any digestion fragment, unlike the original pTβcass. Finally, we 
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verified by digestion with Cla I and Sac II that the insert was indeed in the 
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Primer name Primer sequence (5’ è 3’) 
TRAV 5'UTR XmaI gatcagaatccccgggggagagag 
TRAJ 3'UTR NotI gcctttcactcaggtatacttacagg 
TRBV5-UTR SalI cccgtcgacagcctgattccaccatgagctg 
TRBJ2-3-UTR SacII cccgcggattactagctcccaacttaccgagaaca 
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(b) TCR β genomic DNA 
 
Figure 6.8 Genomic DNA sequences of the TCR chains of the Der p 1 
specific CD8 T cell line. The genomic sequences of the TCR a (a) and TCR b 
(b) chains as amplified by PCR, inclusive of the intron separating the leader 
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Figure 6.9 Cloning of TCRα  chain into pTαcass. (a) The plasmid map of the 
pTαcass vector. (b) Restriction enzyme digest of the pTαcass vector. Sal I and 
BamHI were used to verify the identity of the plasmid. Digestion with Xma I 
and Not I removed the original TCR chain and produced the required sticky 
ends for annealing. (c) Restriction digest of TOPO vector containing the Der p 
1 specific TCR α. (d) PCR screening of colonies following ligation of pTαcass 
vector with Der p 1 specific TCR α. (e) Verification of the pTαcass – TCRa 
plasmid by restriction enzyme digest. 
  








Figure 6.10 Cloning of TCRβ  chains into pTβcass. (a) The plasmid map of 
the pTβcass vector. (b) Restriction enzyme digest of the pTβcass vector. 
Digestion with XhoI and SacII removed the original TCR chain and produced 
the required sticky ends for annealing. (c) Restriction digest of TOPO vector 
containing the Der p 1 specific TCR β. (d) PCR screening of colonies 
following ligation of pTβcass vector with Der p 1 specific TCR β. (e) 
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6.6 Role of CD8 T cells in immune response to mite allergens 
Next, we examined the role played by CD8 T cells in asthmatic lung 
responses to house dust mite allergen. We established an acute asthma model 
using only intranasal challenges with HDM extract (without any priming step 
using allergen proteins in combination with adjuvant as was common in the 
OVA model). Mice were sensitized by intranasal administration of HDM 
extract on day 0, followed by intranasal challenges with house dust mite 
extract on days 7, 9 and 11and were culled on day 14. This protocol is adapted 
from that used in (31, 35). Cell populations present in the BAL fluid were 
analyzed by flow cytometry. Eosinophils were stained Siglet F positive and 
CD11c negative, while macrophages were Siglet F and CD11c positive. Ly6G 
positive and CD11c negative cells were classified as neutrophils. T cells were 
identified by CD3 staining. Examples can be seen in Figure 6.11a.  
We titrated the dosage of HDM extract used to induce the asthmatic lung 
responses in C57BL/6 mice. We found that dosages of 1-10µg HDM induced 
a similar degree of eosinophilia as measured in the BAL fluid (Figure 6.11b). 
Sensitization and challenge with 100µg of HDM extract induced a slightly 
lower degree of eosinophilia compared to 1 or 10µg. We also found that 
increasing dosages of HDM extract resulted in increased recruitment of 
neutrophils into the lung. For our studies, we used dosages of 10µg for our 
sensitization and challenge protocols. 
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Figure 6.11 Murine model for house dust mite-induced asthma. Mice were 
sensitized at day 0 with the indicated quantities of HDM extract and 
challenged on days 7,9 and 11 with the same quantity of HDM extract. Mice 
were culled on day 14 and the BAL cell infiltrate measured by flow cytometry 
(n=3). Control mice were given PBS. (a) shows the gating strategy used to 
identify the various immune cells infiltrating into the lungs. Eosinophils were 
defined as SigletF+CD11c- cells; macrophages as SigletF+CD11c+Ly6G- cells; 
neutrophils as Ly6G+CD11c- cells and T cells as CD3+ cells. (b) Immune cell 
infiltrate into the lung following sensitization and challenge with different 
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We immunized mice with the pVAX-TTFC-FGISNYCQI plasmid DNA 
to induce a CD8 T cell response. We then culled the mice and cultured the 
splenocytes with the FGISNYCQI peptide for 7 days to expand the antigen 
specific T cells. In general, we obtained cultures with tetramer positive 
populations ranging from 25-40%. Dead cells were removed by Ficoll density 
gradient centrifugation prior to adoptive transfer. We transferred enough 
cultured cells to give 2x106 Der p 1 specific CD8 T cells into HDM extract 
sensitized mice on day 7 post-sensitization by intravenous injection into the 
tail vein. For example, for culture with 40% tetramer specific cells, a total of 
5x106 cells were transferred. Mice were then sensitized with HDM extract on 
day 7, 9 and 11 and culled on day 14 (Figure 6.12a). In Tang et al (2012), we 
observed a significant decrease in eosinophil infiltration into the lungs 
following the transfer of OT-I CD8 T cells into mice sensitized and 
subsequently challenged with OVA (146). Similarly, Enomoto et al (2012) 
induced a CD8 T cell response to OVA using SIINFEKL peptide pulsed bone 
marrow-derived dendritic cells (BMDCs) to induce a CD8 T cell response 
following OVA sensitization, prior to challenge with the OVA protein (147). 
They also reported a significant decline in eosinophilia in the presence of 
antigen specific CD8 T cells. With HDM, however, we did not observe any 
significant changes in the cell infiltrate into the lung of mice that had received 
CD8 T cells compared to the control mice that had only received PBS (Figure 
6.12b and 6.12c). We cultured the cells from the draining posterior 
mediastinal lymph node for 3 days in the presence of HDM extract and 
measured the cytokine released into the culture medium. Again, we observed 
no significant difference between the cytokine production in the two groups 
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(Figure 6.12d). We also collected and measured the cytokines in the BAL 
fluid. However, the levels of cytokines levels detected were often very low or 
not detectable and the trend similar to that observed in the MLN culture. 
Tetramer staining did not indicate the presence of Db-FGISNYCQI specific T 
cells in either group. Additionally, we stained lung sections of mice with 
periodic acid-Schiff stain to detect mucus producing cells in the airways 
(Figure 6.12e). We observed no mucus production in the PBS sensitized and 
challenged mice. However, mucus production was observed when mice were 
sensitized and challenged with HDM. Mice adoptively transferred with Der p 
1-specific CD8 T cells showed a similar phenotype as the mice that had not 
received the CD8 T cells. 
To confirm that the CD8 T cells transferred were viable and able to 
respond in an antigen specific manner, we analyzed a sample of these cells 
prior to adoptive transfer (Figure 6.12f). The antigen-specificity of the cells 
was verified by tetramer staining. In response to their cognate antigen, these T 
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Figure 6.12 Adoptive transfer of Der p 1 specific CD8 T cells into the 
murine model of HDM-induced asthma. (a) The sensitization and challenge 
protocol used. CD8 T cells specific for Der p 1 were transferred at day 6 by 
intravenous injection into the tail vein. BAL immune cell infiltrate were 
measured by flow cytometry and tabulated as % of total cells (b) or cell 
number (c). Each point represent a single mouse and the mean reading 
indicated by the line. (d) Cytokine ELISA measurements for culture medium 
of draining lymph node cells cultured with 10µg/ml HDM extract for 3 days. 
The bar indicates the average of reading for all the individual mice. 
Measurements between different experimental groups were compared using 
the Mann-Whitney test. Statistically significant measurements were indicated 
by *, ** or *** depending on the degree of significance and the p value 
indicated.  Unless otherwise indicated, measured values showed no statistical 
significance between different study groups. Additionally, p values may be 
indicated for measurements that showed an obvious difference but did not 
achieve statistical significance (indicated by “ns”). (e) Periodic acid-Schiff 
staining of lung sections from (i) PBS control mice, (ii) HDM sensitized and 
challenged mice without CD8 T cells and (iii) HDM mice that received CD8 T 
cells i.v. Mucus producing cells are stained red. Sections were counterstained 
by haematoxylin. (f) Prior to adoptive transfer, CD8 T cells in culture were 
stained with Db-FGISNYCQI tetramers and assayed for cytokine production 
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In Tang et al, cells were isolated from the OT-I transgenic mice and were 
already antigen specific in nature (146). CD8 T cell responses were induced in 
vivo by the transfer of peptide-pulsed BMDCs by Enomoto et al, 2012 (147). 
In this study, we do not yet have access to TCR transgenic mice that could be 
a source of antigen specific CD8 T cells for adoptive transfer experiments. In 
order to obtain sufficient numbers of Der p 1 specific CD8 T cells, splenocytes 
from plasmid DNA immunized mice were cultured in vitro with the 
FGISNYCQI peptide to expand the antigen specific population. Prior to 
transfer, we ascertained by intracellular cytokine staining that these cells could 
produce IFNγ in response to the Der p 1 peptide (Figure 6.12f). However, the 
in vitro culture of these cells could still have affected their functionality 
following transfer into the recipient mice. Therefore, we next attempted to 
generate a CD8 T cell response in vivo using plasmid DNA immunization. 
Mice were tattooed with 10mg of plasmid DNA encoding the Der p 1 epitope 
at day 0,3 and 6. Mice were sensitized on day 0 with HDM extract. Mice were 
then sensitized and challenged on days 10, 12 and 14 and culled on day 17 
(Figure 6.13a). Based on our previous study with the plasmid DNA 
immunization, the peak responses were observed at days 10-14 post 
immunization. We did not observe any differences in the percentage of 
eosinophils found in the BAL fluid (Figure 6.13b and 6.13c). However, there 
was a significant reduction in the number of eosinophils in the BAL fluid of 
mice that had received the plasmid DNA immunization compared to mice 
immunized with the control vector. There was no significant difference in the 
measurements of the cytokines in the lymph node cell cultures between the 
two groups (Figure 6.13d). The presence of Der p1 specific T cells was 
  
	   CHAPTER	  6:	  DER	  P	  1	  SPECIFIC	  CD8	  T	  CELLS	  AND	  HDM-­‐INDUCED	  ASTHMA	   	  	   	  
181 
determined by IFNγ ELISPOT assay of the splenocytes. Overall, we 
concluded that there were very little differences between groups that had 
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Figure 6.13 DNA immunization with plasmid encoding epitope recognized 
by Der p 1 specific CD8 T cells and the effect on lung responses to HDM. 
(a) The sensitization and challenge protocol used. A CD8 T cell response was 
induced by plasmid DNA immunization. Briefly, mice were immunized 
intradermally with 10µg pVAX-TTFC-FGISNYCQI plasmid DNA using a 
rotary tattoo device. BAL immune cell infiltrate was measured by flow 
cytometry and tabulated as % of total cells (b) or cell number (c). Each point 
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represent a single mouse and the mean reading indicated by the line. (d) 
Cytokine ELISA measurements for culture medium of draining lymph node 
cells cultured with 10µg/ml HDM extract for 3 days. The bar indicates the 
average of reading for all the individual mice. Measurements between 
different experimental groups were compared using the Mann-Whitney test. 
Statistically significant measurements are indicated by *, ** or *** depending 
on the degree of significance and the p value indicated.  Unless otherwise 
indicated, measured values showed no statistical significance between 
different study groups. Additionally, p values may be indicated for 
measurements that showed an obvious difference but did not achieve 
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The inability of the Der p 1 specific CD8 T cells to modify the immune 
responses to HDM similar to that observed in the OVA model could be due to 
several factors. The HDM extract is a heterogeneous mix of proteins; some 
with known biological activities and many other proteins with unknown 
functions. Sensitization and challenge models with OVA involve the use of a 
single uniform protein. However, mice receiving HDM would be exposed to a 
heterogeneous mix of proteins and the content of Der p 1 in the HDM extract 
may be too low to elicit a CD8 T cell response. The content of Der p 1 in 
HDM extract can vary from source to source and likely, even in different 
batches from the same source. Post et al (2012) assayed HDM extracts from 3 
different sources, including the source used in this study (Greer, USA) (242). 
The protein content varied quite significantly between extracts from different 
sources . The study also reported differences in enzymatic and biological 
activities between the different HDM extracts. What is also apparent is that the 
content of Der p 1 in the extracts was low (18ng/50µg protein in the Greer 
extract). Therefore, the lack of immunomodulation by Der p 1 specific CD8 T 
cells could simply be a result of the low availability of the cognate antigen 
recognized by these cells. Also, OVA is not a natural asthma allergen and 
challenges with OVA (without priming with adjuvant) resulted in tolerization 
in the lung. HDM however, contains a mix of protein with known biochemical 
and biological activities that had could actively modify the immune response 
in the lung. Therefore, the responses observed in the OVA model could be 
modified by the pro-Th2 environment produced by the HDM proteins. In the 
same study by Post et al (2012), they showed that the Der p 2 content of the 
Greer HDM extract was more than five times that of Der p 1 (428.9ng/50µg 
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protein). Other components of the HDM were not measured. These other 
proteins such as Der p 2 are known immunomodulators (175). Being present 
in far larger quantities than Der p 1, the responses to the other components of 
HDM could override the effect of the CD8 T cells responding to Der p 1. 
We examined this by repeating the adoptive transfer studies, but by using 
Der p 1 protein as the allergen. We purchased affinity purified, natural Der p 1 
protein from Indoor Biotechnologies. In this model, which more closely 
approximates the OVA model, the allergic lung responses would be induced 
against a single protein (Der p 1) and not a mix of proteins (HDM extract). As 
we found that the Der p 1 protein alone did not induce a robust allergic asthma 
response by intranasal administration alone, we modified the sensitization 
protocol. BMDCs were pulsed overnight with 10mg HDM before being 
transferred intranasally into mice at day 0. Mice were then challenged at days 
7, 9 and 11 with the Der p 1 protein in PBS before the mice were culled at day 
14 (Figure 6.14a). The use of BMDCs for sensitization was adopted from van 
RIjt et al, 2002 (207) but adapted to the BMDC culture protocols used in our 
laboratory. CD8 T cells were adoptively transferred by intravenous injection 
into the tail vein at day 6. In this model, we observed a significant decrease in 
eosinophilic infiltration into the lung in mice that had received Der p 1 
specific CD8 T cells prior to HDM extract challenge (Figure 6.14b and 6.14c). 
We do not observe significant changes in the other immune cells found in the 
BAL, although we do observe a general reduction in cell numbers in these 
cells (but not statistically significant). In mice receiving CD8 T cells, we also 
observed a statistically significant drop in the secretion of a number of Th2 
cytokines, Il-5, IL-10 and IL-13, in the culture medium of lymph node cells 
  
	   CHAPTER	  6:	  DER	  P	  1	  SPECIFIC	  CD8	  T	  CELLS	  AND	  HDM-­‐INDUCED	  ASTHMA	   	  	   	  
186 
cultured with HDM extract (Figure 6.14d).  We also stained the BAL cells for 
Db-FGISNYCQI specific CD8 T cells (Figure 6.14e). We observed a small 
population (1-2%) of tetramer positive cells in the group that had received Der 
p 1 specific CD8 T cells. The control group had negligible staining with the 
tetramer (>1%). Periodic acid-Schiff staining of the lung sections showed that 
mucus-producing cells were present in the airways of mice sensitized and 
challenged with Der p 1. We observed no obvious differences between the 
mucus productions in airways of mice that had received Der p 1-specific CD8 
T cells compared to those that did not (Figure 6.14f). 
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Figure 6.14 Role of Der p 1 specific CD8 T cells in lung responses to Der p 
1. (a) The sensitization and challenge protocol used. Bone marrow derived 
dendritic cells were pulsed overnight with Der p 1 protein prior to intranasal 
administration. CD8 T cells specific for Der p 1 were transferred at day 6 by 
intravenous injection into the tail vein. BAL immune cell infiltrate were 
measured by flow cytometry and tabulated as % of total cells (b) or cell 
number (c). Each point represent a single mouse and the mean reading 
indicated by the line. (d) Cytokine ELISA measurements for culture medium 
of draining lymph node cells cultured with 10µg/ml HDM extract for 3 days. 
The bar indicates the average of reading for all the individual mice. 
Measurements between different experimental groups were compared using 
the Mann-Whitney test. Statistically significant measurements were indicated 
by *, ** or *** depending on the degree of significance and the p value 
indicated.  Unless otherwise indicated, measured values showed no statistical 
significance between different study groups. Additionally, p values may be 
indicated for measurements that showed an obvious difference but did not 
achieve statistical significance (indicated by “ns”). (e) Db-FGISNYCQI 
tetramer staining of BAL cells. (f) Periodic acid-Schiff staining for lung 
sections from (i) mice sensitized and challenged with Der p 1 without Der p 1-
specific CD8 T cells or (ii) Der p 1 mice adoptively transferred with Der p 1-
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In the HDM extract model, sensitization was carried out by administration 
of HDM extract intranasally. However, for the Der p 1 model, we used 
BMDCs for the sensitization step as Der p 1 protein alone did not elicit a 
robust response. To ensure that the results observed in the Der p 1 model was 
not due to the change in sensitization strategy, we repeated the study but using 
HDM extract instead. BMDCs were pulsed with HDM extract overnight and 
transferred intranasally into the mice during the sensitization step (Figure 
6.15a). We did not observe any significant differences in cell infiltration in 
mice that had received the Der p1 specific CD8 T cells and mice that did not 
(Figure 6.15b and 6.15c) nor do we observe any significant differences in 
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Figure 6.15 Sensitization by HDM-pulsed BMDCs followed  by CD8 
adoptive transfer and HDM challenge. (a) The sensitization and challenge 
protocol used. Bone marrow derived dendritic cells were pulsed overnight 
with HDM extract prior to intranasal administration. CD8 T cells specific for 
Der p 1 were transferred at day 6 by intravenous injection into the tail vein. 
BAL immune cell infiltrate were measured by flow cytometry and tabulated 
as % of total cells (b) or cell number (c). Each point represent a single mouse 
and the mean reading indicated by the line. (d) Cytokine ELISA 
measurements for culture medium of draining lymph node cells cultured with 
10µg/ml HDM extract for 3 days. The bar indicates the average of reading for 
all the individual mice. Measurements between different experimental groups 
were compared using the Mann-Whitney test. Statistically significant 
measurements were indicated by *, ** or *** depending on the degree of 
significance and the p value indicated.  Unless otherwise indicated, measured 
values showed no statistical significance between different study groups. 
Additionally, p values may be indicated for measurements that showed an 
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Therefore, our observations suggested that the transfer of Der p 1 specific 
CD8 T cells could attenuate the allergic lung responses to Der p 1 protein but 
not against HDM extract. Again, this leads to the question; was the class I 
MHC epitope present in sufficient quantity to activate the Der p 1 specific 
CD8 T cells. To determine if this was the case, we pulsed BMDCs with the 
following; 10µg HDM extract, 100µg HDM extract or 10µg HDM extract + 
1µM FGISNYCQI peptide. Mice were given these BMDCs on day 0 and day 
7 and culled on day 10. We observed almost no Db-FGISNYCQI tetramer 
positive CD8 T cells in the BAL cells from the mice that had received the 
BMDCs pulsed with 10µg HDM (Figure 6.16a). We do observe some Db-
FGISNYCQI tetramer stained CD8 T cells in mice that had received 100µg 
HDM but the numbers are very low. However, we observed a robust CD8 T 
cell response in the BAL of mice that had received BMDCs pulsed with the 
FGISNYCQI peptide (up to 20% tetramer specific CD8 T cells were 
observed). BMDCs are very effective antigen presenting cells and are able to 
cross present exogenous antigens to CD8 T cells, although in a less efficient 
manner than peptide pulsed BMDCs (243). The efficiency of cross 
presentation is likely to be even lower in the lung had the mice received HDM 
extract intranasally. We also assayed the response of the Der p 1 specific T 
cells to HDM in vitro. Irradiated splenocytes were pulsed with a control 
peptide (ASNENMETM), the Der p 1 epitope (FGISNYCQI) or varying 
concentrations of HDM (up to 50µg/ml). Cells were pulsed with 3H-
thymidine following 3 days of culture and the proliferation of the CD8 T cells 
measured by the rate of incorporation of the radiolabeled thymidine (Figure 
6.16b). We only observed a significant degree of proliferation with Der p 1 
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specific CD8 T cells cultured with the FGISNYCQI peptide pulsed 
splenocytes. 
Finally, we attempted to determine if a robust CD8 T cell response 
against Der p 1 can affect the lung responses to HDM extract. We had 
previously shown that two administrations of BMDCs pulsed with the 
FGISNYCQI peptide could elicit a robust CD8 T cell response in the lung. 
Therefore, we intranasally administered two groups of mice; one with HDM 
pulsed BMDCs and the other with BMDCs pulsed with HDM and 
FGISNYCQI peptide. Mice were challenged a further three more times with 
HDM extract administered intranasally (Figure 6.17a). We reasoned that the 
peptide pulsed BDMCs administered on day 7 may interact with cytotoxic 
CD8 T cells specific for the FGISNYCQI peptide and may hence be less 
effective in eliciting a response to HDM, leading to an aberrant observation. 
By challenging with HDM extract, we ensured that the lung cells were still 
exposed to HDM proteins and any effects observed were due to the direct or 
indirect effect of these CD8 T cells on the lung cells and not on the transferred 
BMDCs. The analysis of BAL cells after day 14 showed that there was a small 
but significant decrease in eosinophil percentage in the lung (Figure 6.17b). 
Also, there were a larger percentage of T cells in the lung. However, cell 
numbers tell a different story. We observed a significantly greater number of 
immune cells in the BAL, predominantly eosinophils and T cells. Both 
eosinophils and T cells were present at greater numbers in the lungs of mice 
that had received peptide pulsed BMDCs compared to mice that had only 
received BMDCs with HDM extract (Figure 6.17c). ELISA analysis of lymph 
node culture medium showed significantly increased IFNγ production in 
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lymph nodes of mice that had received the peptide pulsed BMDCs (Figure 
6.17d). Correspondingly, lymph node cells from this group of mice produced 
less IL-4 and IL-10. However, we observed that the mice that received the 
FGISNYCQI peptide pulsed BMDCs produced significantly higher levels of 
IL-5 and IL-13 cytokines. IL-17A production was also significantly increased 
in the group of mice that had received peptide pulsed BMDCs. Tetramer 
staining of BAL cells confirmed the presence of large numbers of Der p 1 
specific CD8 T cells in the lung lavage of mice that received BMDCs pulsed 
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Figure 6.16 Der p 1 CD8 T cell responses to house dust mite extract. 
(a) Mice were given BMDCs pulsed with HDM (10mg or 100mg) or the 
FGISNYCQI peptide at Day 0 and 7. Mice were culled at Day 14 and the 
BAL stained with Db-FGISNYCQI tetramers. (b) Der p 1 specific CD8 T cell 
line was incubated for 3 days with splenocytes pulsed with 1mM 
ASNENMETM (as control), 1mM FGISNYCQI or HDM (1, 10 and 50mg/ml). 














Figure 6.17 Induction of pulmonary CD8 T cell response by transfer of 
peptide-pulsed BMDCs and the effect on asthma development. (a) The 
sensitization and challenge protocol used. Bone marrow derived dendritic cells 
were pulsed overnight with HDM extract or HDM extract and FGISNYCQI 
peptide prior to intranasal administration. BAL immune cell infiltrate were 
measured by flow cytometry and tabulated as % of total cells (b) or cell 
number (c). Each point represent a single mouse and the mean reading 
indicated by the line. (d) Cytokine ELISA measurements for culture medium 
of draining lymph node cells cultured with 10µg/ml HDM extract for 3 days. 
The bar indicates the average of reading for all the individual mice. 
Measurements between different experimental groups were compared using 
the Mann-Whitney test. Statistically significant measurements were indicated 
by *, ** or *** depending on the degree of significance and the p value 
indicated.  Unless otherwise indicated, measured values showed no statistical 
significance between different study groups. Additionally, p values may be 
indicated for measurements that showed an obvious difference but did not 



























While studies have shown that CD8 T cells can play a significant role in 
the attenuation of asthma in the OVA model, less in known in the context of 
allergic asthma caused by natural allergens such as mite allergens. Here, we 
examined the effect of CD8 T cells on the development of allergic asthma 
responses to HDM protein. Our initial work is focused on the acute model of 
asthma and showed that, unlike OVA, sensitization and challenge with HDM 
extract alone (without the use of adjuvant) was able to induce a robust lung 
response to the allergen, characterized by the infiltration of eosinophils into 
the airways and the secretion of Th2 cytokines. Adoptive transfer of CD8 T 
cells specific for Der p1 did not significantly alter the disease pathology, 
unlike observations made in the OVA allergic asthma model. We verified that, 
using Der p 1 protein rather than the HDM extract, adoptively transferred CD8 
T cells were able to attenuate the allergic lung responses, resulting in reduced 
cell infiltration (in particular eosinophils) and reduced production of Th2 
cytokines. We next showed that HDM extract was inefficient in inducing a 
CD8 T cell response. Finally, we induced a robust CD8 T cell response in the 
lung alongside a HDM extract induced allergic airway inflammation. Rather 
than attenuating the response, we observed in this context that the CD8 T cell 
response in fact augmented the inflammatory response. We observed a greater 
magnitude of eosinophilic infiltration into the lung. Although we measured 
significantly higher levels of IFNγ and reduced IL-4 and IL-10 levels, IL-5 
and IL-13 levels were, in fact, significantly increased.  
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As was discussed in Chapter 1, IL-5 plays a major role in the 
development and function of eosinophils. IL-5 induces the terminal maturation 
of eosinophils and also enhances the survival of eosinophils. Effector 
functions of eosinophils are also enhanced by IL-5. IL-13, too, plays a central 
role in allergic asthma. This cytokine had been shown to be involved in goblet 
cell differentiation, increased airway epithelial permeability, increased airway 
hyperresponsiveness and inducing class switching from IgM to IgE. It had 
been reported that while IL-4 is required for the initiation of Th2 inflammation, 
blockade of IL-4 during antigen challenge did not affect airway inflammation 
and eosinophilia (244). The mouse IL-4, IL-5 and IL-13 genes are tightly 
clustered at the Th2 locus. Initially, all three cytokines were believed to be 
regulated concurrently by GATA-3. However, more recent studies proposed a 
model of regulation where GATA-3 independently binds to regulatory 
elements of the IL-4, IL-5 and IL-13 genes and independently regulate these 
genes (245). This may be a reason for our observations that the IL-4 
production was reduced while Il-5 and IL-13 production was increased in the 
mice that had a robust CD8 T cell response to Der p 1. Other than T cells, 
mast cells and eosinophils had been shown to be a source of IL-5. Although 
Th2 helper cells are known as the predominant source of IL-13, other cells 
such as mast cells, basophils, and eosinophils had been shown to produce this 
cytokine. Therefore, it is also possible that the source of the increased IL-5 
and IL-13 production was not the T helper cells but rather these other cell 
types. Interestingly, CD8 T cells had also been shown to produce IL-5 and IL-
13 (146, 246). 
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Therefore, it can be concluded that the role of CD8 T cells in allergic 
asthmatic response to HDM is more complex than that for the OVA model. 
The first confounder would be the availability of sufficient antigen to 
stimulate a CD8 T cell response in the first place. Here, we showed that HDM 
extract was very inefficient in inducing a CD8 T cell response, even when 
BMDCs were used as antigen-presenting cells. The HDM extract is a 
heterogeneous mix of different proteins in which the Der p 1 protein 
comprises of only a small fraction (242). In the OVA model, mice were 
inoculated with pure OVA protein. Therefore, the SIINFEKL epitope was 
available in significantly greater quantities than the Der p 1 epitope 
(FGISNYCQI) in the same quantity of HDM extract. In the lung, the CD103+ 
population of dendritic cells is the primary dendritic cell population that 
process viral antigens and cross present inhaled antigens to CD8 T cells (247, 
248). For cross presentation to occur, sufficient Der p 1 must be taken up by 
these cells and cross presented to the CD8 T cells. But these cells are available 
in limited numbers in the lung. We have shown in vivo that BMDCs 
(professional antigen presenting cells) pulsed with HDM extract overnight 
were still insufficient to induce a robust CD8 T cell response in the lung. 
Therefore, it is highly unlikely that instilling the same quantity of HDM 
extract into the entire mouse lung could result in sufficient cross presentation 
to induce a sufficiently robust CD8 T cell response against Der p 1 to affect 
the allergic asthma response to HDM extract. Most studies with OVA used 50-
100µg of OVA protein for the intranasal challenges, far exceeding the quantity 
of Der p 1 present in normal exposures to HDM. This may explain 
observations that lung dendritic cells could cross-present OVA effectively 
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(249). We can see that if purified Der p 1 protein is used instead of HDM 
extract, the lung responses were indeed attenuated, similar to that described in 
the OVA model. Also, a study in patients allergic to cats showed that while 
CD4 T cell numbers rose 6 hours following Fel d 1 challenge, CD8 T cell 
numbers remained constant (250). These observations would suggest that CD8 
T cells might not be involved in the acute response to real allergens. This is 
possibly due to the fact that cross presentation of exogenous antigens to CD8 
T cells are markedly less efficient than the presentation of endogenous 
antigens. Therefore, the contribution of CD8 T cells to asthma pathology may 
not arise following acute allergen exposure but rather as a result of chronic 
airway inflammation. 
Lastly, we observed that, despite inducing a robust CD8 T cell response 
in the lung concurrently with the HDM extract challenge, no attenuation of the 
allergic asthma response was observed. This is despite reports that CD8 T 
cells could regulate the lung inflammatory responses through perforin-
mediated cell killing or the production of IFN-γ (146, 147). In fact, increased 
in inflammatory cell infiltration and some Th2 inflammatory cytokines such as 
IL-5 and IL-13 was observed. This illustrates the complexity of the HDM 
extract, a feature not found with OVA. In HDM extract, there exist a number 
of different proteins with biochemical and biological actions that directly 
modifies the immune response. These include proteases and the adjuvant 
action of Der p 2 on the TLR4 signaling pathway. Therefore, the use of CD8 T 
cells to attenuate asthma, while seemingly feasible in the OVA model, would 
be more complicated in the HDM model and would require far more study. In 
fact, in clinical studies of chronic asthma, CD8 T cells responding to allergens 
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appear to directly correlate with disease severity (251, 252). These 
observations agree with our data suggesting that a CD8 T cell response would, 
in fact, exacerbate the allergic airway inflammation. The availability of the 
TCR transgenic mice with CD8 T cells specific for HDM epitope would 
greatly facilitate further studies into this aspect of the allergic response to 
HDM, especially in the chronic model of asthma where these cells appear to 
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Chapter 7. Final discussion 
 
 
7.1 Summary of findings 
Epitope mapping studies 
We used a DNA immunization strategy to induce T cell responses against 
mite allergens Blo t 5 (from Blomia tropicalis) and Der p 2 (from 
Dermatophagoides pteronyssinus). We were keen to identify any class I MHC 
epitopes, if any, as we considered the possibility of generating additional TCR 
transgenic mice recognizing these allergens as well as Der p 1. Therefore, we 
required an immunization strategy that was able to induce sufficient antigen 
presentation via class I MHC to induce a CD8 T cell response, as well as 
inducing a CD4 T cell response. In our initial trials, we incorporated a known 
epitope recognized by CD8 T cells to the plasmid encoding the allergen of 
interest and demonstrated that our immunization strategy was able to induce a 
CD8 T cell response to the epitope. 
Unfortunately, we were not able to identify an epitope from Der p 2 or 
Blo t 5 that was able to induce a CD8 T cell response. To confirm this, we 
screened for a CD8 T cell response using two different methods; IFNγ 
ELISPOT and tetramer-guided epitope mapping using peptide-exchanged 
class I MHC tetramer with predicted peptides. We consistently obtained a 
positive result with the positive control plasmid, with the inserted SIINFEKL 
epitope, and therefore, were confident that the immunization process was 
effective. 
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However, we did identify a number of class II MHC epitopes recognized 
by CD4 T cells for both Der p 2 and Blo t 5. We compared the epitopes that 
were identified by other groups previously. The epitopes identified in our 
study correlated well with published epitopes. Although we did not identify 
any new epitopes for Der p 2, the result was a useful verification of our 
methodology. The previous studies used Der p 2 protein and adjuvants as the 
immunogen and epitope identification were assayed by measuring T cell 
proliferation (194, 208). Here, we showed that, using plasmid DNA and 
intradermal skin tattoo, we were able to elicit T cell responses to the same 
epitopes. This method of immunization is modular as different genes of 
interests could be rapidly cloned into the pVAX vector and is more 
economical than the use of recombinant proteins for immunization. 
Additionally, immunization by the use of exogenous proteins may not induce 
a robust CD8 T cell response, as it would be affected by cross-presentation 
efficiency. 
We identified novel class II MHC epitopes for Blo t 5 in both C57BL/6 
and BALB/C mice. For the C57BL/6 epitopes, we went on to demonstrate that 
these T cells could be recruited to the lungs and contribute to allergic airway 
inflammation. Following DNA immunization, we measured using ELISPOT, 
the proportion of IFNγ and IL-4 producing CD4 T cells that were induced 
against these epitopes. We observed that a majority of these CD4 T cells 
produced IFNγ and only a small number produced IL-4. However, when the 
mice were challenged intranasally with Blo t 5 following DNA immunization, 
we clearly observed a Th2 lung inflammation with the infiltration of 
eosinophils and the production of Th2 cytokines IL-5 and IL-13. Finally, we 
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showed that these peptides could potentially be used for immunotherapy to 
attenuate the allergic lung responses to Blo t 5. 
TCR transgenic mice and class I MHC tetramers as reagents for the 
study of HDM induced allergic asthma 
Efforts to study the role of CD8 T cells in the murine model of HDM 
induced allergic asthma had long been hampered by a lack of tools. In this 
study, we focused on the creation of useful research tools such as transgenic 
mice with CD8 T cells specific for HDM allergen and class I MHC tetramers.  
We cultured a T cell line specific for the Der p 1 epitope, FGISNYCQI, to 
clonality. We then proceeded to characterize the TCR usage using 5’ RACE. 
The genomic T cell receptor genes were cloned into pTαcass and pTβcass 
cassette vectors for generation of TCR transgenic mice (233). Although many 
studies had been carried out on CD8 T cells in the context of allergic asthma 
inflammation, these studies used the ovalbumin sensitization and challenge 
model as a surrogate. The availability of the OT-I TCR transgenic mice 
greatly facilitated experiments, providing a useful source of antigen-specific 
CD8 T cells. Although T cell lines specific for HDM allergens could be 
generated, and indeed were used in this study, the process in labor intensive 
and the batch-to-batch variation between batches of CD8 T cells could be 
great. Therefore, we plan to proceed to generate a TCR transgenic mouse with 
CD8 T cells specific for Der p 1. This would be the first instance that such a 
tool is available for a mite allergen. 
Class I MHC tetramers were first introduced in 1996 (186). Class I MHC 
tetramers quickly proved to be extremely useful reagents for visualization of 
antigen-specific T cells. Prior to the availability of this reagent, function 
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assays such as the measurement of antigen-induced proliferation or 
intracellular cytokine staining were used to identify antigen-specific T cells. 
However, these assays require much more manipulation, which often can alter 
the very response being measured. The use of functional assays often lead to 
underestimation of the number of antigen-specific cells and were prone to high 
background readings due to the bystander activation of non-antigen specific 
cells. Here, we refolded class I MHC tetramers with a UV-labile peptide (178, 
179). Following UV exposure, these class I MHC molecules could be 
exchanged for a different peptide. Therefore, class I MHC molecules with 
specificity for different epitopes could be rapidly produced. This also allowed 
the use of class I MHC tetramers for epitope screening purposes. In this 
manner, we were able to rapidly produce Db-FGISNYCQI tetramers that were 
able to stain Der p 1 specific CD8 T cells, even in lavage and lung 
homogenates. This allowed us, for the first time, to directly measure CD8 T 
cells responses in the lung following HDM exposure. Previous studies with 
HDM specific T cells measured T cell proliferation ex vivo, which may lead to 
an overestimation of antigen specific T cells. 
CD8 T cells and asthma 
We established a murine model of acute HDM induced asthma in our 
laboratory. As had been described in other studies, HDM allergen, unlike 
OVA, was able to induce the symptoms of allergic airway inflammation 
following intranasal installation, without the obligatory use of adjuvants that 
characterized the OVA model. Using this model, we explored the possibility 
of using allergen-specific CD8 T cells to modulate the allergic lung responses. 
Using the ovalbumin model, many groups including our own had 
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demonstrated that CD8 T cells were indeed able to attenuate OVA-induced 
Th2 responses in allergic airway inflammation (144, 146, 147). We expanded 
Der p 1 specific T cells in vitro and adoptively transferred these cells into 
HDM-sensitized mice prior to allergen challenge. We did not observe 
attenuation or exacerbation of the allergic airway inflammation by the 
transferred CD8 T cells. We also were not able to observe any Db-
FGISNYCQI tetramer positive cells in the lung lavage. Next, we induced 
allergic asthma using a single homogeneous protein (purified Der p1) and 
BMDCs, a model more closely resembling the OVA model. In this manner, 
we observed that the transferred CD8 T cells were able to attenuate the Th2 
inflammatory responses in the lung. We observed a decrease in eosinophilia 
and overall immune cell infiltration into the lung following allergen 
challenges. We also measured a decline in Th2 cytokines IL-5 and IL-13 when 
Der p 1-specific CD8 T cells were introduced prior to allergen sensitization. 
Following this, we hypothesized that the quantity of Der p 1 present in the 
HDM extract may be too low to induce a CD8 T cell response. We assayed, in 
vitro and in vivo, the ability of HDM extract to induce Der p 1 specific CD8 T 
cell responses. Using BMDCs pulsed with HDM or FGISNYCQI peptide, we 
showed that only BMDCs pulsed with the peptide was able to induce 
significant infiltration of CD8 T cells that were positively stained with Db-
FGISNYCQI. BMDCs pulsed with HDM only did not elicit CD8 T cells 
responses against the Der p 1 epitope. We conclude that the Der p 1 in the 
HDM extract was likely to be available in too low a concentration to be 
efficiently cross presented by the BMDCs, although it is not possible to 
discount other mechanisms that blocked cross-presentation being involved. 
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Our in vivo observations correlated with our in vitro data. Using the Der p 1 
specific CD8 T cell line, we measured the proliferative responses of these cells 
when cultured with peptide or HDM pulsed splenocytes. We only observed 
significant proliferation with the use of peptide pulsed splenocytes. HDM 
extract contains a homogeneous mix of proteins, some of which are allergens. 
These results suggest that the concentration of individual proteins in the HDM 
extract may be too low to elicit a robust CD8 T cell response. As the HDM 
extract dosage used in our studies are likely to be far higher than levels found 
in natural exposures, it seems unlikely that there would be sufficient Der p 1 in 
inhaled HDM allergens to induce a CD8 T cell response. As such, despite 
some promising observations in the OVA model, CD8 T cells may not 
necessarily be a viable target in HDM mediated asthma.  
We next asked the question; should a CD8 T cell response be elicited in 
the lung during allergen challenge, would the CD8 T cells be able to influence 
the allergic inflammatory response? To induce a robust CD8 T cells response; 
we intranasally administered FGISNYCQI peptide pulsed BMDCs 
concurrently with HDM extract challenge. Tetramer staining showed the 
presence of a sizable population of Der p 1-specific CD8 T cells. In the earlier 
studies carried out in our group, IFNγ from CD8 T cells was key to attenuating 
the Th2 responses in the lung (146). Indeed, we did observe a marked increase 
in IFNγ in the draining lymph node cultures of mice that had received peptide-
pulsed BMDCs. Although we recorded a statistically significant decline in the 
percentage of eosinophils in mice that had a robust Der p1-specific CD8 T 
cells, we believe that the net effect is negligible. We observed a greater 
number of immune cells in the lavage of mice that had a CD8 T cell response. 
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This included a significantly higher number of T cells. Crucially, we did not 
observe a decrease in eosinophil numbers, but rather there were actually 
increased number of eosinophils in the lavage. Therefore, it would suggest that 
the presence of activated CD8 T cells in the lung during allergic inflammation 
might actually lead to increased pulmonary inflammation. This agrees with 
clinical observations that lung CD8 T cell numbers positively correlated with 
disease severity (251, 252). Studies involving respiratory syncytial virus 
infection models also showed that CD8 T cells contribute to the development 
of AHR and eosinophilia (253). CD8 T cells generally respond poorly to 
exogenous antigen and may not be rapidly recruited to the lung following 
allergen exposure, unlike CD4 T cells. However, the presence of CD8 T cells 
in severe asthma suggests that these cells may be gradually recruited as a 
result of the chronic airway inflammation. However, once recruited to the 
inflamed lungs, these CD8 T cells could contribute to the allergic airway 
inflammation and increase the severity of the disease. 
While IL-4 levels were reduced in mice that had received peptide-pulsed 
BMDCs, we recorded an increase in IL-5 and IL-13. This suggested that the 
levels of IL-4 may have been repressed by the presence of higher 
concentrations of IFNγ, but despite this, does not appear to have an effect on 
the development of allergic airway inflammation. This correlates with the 
observations that, while IL-4 is required for the initiation of Th2 inflammation, 
blockade of IL-4 during antigen challenge did not affect airway inflammation 
and eosinophilia (244). This might suggest that induction of a CD8 T cell 
response prior to allergen sensitization may have a beneficial effect by 
suppressing IL-4 production during allergen sensitization. However, in the 
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HDM model, this may be inadequate if the concentration of antigen is 
insufficient to elicit a CD8 T cells response.  
Therefore, using a HDM model of allergic asthma, we demonstrated that, 
in contrast to many reports using the ovalbumin model of asthma, CD8 T cells 
were not able to attenuate the development of allergic airway inflammation. 
Additionally, the presence of activated, allergen-specific CD8 T cells may 
exacerbate the pulmonary inflammatory response. 
7.2 Limitation of current study 
Assessment of other salient features of allergic asthma 
Many studies have described a role for CD8 T cells in suppression of IgE 
production (221, 222).  Due to time constraint, we had yet to assay for HDM 
specific IgE. We plan to optimize IgE ELISA assays for HDM allergens to 
establish if Der p 1-specific CD8 T cells would be able to attenuate IgE 
responses and if this effect would also affect IgE directed against other HDM 
allergens such as Der p 2. However, we postulate that, since recruitment of 
CD8 T cells to the lung was not observed in the HDM sensitization and 
challenge model, it would be somewhat unlikely that such an effect be 
observed.  
Similarly, we plan to assay for the effect of CD8 T cells on AHR. 
Previous studies on the asthma model in our laboratory showed that the 
transfer of OVA specific CD8 T cells did not affect AHR measurements (146). 
Again, we believe that this is unlikely given the inability of HDM to induce 
CD8 T cell recruitment to the lung. 
In the study of Blo t 5 CD4 T cell epitope, we have also planned to 
measure IgE induction and AHR responses following Blo t 5 challenge to 
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determine the influence of allergen-specific T cells on lung function and 
immunoglobulin class-switching. 
The use of in vitro cultured CD8 T cells for adoptive transfer 
Adoptive transfer studies were performed using Der p 1 –specific CD8 T 
cells that had been expanded in vitro prior to use. Not all the cells in the 
culture were antigen specific. We attempted to standardize the number of Der 
p 1 specific T cells transferred into each mouse (2x106 cells /mouse). In 
general, this involves the transfer of approximately 4-5x106 total cells into 
each mouse. Although tetramer staining and intracellular cytokine staining 
were performed prior to transfer to assess the function of the cells, it is 
unavoidable that there would be batch-to-batch variations that may affect the 
results of these experiments. However, in the experiments using purified Der p 
1, we showed that these T cells were consistently recruited to the lungs and 
attenuated the development of allergic inflammation. The use of TCR 
transgenic mice would provide a more consistent source of T cells for future 
studies. 
The nature of the HDM extract 
We also observed differences in HDM extracts obtained from different 
sources. We had sourced for HDM from Greer laboratories and the Sriraj Dust 
Mite Center for Services and Research, Thailand. Mite extracts from different 
sources varied considerably in their allergenicity (242). For the assays 
described here, mites from Greer Laboratories were used and efforts were 
made to ensure that the mite extract used originate from the same 
manufacturing batch. However, the remains the possibility that the Der p 1 
levels may vary significantly from batch to batch. It would be instructive to 
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measure the actual Der p 1 content in HDM extracts from different sources 
and assay their ability to induce a CD8 T cell response. . Various components 
of the extract would need to be considered when comparing HDM extracts 
from various sources. Endotoxin levels general varies and it would be useful 
to test the endotoxin levels prior to use and if necessary, endotoxin should be 
removed before use. It would also be useful to quantitate major components of 
the allergens such as Der p 1 and Der p 2. By standardizing the quantity of 
these allergic components, we could better compare between the nature of 
extracts from different sources. 
Blo t 5-specific T cells produced IFNγ  as well as Th2 cytokines 
We observed that a large proportion of the Blo t 5-specific CD4 T cells 
recruited to the lung still produced low levels of IFNγ, as evidenced by 
intracellular cytokine staining and ELISA measurements. However, we clearly 
observed eosinophilia and production of high levels of Th2 cytokines by these 
cells as well. A Th1 inflammatory response is believed to negatively regulate 
Th2 inflammation (108). However, we did not observe this in our study as 
Th2-type lung inflammation accompanied by production of both Th1 and Th2 
cytokines was observed. Clearly, more study in this aspect is required. 
7.3 Future work 
Measurements of IgE production, airway remodeling and AHR 
 
 In this study, we measured eosinophilia, immune cell infiltration into 
the lungs and production of Th2 cytokines as a measure of allergic airway 
inflammation. Due to the lack of time, we have not measured other features of 
allergic asthma such as AHR and IgE production. 
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 We plan to optimize ELISA assays for Der p 1 and Blo t 5 specific IgE 
antibodies to measure serum IgE levels. Currently, our laboratory does not 
have an optimized assay for these responses. We have stored serum from the 
mice used in this study for this purpose. We could, of course, also measure 
total IgE levels as a reflection of IgE induction by HDM or Blomia tropicalis 
allergens but we believe that it would be more informative to assay for the 
allergen specific IgE. 
 Also, we would proceed to measure AHR responses in the HDM 
model following CD8 transfer to ascertain if the presence of Der p 1 specific 
CD8 would have an effect on AHR. 
 We used an acute model of allergic asthma for these studies. Mice 
were sensitized and challenged and culled by day 14. However, structural 
changes and IgE production may not be fully developed by this time point. 
Therefore, we would need to explore the possibility of using a longer period of 
sensitization and challenge.  
CD8 T cells in a chronic asthma model 
 There appears to be two sides in the CD8 story. In the murine model of 
asthma, specifically the ovalbumin sensitization and challenge model, many 
reports had described the role of CD8 T cells in the attenuation or 
exacerbation of the allergic airway inflammation in an acute manner (146-
148). In our laboratory as well, we had reported that activated OT-I CD8 T 
cells were rapidly recruited to the lung following ovalbumin challenge (146).  
 In clinical studies of asthma sufferers, however, CD8 T cells appear to 
be more relevant in the chronic disease. In many patients, CD8 T cells 
numbers in the sputum and lung correlated directly with the severity of the 
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disease and lung function (251, 252). Lung biopsies of cat allergy patients 
showed that CD4 T cells but not CD8 T cells increased in number 6 hours 
following Fel d 1 challenge (250). These observations suggest that, in clinical 
asthma, CD8 T cells may contribute in the chronic phase of the disease rather 
than in the acute phase as reported in the murine ovalbumin-based model. This 
is perhaps understandable as the efficiency of the cross-presentation of 
exogenous antigen is low and the CD8 T cell responses engendered are likely 
to be far below that expected against endogenous antigens. 
We had demonstrated here that CD8 T cells appear to play a minimal role 
in the acute phase of the allergic airway inflammation caused by HDM. 
However, we believe that it would be highly relevant to study the role played 
by these cells during chronic inflammation. The link between CD8 T cells and 
severity of symptoms suggest that these cells may become increasingly 
relevant with the progression of the disease and a possible target for therapy in 
severe asthma patients. Therefore, we plan to analyze the role of allergen 
specific CD8 T cells in a chronic murine model of asthma. To this end, we 
believe that class I MHC tetramers and allergen-specific TCR transgenic mice 
would be invaluable tools for this follow-up study. 
CD8 T cells against a different specificity 
In this study, we studied the effect of the adoptive transfer of Der p 1-
specific CD8 T cells into the murine model of HDM induced allergic asthma. 
While we did not observe significant recruitment of these CD8 T cells into the 
lung, we did observe that a population of CD8 T cells in the draining lymph 
node were activated and produced IFNγ following in vitro culture. While we 
cannot discount the possibility of by-stander activation, there is the possibility 
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that a CD8 T cell response was being induced against another component of 
the HDM extract (Figure 7.1).  
We have demonstrated that the plasmid DNA immunization method 
induced both CD4 and CD8 T cell responses. The modular nature of this 
method makes it possible to generate plasmids encoding various allergens 
quickly. Using this method, we screened responses against a major HDM 
allergen, Der p 2, but were unable to identify any epitopes recognized by CD8 
T cells. We aim to screen a number of different allergens for the presence of 
CD8 T cell epitopes. Using ligand exchange class I MHC tetramer technology, 
we could quickly produce class I MHC tetramers recognizing CD8 T cells of 
the desired specificity. These tetramers could then be used to probe for the 
presence of these T cells in mice with HDM induced allergic airway 
inflammation.
 
Figure 7.1 CD4 and CD8 T cell responses in HDM culture of MLN. MLN 
cells from HDM sensitized and challenged mice were cultured for 3 days with 
10µg/ml HDM. Cells were surface stained for CD4 and CD8 and intracellular 
cytokines (IL-4 and IFNγ). Cells were gated on live cells followed by either 
CD4 or CD8. 
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TCR transgenic mice with CD4 T cells recognizing allergen proteins 
 Having established the protocols for establishing an antigen-specific T 
cell line and for the cloning of the TCR genes, we would now be able to 
generate TCR transgenic mice with T cells specific for other allergens. In this 
study, we had identified class II MHC epitopes from Der p 2 and Blo t 5. 
Given the central role of CD4 T cells in asthma pathogenesis, TCR transgenic 
mice against these epitopes would be invaluable tools for further studies into 
the development of allergic airway inflammation caused by HDM or Blomia 
tropicalis. 
T cells epitopes as tools for immunotherapy 
Allergen-specific immunotherapy (SIT) is not a new concept. In 1911, 
Leonard Noon experimented on the use of small quantities of pollens as a 
form of prophylactic inoculation against hay fever. SIT remains the only 
causative treatment for respiratory allergies such as asthma or rhinitis. Unlike 
other asthma treatment regimes, SIT addresses not just the symptoms but also 
the cause of the allergy. The protective effects of SIT therapy are mediated by 
the induction of IgG antibodies and the generation of regulatory T cells. IgG 
antibodies bind to the epitopes on the allergens and prevent allergen binding to 
IgE, hence preventing the cross-linking of FcεR1 on the surface of mast cells 
and basophils, hence preventing the initiation of the allergic immune response 
to the allergen. Several groups had developed recombinant hypoallergenic 
allergen proteins that had reduced reactivity to IgE but with the T cell epitopes 
preserved (reviewed in (254)). This reduces the IgE-mediated side effects but 
maintained the availability of T cell help to induce IgG production (255). 
Although this has been shown to reduce IgE-mediated allergic responses, a 
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number of patients presented with T cell mediated late-phase side effects. To 
address this, Niespodziana et al (2011) proposed a fusion construct containing 
hepatitis virus PreS domain and a portion of Fel d 1 (from cat dander) that 
elicited IgG responses but with the T cell-reactive epitopes deleted. The PreS 
domain of hepatitis virus contains T and B cell epitopes. Therefore, T cell help 
can be made available to generate Fel d 1 specific IgG antibodies but yet 
prevent the induction of allergen specific T cell responses (256). Another 
subset of allergen-specific immunotherapy hinges on the induction of Tregs to 
suppress immune responses against the allergen. Peptide immunotherapy uses 
synthetic peptides that contain T cell epitopes. These peptides are were 
delivered intradermally, a route of immunization that is believed to induce 
regulatory T cell responses (135). Results from clinical trials using a set of 7 
epitope containing peptides from Fel d 1 showed that many patients 
demonstrated significant clinical improvement after 1 year of treatment (206). 
Blomia tropicalis allergens remains poorly understood despite their 
ubiquity in tropical region. Here, we had identified a number of novel murine 
T cell epitopes from a major Blomia tropicalis allergen, Blo t 5. Structural 
studies had identified the antibody binding sites to this allergen (185, 210). 
This would therefore permit the study of allergen immunotherapy in the 
murine model of Blomia tropicalis induced asthma. This would provide better 
understanding of the mechanisms involved and allow for the exploration of 
possible therapeutic approaches using recombinant hypoallergenic proteins. 
Our preliminary studies also suggest that these epitopes could induce a 
regulatory response when administered as a form of peptide immunotherapy. 
The use of the newly identified Blomia tropicalis epitopes in these manners 
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could help elucidate the mechanism behind tolerance to allergens and improve 
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